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RÉSUMÉ 
_____________________________________________________________ 
 
Les anti-infectieux sont parmi les médicaments les plus utilisés pendant la 
grossesse. Les indications pour l’utilisation de ces médicaments, telles que 
les infections bactériennes, figurent parmi les facteurs de risque les plus 
importants pour la prématurité et les enfants nés petits pour l'âge gestationnel 
(« Small-for-gestational-age », SGA). Ces complications de la grossesse 
peuvent avoir des incidences sur la santé du nouveau né et sur son 
développement futur. Compte tenu des impacts sur la santé de la mère et de 
l’enfant, la prise en charge et le traitement efficace de ces infections sont 
impératifs. Cependant,  l'utilisation des anti-infectieux, pour éviter des issues 
de grossesse défavorables, fait l’objet d’une controverse dans la littérature. 
Cette controverse est en partie liée à la qualité méthodologique discutable 
des études disponibles sur le sujet. 
 
Les quatre études présentées dans cette thèse ont donc pour objectif 
d’investiguer l’utilisation des anti-infectieux durant la grossesse ainsi que 
d’évaluer le risque de prématurité et de SGA après utilisation de ces 
médicaments en période gestationnelle. Une révision systématique de la 
littérature sur l’utilisation du métronidazole durant la grossesse est également 
présentée. Nous avons utilisé, comme source de données le Registre des 
Grossesses du Québec, une cohorte longitudinale conçue à partir du 
jumelage de trois bases de données administratives de la province du 
Québec (RAMQ, Med-Echo et ISQ). Le registre fournit des informations sur 
les prescriptions, les services pharmaceutiques et médicaux, ainsi que des 
donnés sur les soins d’hospitalisation de courte durée et démographiques. 
Les deux premières études présentées dans cette thèse ont eu pour objectif 
d’évaluer la prévalence, les tendances, les indications et les prédicteurs de 
l’utilisation des anti-infectieux dans une cohorte, extraite du registre, de 97 
 iv
680 femmes enceintes. A l’aide d’un devis cas-témoins, les 2 dernières 
études ont mesuré l’association entre l’utilisation d’anti-infectieux durant les 2 
derniers trimestres de grossesse et le risque de prématurité et de SGA, 
respectivement. Un cas de prématurité a été défini comme un accouchement 
survenu avant 37 semaines de gestation. Un cas de SGA a été défini comme 
l’accouchement d’un enfant dont le poids à la naissance se situe sous le 
10ème percentile du poids normalisé à la naissance (compte tenu de l’âge 
gestationnel et du sexe du bébé). Les données ont été recueillies pour les 
agents systémiques oraux, ainsi que pour les classes et les agents 
individuels.  
 
Nos résultats ont montré que la prévalence de l’utilisation des anti-infectieux 
durant la grossesse était comparable à celle d’autres études déjà publiées 
(25%). Nous avons observé une augmentation de l’utilisation des agents plus 
anciens et ayant des profils d’innocuité connus. Les prédicteurs de l’usage en 
début de grossesse identifiés sont : avoir eu plus de deux différentes 
prescriptions (OR ajusté = 3,83,  IC 95% : 3,3-4,3), avoir eu un diagnostic 
d’infection urinaire (OR= 1,50, IC 95% : 1,3-1,8) et un diagnostic d’infection 
respiratoire (OR= 1,40, IC 95% : 1,2-1,6). L’utilisation des macrolides a été 
associée à une diminution du risque de prématurité (OR =0,65, IC 95% : 
0,50-0,85). En revanche, les femmes ayant été exposées au métronidazole 
ont vu leur risque augmenté de 80% (OR=1,81, IC 95% : 1,30-2,54). 
L’utilisation d’azithromycine a été associée à une diminution importante du 
risque chez les femmes ayant un diagnostic de rupture prématurée des 
membranes (OR=0,31, IC 95% : 0,10-0,93).  Cependant, l'utilisation de 
sulfaméthoxazole-triméthoprime (SXT) a été significativement associée à une 
augmentation du risque de SGA (OR= 1,61, IC 95% : 1,16-2,23), tandis que 
celle des anti-infectieux urinaires a été associée à une diminution du risque 
(OR= 0,80, 95%CI : 0.65-0.97).  
 
 v
Les conclusions de nos travaux suggèrent que l’utilisation des macrolides et 
des pénicillines diminuent le risque de prématurité et de SGA. Nous devons 
considérer l'utilisation de différents choix thérapeutiques tels que 
l’azithromycine, lors de la prise en charge des infections pouvant induire la 
prématurité et le SGA. 
 
Mots clés : anti-infectieux, grossesse, prématurité, petit pour l’âge 
gestationnel, Registre des Grossesses du Québec, devis cas-témoin.   
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ABSTRACT 
_____________________________________________________________ 
 
Anti-infective drugs are among the most used medications during pregnancy. 
Gestational infections are related to some adverse pregnancy outcomes, 
such as preterm birth and infants born small for their gestational age (SGA), 
which increases the risk of mortality and long-term morbidity. Given its health 
impacts, prompt management and treatment of these infections are 
warranted. However, there is some controversy on the use of anti-infective 
drugs to prevent adverse pregnancy outcomes, such as preterm birth. 
Furthermore, there is growing concern regarding its independent effects on 
these outcomes, when treatment of maternal infections is instituted.  
 
Therefore, we conducted 4 large population-based studies aimed to 
investigate the gestational use of anti-infective drugs during pregnancy and 
the risk of preterm birth and SGA. In addition, we systematically reviewed the 
available evidence on the use of metronidazole during gestation. We used 
data from the Quebec Pregnancy Registry, a longitudinal population-based 
cohort established with the linkage of three administrative databases from the 
province of Quebec (RAMQ, Med-Echo and ISQ). Data are available on 
prescriptions, pharmaceutical and healthcare services, acute care 
hospitalization and patient demographics. For study 1 and 2, we conducted a 
drug utilisation review within a cohort of 97 680 pregnant women. Study 3 and 
4 were two independent case-control studies. Cases of preterm birth were 
defined as those with a delivery occurring before the 37th week of gestation 
(study 3). Cases of SGA were defined as a pregnancy resulting in a baby’s 
weigh adjusted for gestational age and gender <10th percentile, according to 
the Canadian gender-specific reference curves (Study 4). Oral use of anti-
infective drugs during the last two trimesters of pregnancy was the exposure 
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definition for both studies. Independent analyses were done to assess the risk 
for different classes of anti-infectives and individual agents.  
 
Our results indicate that the use of anti-infective drugs during pregnancy is 
prevalent (25%). Use of well-known agents increased once pregnancy was 
diagnosed, and the most frequent indications for use were respiratory and 
urinary infections. Predictors associated with use were having more that 2 
different prescribers (adj. OR= 3.83,  95% CI: 3.3-4.3), having a diagnosis of 
urinary tract infections (adj. OR= 1.50, 95% CI: 1.3-1.8) and respiratory tract 
infection (adj. OR= 1.40, 95% CI: 1.2-1.6). The use of macrolides was 
associated with a decreased risk of preterm birth (adj. OR=0.65, 95% CI: 
0.50-0.85), whereas metronidazole increased the risk (adj. OR=1.81, 95% CI: 
1.30-2.54). Azithromycin had a protective effect in women with premature 
rupture of membranes (adj. OR=0.31, 95% CI: 0.10-0.93). Use of 
sulfamethoxazole/trimethoprim was associated with an increased risk of SGA 
(adj. OR= 1.61, 95%CI: 1.16-2.23), whereas the use of urinary anti-infectives 
decreased the risk (adj. OR= 0.80, 95%CI: 0.65-0.97). 
 
The results of this thesis suggest that the use of macrolides and penicillins 
decrease the risk of preterm birth and SGA. Health care professionals should 
consider other therapeutic alternatives to metronidazole and sulfonamides, 
such as azithromycin.  
 
Keywords : anti-infective drugs, pregnancy, preterm birth, small for 
gestational age, Quebec Pregnancy Registry, case-control study. 
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Chapter 1  
INTRODUCTION 
_____________________________________________________________ 
 
Anti-infective drugs are among the most frequently used medications during 
pregnancy [1]. It is estimated that 17 to 41% of pregnant women are exposed 
to these drugs at least once during gestation [2-4].  
 
Given that 50% of the fetus genetic material is derived from the father, the 
fetus’s susceptibility to rejection by the maternal immune system is similar to 
the susceptibility of a transplanted organ. Evidence indicates that the 
maternal immune system may tolerate fetal antigens by suppressing cell-
mediated immunity while retaining normal humoral immunity. These changes 
occur at the maternal-fetal interface but may also affect systemic immune 
responses to infection.  In fact, these immunologic adaptations of pregnancy 
may induce a state of increased susceptibility to certain intracellular 
pathogens, including viruses and bacteria, which increase the risk of infection 
[5]. Therefore, when compared to their non-pregnant counterparts, pregnant 
women are more susceptible to infections, being hence more prone to use 
antimicrobial drugs [6].  
 
When occurring at specific periods, prevalent indications for anti-infective use 
during gestation are related to some adverse pregnancy outcomes. For 
example, urinary tract infections (UTIs) diagnosed during the last two 
trimesters of pregnancy, are associated with an increased risk of premature 
rupture of membranes (PROM), preterm birth and infants born small for their 
gestational age (SGA) [7, 8]. These babies are at increased risk of long-term 
morbidity, including neurologic and behaviour problems, delayed growth 
during childhood, hypertension, obesity, and type II diabetes in adulthood [9]. 
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Furthermore, bacterial infections during pregnancy are responsible for most of 
ante-partum admissions to the maternal–fetal medicine units [10]. Hence, 
given its impacts on the health of the mother and the fetus, when an infection 
occurs during gestation, prompt management and antibiotic treatment is 
warranted [11]. Indeed, the effective treatment of gestational infections is one 
of the main causes of the decrease in maternal and prenatal mortality in 
industrialized countries [12]. 
 
Over the years, there has been growing concern regarding the independent 
effect of anti-infective drugs used during gestation on adverse pregnancy 
outcomes, when treatment of maternal infections is instituted [13, 14]. There 
is increasing evidence that some classes of antimicrobials commonly 
prescribed during pregnancy may present unsuspicious non-antibiotic 
properties in the modulation of important physiological process, which are 
essential for the fetal development and maturation, such as bone metabolism, 
angiogenesis and apoptosis inhibition [15, 16]. Furthermore, It has been 
hypothesized that the action of some anti-infective drugs can culminate in the 
release of a microorganism’s metabolic products into the maternal genito-
urinary tract [17]. This effect could trigger the inflammatory pathway leading to 
placenta-mediated adverse outcomes, such as preterm birth and SGA [18, 
19]. This issue remains unsolved, and there is still some controversy on the 
use of some classes of these drugs for the treatment of gestational infections 
and prevention of these adverse outcomes [20]. Thus, the independent effect 
of anti-infective drugs on preterm birth and SGA requires further investigation. 
 
This thesis presents 5 studies conceived to furnish new evidence-based data 
on the use of anti-infective drugs during pregnancy. A drug utilization review 
(Study 1 and 2) that describes prevalence, trends, indications and predictors 
of use, is followed by the risk assessment of preterm birth (Study 3) and 
small-for-gestational-age newborns (Study 4) after exposure to anti-infective 
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drugs, according to trimester of exposure and class of anti-infective.  
Moreover, this thesis includes a review of the available evidence on the use 
of metronidazole during pregnancy (Study 5). The main results are presented 
in the form of articles already published in scientific journals, or in the form of 
manuscripts submitted for publication.  
  
Chapter 2 
LITERATURE REVIEW 
_____________________________________________________________ 
 
An anti-infective drug is a compound or substance that kills or slows down the 
growth of microorganisms, such as bacteria and fungus [21]. The term is 
often used synonymously with the term antibiotic.  However, the later term 
defines any substance that: 1) must be produced by a living organism and, 2) 
is antagonistic to the growth of other microorganisms in high dilution [22]. 
Therefore, this definition exclude substances that kill bacteria but are not 
produced by microorganisms, and also exclude important synthetic 
antibacterial compounds, such as sulfonamides [23]. In this manuscript, we 
opted to use the broader term “anti-infective drug” when referring to 
antimicrobial drugs used in the treatment of bacterial, fungal or parasitical 
infections, regardless its chemical or biosynthetic origins.  
 
The following sections describe the available evidence on the use of anti-
infective drugs during pregnancy. More specifically, this chapter covers a 
detailed description of the classes of anti-infective drugs available, its main 
indications for use during pregnancy, and its potential impacts on two 
pregnancy outcomes of interest: preterm birth and SGA.  
 
2.1. ANTI-INFECTIVE DRUGS AND PREGNANCY 
 
2.1.1. Classification of anti-infective drugs 
 
Several methods have been proposed to classify anti-infective agents, and all 
are hampered by exceptions and overlaps. One of the most common 
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classifications is based on the drug’s chemical structure, mechanism of 
action, and indication for use [24-29]: 
 
2.1.1.1. Beta-Lactam antibiotics and Other Inhibitors of the 
microorganism cell wall synthesis  
 
These include the beta-lactam drugs (penicillins and cephalosporins), and 
miscellaneous agents with different chemical structures. Penicillins can be 
sub-grouped into narrow spectrum antibiotics (penicillins G, V and oxacillin) 
and wider spectrum (ampicillin, amoxicillin, piperacillin). Cephalosporins can 
be grouped into 1st generation agents (narrow spectrum, such as cefazolin 
and cephalexin) and wider spectrum agents of 2nd generation (cefotetan, 
cefoxitin, cefuroxime, cefaclor), 3rd generation (ceftazidime, cefoperazone, 
cefotaxime, ceftriaxone) and 4th generations (cefepime). Miscellaneous anti-
infectives are represented by the carbapenens (imipenem, meropenem and 
ertapenem), aztreonam, cycloserine, vancomycin, bacitracin, and imidazole 
antifungal agents (miconazole, ketoconazole, and clotrimazole) [27]. 
 
During pregnancy, beta-lactam agents are active against a wide range of 
respiratory, gastrointestinal, cutaneous and urinary infections caused by 
microorganisms, such as Gram-positive cocci (Enterococcus spp., 
Staphylococcus spp., Streptococcus spp.), Gram-negative cocci (Nesisseria 
spp.), Gram-negative bacilli (Escherichia coli, Haemophylus influenzae, 
Klebsiella spp., Proteus spp., Pseudomonas spp., Salmonela spp.) and 
Spirochetes [24, 27, 30-32]. 
 
2.1.1.2. Inhibitors of the microorganism cell membrane 
 
This class includes agents that act directly on the microorganism cell 
membrane, affecting permeability and leading to leakage of intracellular 
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compounds. Some representants of this class include the polymyxin, 
colistimethate, and the polyene antifungal agents, such as nystatin and 
amphotericin B [25]. 
 
Polymyxin has a bactericidal action against almost all gram-negative bacilli 
except the Proteus group. Nystatin and amphotericin B are effective against 
Candida spp. and Cryptococcus spp.  [24, 27]: 
 
These drugs are barely used during gestation [30-32]. 
 
2.1.1.3. Inhibitors of the bacterial protein synthesis 
 
These bacteriostatic agents affect the function of the 30 S or 50 S ribosomal 
subunits to cause a reversible inhibition of protein synthesis. They can be 
grouped into broad-spectrum agents, such as chloramphenicol and 
tetracyclines (tetracycline, doxycycline, minocycline, tigecycline), moderate 
spectrum agents, such as macrolides (erythromycin, azithromycin and 
clarithromycin) and narrow spectrum (lincosamides, streptogramins and 
linezolid) [28]. The aminoglycosides irreversibly inhibit protein synthesis, 
being therefore, bactericidal agents. Some examples of aminoglycosides 
include gentamicin, neomycin, amikacin, tobramycin and kanamycin [25]. 
 
Tetracyclines are active against Treponema pallidum, Chlamydia spp., 
Mycoplasma spp. and Rickettsia spp. Macrolides are used against Gram-
positive bacteria, Streptococcus pneumoniae and Haemophilus influenzae. 
The antimicrobial spectrum of macrolides is slightly wider than that of 
penicillin, and, therefore, macrolides are a common substitute for patients 
allergic to penicillins. Beta-hemolytic streptococci, pneumococci, 
staphylococci, and enterococci are usually susceptible to macrolides. Unlike 
penicillin, macrolides have been shown to be effective against Legionella 
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pneumophila, Mycoplasmum spp., Mycobacterium, and Chlamydia spp. 
Aminoglycosides are effective against Gram-negative bacteria, such as 
Escherichia coli and Klebsiella spp., particularly Pseudomonas aeruginosa 
[24, 27, 28]. 
 
Tetracyclines and aminoglycosides are not recommended during pregnancy. 
The main risk of tetracycline use during pregnancy is a yellow-brown 
discolouration of teeth as a result of deposition by chelation of this agent in 
calcifying teeth of the infant [33]. Azithromycin is indicated for the treatment of 
not only upper and lower respiratory tract and cutaneous infections, but also 
treatment for urethritis and cervicitis caused by Chlamydia trachomatis. 
During pregnancy, spiramycin is used primarily in the treatment of protozoal 
infections and specifically for the treatment of toxoplasmosis. Clarithromycin 
is a treatment option in pregnant patients who cannot tolerate erythromycin 
because of adverse effects [30-32]. 
 
2.1.1.4. Antimetabolites agents 
 
Some agents of this group specifically inhibit essential metabolic steps that 
are essential to microorganisms. Examples of anti-infective of this group 
include sulfonamides (sulfisoxazole, sulfacetamide) and the combination 
trimethroprim-sulfamethoxazole [34, 35]. Other agents directly affect nucleic 
acid metabolism, such as the fluoroquinolones of 1st generation (norfloxacin), 
2nd generation (ciprofloxacin and ofloxacin), 3rd generation (levofloxacin) and 
4th generation (moxifloxacin) [36]. 
 
Sulfonamides are active against Gram-positive and negative organisms, 
Chlamydia spp., and Nocardia spp. The combination trimethroprim-
sulfamethoxazole is effective against E.coli spp., Haemophylus influenzae 
and Moraxella catarrhalis. Fluoroquinolones are effective in the treatment of 
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infections of the urogenital and gastrointestinal tracts caused by Gram-
negative organisms, including E. coli, Klebsiella spp., Campylobacter spp., 
Enterobacter spp., Pseudomonas aeruginosa, Salmonella spp., and Shigella 
spp. [24]. 
 
Trimethoprim and sulphonamides are widely prescribed for the treatment of 
UTIs during pregnancy. However, the use should be avoided during the first 
trimester and late in gestation, respectively [37]. Fluoroquinolones have been 
associated to the development of arthropathy in immature animals and are 
not recommended for routine use during pregnancy [30-32]. 
 
2.1.1.5. Antimycobacterial drugs 
 
Agents of this class are active against Mycobacterium spp. During pregnancy, 
these drugs are used against tuberculosis, leprosy and atypical 
mycobacterium infections [30, 31]. 
 
2.1.1.6. Miscellaneous and Urinary anti-infective agents 
 
Metronidazole, nitrofurantoin and nalidixic acid are the most important agents 
of this class. Metronidazole is effective against Bacteroides spp., Clostridium 
spp., Gardenerella vaginalis, Helycobacter pylori, and Pseudomonas spp.   
Nalidixic acid and Nitrofurantoin are active against many urinary tract 
pathogens, but not Proteus spp., or Pseudomonas spp.  [24]. 
 
Metronidazol is used for the treatment of bacterial vaginosis and 
trichomoniasis during pregnancy. Nitrofurantoin is used for the as a second-
line treatment for asymptomatic bacteriuria and cystitis during pregnancy [30-
32]. 
 
 9
The most common infections diagnosed during pregnancy include respiratory 
tract infections, gastroenteritis, urinary tract infections and bacterial vaginosis 
[11, 38, 39]. Other less prevalent conditons include sexually transmitted 
infections, malaria, tuberculosis and cutaneous bacterial infections [40-42]. A 
more detailed description of the most important gestational infections can be 
found in the section 2.2.  
 
2.1.2. Epidemiology of anti-infective drug use during pregnancy 
 
The question of whether to prescribe anti-infective drugs to pregnant women 
is a dilemma faced by health care providers on a daily basis. The potential 
benefits need to be weighed against the risk to the fetus [31]. Physicians 
have been reluctant to prescribe anti-infective drugs for pregnant women 
because a few of them are on the list of human teratogens (e.g., 
tetracyclines) [30]; others have been teratogens in animal experiments (e.g., 
fluoroquinolones) [43]. In addition, a few may have a toxic effect postnatally 
(e.g., nitrofurantoin) [44].  
 
There is discrepancy in results of the studies that investigated the use of anti-
infective drugs during pregnancy. Therefore, useful comparisons between 
studies and interpretation of results can be challenging [45]. Prevalence of 
anti-infective drug use during pregnancy varies. 
      
The use of medications by pregnant women was recorded in South Africa, 
and the results showed that the most commonly used medicines were 
analgesics, antibiotics, laxatives and antacids [46]. In Brazil, a retrospective 
cohort study showed that antibiotics were the third most common group of 
medications used during pregnancy [47]. In a Cuban study the prevalence of 
use was of only 4.7% [48]. 
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A study conducted in Hungary showed that 17.2% of pregnant women were 
exposed to antibiotics at some point during gestation. Most women received 
penicillin (14.5%), while 1.2% and 0.7% of pregnant women were treated by 
cephalosporins and tetracyclines, respectively [3]. In Germany, 20% of 
pregnant women received antibiotics during gestation [2]. Higher frequency of 
use was observed in Denmark (28.7%) [49]. In Finland, penicillin, 
erythromycin and pivmecillinam were the most often used antibiotics during 
pregnancy comprising together 65.4% of all anti-infective prescriptions [50]. 
Antibiotics were the most commonly prescribed medications in a study 
conducted in Australia [51]. High incidence of anti-infective use in pregnancy 
was also observed in the United States [4, 52], where the use of 
nitrofurantoin, sulfonamides was considered excessive [53]. In the United 
Kingdom, 30% of women were exposed to at least one anti-infective drug 
during gestation [54]. 
 
A recent cross-sectional study conducted in a teratology information service 
in Canada (IMAGe center at CHU Ste-Justine in Montreal) showed that 
gestational exposure to anti-infectives was the third most frequently inquired 
class of medication by health professionals; from a total of 11 076 requests 
regarding medication exposure during pregnancy, 6.3% were related to anti-
infective drugs [55].  
 
2.2. INDICATIONS FOR ANTI-INFECTIVE DRUG USE DURING 
PREGNANCY 
 
Anti-infective drugs are used in pregnancy for two principal purposes: curative 
(when an infection has already been installed) and prophylactic (to prevent 
infection caused by pathogenic microorganisms and its related complications 
for pregnancy) [56]. In practice, however there are few indications for the use 
of prophylactics antibiotics in pregnancy, such as group B streptococcal 
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infections (GBS) of the newborn and caesarean section [57, 58]. Prevalent 
infections during pregnancy include respiratory tract infections, UTIs and 
bacterial vaginosis (BV) [38]. Respiratory infections diagnosed during 
pregnancy are mostly of viral etiology [59-61]. In this thesis, we focus on anti-
infective drugs used to treat bacterial infections. Hence, we will consider the 
most important conditions that require antibacterial treatment during 
pregnancy, such as UTIs and BV [62, 63].  
 
2.2.1. Urinary tract infections 
 
UTIs are one of the most common medical complications of pregnancy [11]. 
These infections are characterized by the presence of microorganisms in the 
genito-urinary tract that cannot be explained by contamination. These agents 
have the potential to invade the tissues of the urinary tract and adjacent 
structures. The infection may be limited to the growth of bacteria in the urine 
(which frequently doesn’t produce symptoms) or it can result in several 
syndromes associated with an inflammatory response to remove the bacterial 
invasion. Actually, the term UTI represents a wide variety of conditions, 
including asymptomatic bacteriuria, urethritis, cystitis, acute pyelonephritis 
and pyelonephritis associated with bacteremia or sepsis [24]. 
 
2.2.1.1. Epidemiology of UTIs 
 
It is estimated that 2 to 10% of pregnant women suffer from any form of UTIs 
[8]. These infections complicate up to 20% of pregnancies [10]. Acute cystitis 
is prevalent in 1 to 4% of pregnant women [64]. Despite the relatively low 
prevalence of pyelonephritis during pregnancy (0.5 to 2%), it is estimated that 
20% to 40% of pregnant women with asymptomatic bacteriuria will develop 
acute pyelonephritis later in gestation [65]. Although the incidence of acute 
cystitis in pregnant women is similar to that in their nonpregnant counterparts, 
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the incidence of acute pyelonephritis in pregnant women with bacteriuria is 
significantly increased, compared with nonpregnant women [66]. Many 
studies have reported that pyelonephritis is more common during the second 
half of pregnancy, with an incidence peak during the last two trimesters of 
pregnancy [67-69]. Predictors of UTIs’ asymptomatic forms include: welfare 
status, increasing maternal age, multiparity, unprotected vaginal intercourse, 
history of childhood UTIs and history of recurrent UTIs. The prevalence is 
also markedly increased if women present certain pre-existing medical 
conditions, such as diabetes mellitus, sickle cell disease, immunodeficiency 
states, urinary tract anatomic anomalies, spinal cord injuries and psychiatric 
illnesses [70].  
 
2.2.1.2. Microbiology of UTIs 
 
The microorganisms causing UTIs usually originate from the gastrointestinal 
flora of the host. The most common agent implicated in uncomplicated UTIs is 
Escherichia coli, which accounts for 85% of non-hospital setting infections 
[69, 71, 72]. Other microorganisms such as Staphylococcus saprophyticus, 
Proteus spp., Pseudomonas aeruginosa, Enterococcus spp. and Ureaplasma 
urealyticum have also been implicated [11]. Organisms causing bacteriuria 
are similar in both pregnant and nonpregnant women [66]. 
 
2.2.1.3. Clinical presentation of UTIs 
 
Asymptomatic bacteriuria is characterized by bacterial colonization of the 
urine, with no clinical symptoms [73]. Asymptomatic bacteriuria is defined by 
two consecutive clean-catch urine cultures with more than 108 colonies of 
bacteria/L of urine, with a single type of bacteria [74]. It was observed that 
30% of women with asymptomatic bacteriuria developed symptomatic UTI 
during gestation [75]. Urethritis is characterized by urethral colonization 
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resulting in dysuria and polyuria. Cystitis is the infection of the bladder. 
Common clinical manifestations are dysuria, polyuria, suprapubic discomfort, 
and in some cases, hematuria [37]. Pyelonephritis is an ascending UTI that 
has reached the pelvis of the kidney, and represents the most severe form of 
UTI [76]. Clinical signs and symptoms of pyelonephritis include flank pain or 
abdominal pain, fever, anorexia, nausea and vomiting often associated with 
variable degrees of dehydration, chills, headache, and tachypinea. 
Respiratory failure and sepsis can be present in severe forms. Fever is 
elevated in the acute forms [77]. 
 
2.2.1.4. UTIs and maternal outcomes 
 
Maternal complications of UTI are a result of the tissue damage caused by 
bacterial endotoxins, especially in pyelonephritis [78]. The most dramatic 
maternal complication associated with UTIs is bacteremia and septic shock, 
induced by resistant pyelonephritis [11]. Other maternal complications that 
have been associated with UTIs during pregnancy are hypertension and 
preeclampsia [79, 80], anemia [81], chorioamnionitis and endometritis [76, 
82]. 
 
2.2.1.5. UTIs and pregnancy outcomes 
 
The association between perinatal outcomes and UTIs has been studied for 
many years [11, 63]. From a global health perspective, UTI is one of the most 
important and potentially preventable causes of preterm birth [83]. 
Intrauterine infections are thought to be responsible for up to 50% of extreme 
preterm births of less than 28 weeks of gestation, where both neonatal 
mortality and morbidity are high [83]. Among other recognized perinatal 
complications of UTIs, we highlight low birth weight infants, premature rupture 
of membranes, intrauterine growth restriction, cerebral palsy/mental 
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retardation and perinatal death [19, 63, 84]. There has also been a 
hypothesis suggesting that UTI during pregnancy is associated with child 
developmental delay and mental retardation [85]. 
 
2.2.1.6. Treatment of UTIs during pregnancy 
 
Once the clinical diagnosis of UTI is established, treatment is mandatory even 
without confirmation of the etiological agent by culture. As a consequence, 
the initial antibiotic therapy has the drawback of being empirical, and a variety 
of different antimicrobial agents can be used for treatment [86]. It is important 
to remember that therapy must be safe for both mother and fetus. Table 1 
summarizes most common therapeutic regimens currently proposed for the 
treatment of UTIs during pregnancy, according to the type of UTIs [11, 63, 77, 
87-90]. 
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Table 1. Most common therapeutic regimens currently proposed for the 
treatment of UTIs during pregnancy (Abbreviations: po: by mouth; q: every; bid: twice a day; 
tid: three times a day; qid: four times a day; SXT: Trimethoprim/Sulfamethoxazole; IM: intramuscularly; 
IV: intravenously). 
 
Urinary 
tract 
infection 
Treatment 
regimen 
Treatment options Comments 
 
Asymp-
tomatic 
bacteriuria 
 
Current standard 
of practice is to 
treat pregnant 
patients who 
have 
asymptomatic 
bacteriuria with at 
least 3 to 7 days 
of an oral anti-
infective agent 
[34, 86, 91-93]. 
 
Cephalexin 250-500 mg, 
po, qid. 
 
Nitrofurantoin 100 mg, 
po, qid or  Nitrofurantoin 
(monohydrate/macro-
crystals) 100 mg, po, bid, 
7 days. 
 
Amoxicillin 500 mg, po, 
tid. 
 
Norfloxacin 400 mg, po, 
bid. 
 
Cefuroxime 250 mg, po, 
tid. 
 
SXT (320/1600 mg) po, 
once a day (avoid use 
during first trimester). 
 
Single-dose 
regimens have been 
used, but showed 
lack of efficacy. 
Some authors do not 
recommend during 
gestation. 
 
SXT was associated 
with a theoretical 
increased risk of 
neural tube defects 
and it may lead to 
neonatal kernicterus.
 
Nitrofurantoin was 
associated with 
theoretical risk of 
fetal hemolytic 
anemia. 
 
 16
 
Urethritis 
and 
cystitis 
 
 
 
Given that the 
pathogens 
associated with 
urethritis and 
cystitis are the 
same as those 
causing  
asymptomatic 
bacteriuria, the 
treatment of 
cystitis in 
pregnancy is the 
same as the 
treatment for 
asymptomatic 
bacteriuria, 
longer courses of 
therapy are 
usually 
recommended 
(7-10 days) [86]. 
 
 
 
 
 
 
 
 
 
Cefuroxim 250 mg, po, 
tid. 
 
Nitrofurantoin 100 mg, 
po, qid or  Nitrofurantoin 
(monohydrate/macro-
crystals) 100 mg, po, bid. 
 
Amoxicillin 500 mg, po, 
tid. 
 
SXT (320/1600 mg) po, 
once a day (avoid use 
during first trimester). 
 
 
 
 
 
 
 
 
 
 
 
 
These agents are 
FDA class B 
category [11]. 
 
Continuation of Table 1 
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Pyelo-
nephritis 
 
Initial treatment 
must be 
parenteral [94]. 
First-line therapy 
often includes a 
first-generation 
cephalosporin. In 
an inpatient 
setting, 
parenteral 
antimicrobial 
therapy usually is 
continued until 
the patient is 
afebrile for 48 
hours [95]. The 
patient is 
switched to oral 
antimicrobial 
therapy for 2 
weeks (total). 
 
Ampicillin 2 grams, IV, 
q6h (+) Gentamicin 1.5-
1.7/mg/kg, IV, q6 h. 
 
Gentamicin 1.5-
1.7/mg/kg, IV, q8h 
Ampicillin-sulbactam 3 
grams, IV, q6 h. 
 
Ceftriaxone 1 gram, 
IV/IM, q24 h. 
 
Cefuroxime 0.75–1.5 
grams, IV, q8 h. 
 
Cefazolin 2 grams, IV, 
q6–8 h. 
 
Mezlocillin 3 grams, IV, 
q6 h. 
 
Piperacillin 4 grams IV q8 
h. 
 
Ticarcillin/clavulanate 3.1 
grams, IV, q6h. 
 
 
Ampicillin 
monotherapy 
showed high 
incidence of 
resistant bacteria, 
and therefore, 
usually is used in 
conjunction with 
gentamicin. 
To avoid 
exacerbation of the 
renal insufficiency 
that commonly 
accompanies 
pyelonephritis, drug 
serum levels should 
be monitored when 
using 
aminoglycosides, 
such as gentamicin 
[95]. 
 
 
Continuation of Table 1 
 18
2.2.2. Bacterial vaginosis 
 
2.2.2.1. Definition and microbiology 
 
Bacterial vaginosis (BV) is a polymicrobial, superficial vaginal infection in 
which the normal vaginal lactobacilli flora is replaced by anaerobic bacteria 
and mycoplasmas, including Gardenerella vaginalis, Fusobacterium spp., 
Prevotella spp., Pepostreptococcus spp., Porphyromonas spp., Bacteroides 
spp., Mobiluncus spp. and Mycoplasma hominis [96].  Although most of these 
organisms are present in small numbers in the normal vagina, Mobiluncus is 
rarely found and is a sensitive marker for the diagnosis of BV [96]. On the 
other hand, the presence of Gardnerella has been reported in up to 50% of 
women with no signs or symptoms of BV; therefore, the finding of this agent is 
not diagnostic for BV [96]. In fact, it seems that the decrease in the population 
of Lactobacillus spp. as opposed to the increase in other organisms, 
influences the vaginal flora and may be the most important predictor for 
subsequent BV development [62, 97]. 
 
2.2.2.2. Epidemiology of BV 
 
BV is a prevalent condition and the first cause of vaginitis during gestation 
[98]. Although the infection is present in almost 20% of pregnant women, it is 
difficult to know the exact prevalence of this condition, because many cases 
are asymptomatic or naturally occur at regular times during the menstrual 
cycle [96]. Most of the epidemiologic studies conducted to determine risk 
factors for BV, have concentrated on symptomatic cases and included results 
from women seeking care in STIs clinics or obstetric offices [62]. The current 
predictors of BV have been limited to race, sexual activity, socioeconomic 
status, and perhaps vaginal douching. African-American pregnant women 
showed 2.5-fold increased risk of BV when compared with white pregnant 
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women [99]. Women with lower socioeconomic status and women self 
reporting higher levels of psychosocial stress also have increased rates of BV 
[97]. Studies have found that early sexual activity, high number of lifetime 
sexual partners, and a prior sexually transmitted disease also increase the 
risk of BV [96]. Although sexually transmitted diseases and BV commonly 
coexist, BV is not considered a sexually transmitted disease [39]. It has been 
hypothesized that some behaviors, such as vaginal douching, could be 
potential risk factors for BV [100]. 
 
2.2.2.3. Clinical presentation of BV 
 
The metabolism of invasive microorganism in BV increases the production of 
volatiles aromatic amines (such as putrescin and cadaverin) resulting in the 
characteristic fishy odor discharge presented by the patients [39]. The 
infection is clinically characterized by the presence of three of the five 
following Amsel criteria [101]: release of the amine fishy odour, release of 
amine odour after addition of potassium hydroxide, vaginal pH greater than 
4.5, clue cells in the vaginal fluid and milky homogenous vaginal discharge. 
 
2.2.2.4. BV and pregnancy outcomes 
 
Previously considered a benign infection, BV has been related to many 
gynecologic conditions and complications of pregnancy including pelvic 
inflammatory disease (PID), post-hysterectomy vaginal cuff cellulitis, 
endometritis, amniotic fluid infection, preterm delivery, preterm labor, 
premature rupture of the membranes, and, possibly, spontaneous abortion 
[96, 102]. The presence of BV at a particular gestational age may be an 
indicator for subsequent development of pregnancy adverse outcomes. The 
risk may change based on BV positivity during different stages of gestation; 
the risk of preterm delivery due to BV in the first trimester, may be different 
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compared to the risk of preterm delivery in the second and third trimesters, 
when there is profuse placental functioning [96, 102].  
 
The biological pathway linking BV and adverse pregnancy outcomes has 
been extensively studied but it has not been completely elucidated [103]. It is 
admitted that vaginal flora in BV is able to produce endotoxins that rends 
some women more susceptible to initiate the cytokines and prostaglandins 
cascade that culminate in preterm labour [104]. Microorganisms causing BV 
may ascend and infect cervix, placenta, aminiotic fluid and produce proteolitic 
enzymes that may culminate in premature rupture of membranes [105]. It was 
already demonstrated that bacterial production of phospholipases, mucinases 
and sialidases is more proeminent in women with BV. Those enzymes could 
interfere with normal physiology of tissues, increasing the chance of PID 
installation, premature rupture of membranes, preterm labour, 
chorioamniotitis and other complications [106]. 
 
2.2.2.5. Treatment of BV during pregnancy 
 
Although BV is associated with adverse pregnancy outcomes, the only 
established benefit of therapy for BV in pregnant women is the reduction of 
signs and symptoms of vaginal infection [32]. Available evidence does not 
suggest any benefit in screening and treating asymptomatic pregnant women 
if the aim of therapy is to prevent preterm birth [107]. Therefore, treatment is 
only recommended for women with symptoms [108]. Because recurrence of 
BV is common, pregnant women should be advised to return for evaluation if 
symptoms recur. Therapeutic regimens include use of oral metronidazole or 
clindamycin [32].  
 
Topical intra-vaginal treatment with clindamycin is not recommended, given 
that the use of this drug is associated with an increased risk of low birth 
 21
weight and neonatal infections [32, 102, 109-111]. Metronidazole is an anti-
infective drug used against anaerobic organisms. This agent is able to cross 
the placenta throughout gestation, and data from animal studies suggests 
teratogenic properties for this drug [112]. However, there is no evidence that 
using metronidazole during pregnancy increases the rate of major birth 
defects or that there are any detectable adverse effects on fetuses [113]. 
Some studies suggest that the use of metronidazole during the last two 
trimesters of pregnancy may result in a qualitative imbalance of the normal 
vaginal flora [114, 115]. One of its consequences is the growth of harmful 
microorganisms, leading to ascending infection, stimulation of the local 
inflammatory process and early delivery. Therefore, the use of metronidazole 
during pregnancy has been controversial [113]. 
 
Table 2 summarizes most common therapeutic regimens currently proposed 
for the treatment of BV during pregnancy [32].  
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Table 2. Most common therapeutic regimens currently proposed for the 
treatment of BV during pregnancy (Abbreviations: po: by mouth; q: every; bid: twice a day; tid: three 
times a day; qid: four times a day; SXT: Trimethoprim/Sulfamethoxazole; IM: intramuscularly; IV: intravenously). 
 
Bacterial 
vaginosis 
Treatment 
regimen 
Treatment 
options 
Comments 
 
Metronidazole 
 
Current standard 
of practice is to 
treat pregnant 
patients who are 
symptomatic for 
BV with oral 
metronidazole. 
 
 
500 mg po bid for 
7 days. 
 
Metronidazole 
250 mg po tid for 
7 days. 
 
Topical 
treatments are 
not 
recommended. 
 
Multiple studies 
and meta-
analyses have 
not demonstrated 
an association 
between 
metronidazole 
use during 
pregnancy and 
birth defects. 
 
 
 
Clindamycin 
  
300 mg po tid for 
7 days. 
 
Topical use is not 
recommended. 
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2.3. RISKS OF ANTI-INFECTIVE DRUGS USE DURING PREGNANCY 
The rational use of anti-infective drugs during pregnancy is associated with 
an improvement of quality of live and decrease in the rates of maternal and 
fetal mortality [12]. However, as with the use of other medications, the 
potential benefits of use need to be weighed against the risk for the fetus [31]. 
Furthermore, a direct independent effect of the drug itself on pregnancy 
outcomes cannot be excluded. 
Some suggestions on the use of anti-infective drugs during pregnancy include 
[31]:  
• Use of anti-infectives only if absolutely indicated. This includes 
treatment of confirmed infection, prevention of ascending infection, and 
prevention of early-onset neonatal sepsis; 
• If possible, avoid the initiation of therapy during the first trimester of 
gestation; 
• Selection of a safe medication, which often means an older drug with a 
proven track record of safety in pregnancy; 
• Single-agent therapy is preferred over polypharmacy; 
• Narrow-spectrum agents are preferred over those with a broad 
spectrum for the treatment of established infection; 
• Use of the lowest effective dose. 
 
Most of the available evidence on the use of anti-infective drugs during 
pregnancy was devoted to their potential teratogenic properties [33]. 
Teratogenesis is defined as the structural or functional dysgenesis of fetal 
organs. The typical manifestations of teratogenesis are restricted growth or 
death of the fetus, carcinogenesis, and congenital malformations, which are 
defined as defects in organ structure or function. These malformations may 
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vary in severity, with the most severe being life threatening or requiring major 
surgery [116].  
 
A wide range of anti-infective agents is now available and teratogenic effects 
have been proved for relatively few [33]. However, only some classes of 
compounds have shown to be completely safe in regards to other pregnancy 
outcomes [31]. In addition, most clinicians felt that current resources and 
information about these medications are not adequate, and that their training 
on this topic at the undergraduate and postgraduate level is insufficient [117].  
 
The following sections summarize the available evidence on the risk of there 
relevant adverse outcomes after gestational exposure to anti-infectives: 
congenital malformations, preterm birth and small for gestational age 
newborns.  
 
2.3.1. Anti-infective drugs and the risk of congenital malformations 
 
Several observational studies have been conducted to evaluate the 
association between anti-infective drugs during pregnancy and the risk of 
congenital malformations. Considering the low prevalence of this adverse 
outcome in the general population (1 to 3%) [118, 119], the majority of these 
studies had small sample sizes, and hence, lack statistical power to assess 
risk of specific malformations groups (see Table 3 for sample size 
information).  
 
Penicillins and other beta-lactams have not shown to be teratogenic in 
humans [56]. Jepsen et al. [120] analyzed pregnancy outcomes after 
exposure to amoxicillin in a cohort of pregnant women obtained from 
population-based registries in Denmark. The authors did not find any 
increased risk of congenital malformations associated with amoxicillin 
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exposure during pregnancy (OR= 1.16, 95% CI: 0.54-2.50). Czeizel et al. 
[121] found similar results in a case-control study that investigated the risk of 
congenital abnormalities after exposure to cephalosporins (OR= 1.3, 95%CI: 
0.9-1.8). No significant increase in the risk was found in another cohort of 
women exposed to cefuroxime during the first trimester [122] (RR=1.56, 
95%CI: 0.27-9.15). Furthermore, the same team conducted a similar study 
with women exposed to amoxycillin/clavulanic acid, and again, no evidence of 
birth defects was detected (RR= 0.62, 95%CI: 0.15-2.55) [123].  
 
Evidence of safety is also available for macrolides. A prospective multicentre 
study on the use of clarithromycin during pregnancy, conducted by Einarson 
et al. [124], compared women exposed to this agent during the first trimester 
of pregnancy to women exposed to other antibiotics. There were no 
significant differences between the two groups in the rates of major and minor 
malformations; 2.3 versus 1.4% for major (p= 0.86) and 5.4 versus 4.9% for 
minor (p = 0.96). Czeizel et al. [125, 126] evaluated the human teratogenic 
potential of oral use of erythromycin, spiramycin, roxithromycin, oleandomycin 
and josamycin treatment during pregnancy in a population-based dataset of 
the Hungarian Case-Control Surveillance of Congenital Abnormalities. Data 
were available for 38 151 subjects and no evidence of increased risk was 
found (OR= 1.1, 95% CI: 0.9-1.4).  Congenital malformations after exposure 
to azithromycin was also evaluated in a more recent cohort study [127]. The 
results showed no statistically significant rates of major malformations, 
suggesting that gestational exposure to azithromycin is not associated with 
an increase rate of birth defects (p value= 0.89). Exposure to azithromycin, 
clarithromycin and roxithromycin during the first trimester of pregnancy was 
not associated with an increased risk of birth defects in another cohort study 
conducted in Israel by Bar-Oz et al. [128]. Exposure to roxithromycin alone 
had been previous evaluated in a smaller cohort study conducted by Chun et 
al. and no evidence of risk was detected. The authors did not observe any 
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major malformation in the exposed group whereas three cases were detected 
(1.8%) in the non-exposed group [129]. 
Given the potential impacts of UTIs during pregnancy, the safety of anti-
infective drugs used to treat this condition was extensively studied. One of the 
first prospective cohort studies lead by Nesbitt et al. [130] did not show 
evidence of birth defects after exposure to nitrofurantoin (RR= 1.36, 95% CI: 
0.037-70). Heiley et al. [131] analyzed data issued from medical records, and 
also found no significant evidence of risk after exposure (RR= 1.98, 95% CI: 
0.11-35.1). Same conclusion was obtained in a meta-analysis of 
observational studies that assessed the risk of birth defects after exposure to 
nitrofurantoin during the first trimester of gestation (OR= 1.29, 95%CI: 0.25-
6.57) [132].  More recent evidence corroborates previous data, and current 
consensus is that nitrofurantoin is safe in what concerns congenital 
malformations [133]. However, these studies lack statistical power to detect 
no association. Furtheremore, this agent can induce hemolytic anemia in the 
fetus or newborn, particularly in those with glucose-6-phosphate 
dehydrogenase deficiency [134].  
Trimethoprim-sulfamethoxazole (TMP-SMX) is another medication widely 
used to treat UTIs. Sulfonamides as a group do not appear to pose a serious 
teratogenic threat; a study conducted by Ratanajamit et al. found no evidence 
of birth defects after exposure to sulfamethizole (OR= 1.17, 95% CI:  0.95-
1.43) [135]. The same study, however, indicate a non-significant increased 
risk of miscarriage after exposure to this agent (OR=1.66, 95% CI: 0.92-2.99). 
Trimethoprim is a folic acid antagonist and its use during the first trimester 
has been associated with structural defects, such as neural tube and 
cardiovascular defects [35]. Furtheremore, there is an increased risk of 
kernicterus in the fetus if TMP-SMX is administered during the last six weeks 
of pregnancy [35]. 
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Quinolones and fluoroquinolones are also commonly used for the treatment 
of UTIs. The association between fluoroquinolones and arthropathy, although 
observed in animals models and rarely reported in humans, has resulted in 
the restricted use of these drugs during pregnancy [33]. As a consequence, 
the safety of these drugs has been explored in a number of studies. 
Berkovitch et al. investigated the effect of gestational exposure to norfloxacin 
and ciprofloxacin on the musculoskeletal development of the fetus and found 
no increased risk of malformations or musculoskeletal defects [36]. Data from 
a prospective follow-up study conducted on the European Network of 
Teratology Information Services, showed no specific patterns of congenital 
abnormalities after exposure to quinolones [136]. A comparison of 
ciprofloxacin, norfloxacin, and ofloxacin, was examined by a observational 
cohort study conducted by Wilton et al. furnishing the same conclusion [137].  
 
A multicenter prospective controlled study concluded that the use of 
fluoroquinolones during embryogenesis is not associated with an increased 
risk of major malformations (RR= 0.85; 95% CI: 0.21-3.49). There were no 
clinically significant musculoskeletal dysfunctions in children exposed to 
fluoroquinolones in utero [138]. Larsen et al. using administrative data, found 
no significant risk of congenital anormalities, after exposure to such drugs 
(RR= 1.30, 95% CI: 0.30-5.30) [139]. A large case-control study conducted by 
Czeizel et al. using data from the Hungarian Case-Control Surveillance of 
Congenital Abnormalities found a higher prevalence of pyloric stenosis in 
seven infants born from mothers who received nalidixic acid treatment during 
the last months of pregnancy (OR= 11.0, 95% CI: 1.3-91.4) [140]. The 
authors however, did not assess use during the first trimester of gestation. 
Therefore, most of the available evidence seems to indicate absence of 
teratogen properties for these drugs. Nevertheless, because of the relatively 
higher cost of these agents and the concern about the bacterial resistence 
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with frequent use, fluoroquinolones should not routinely be employed as first-
line agents in uncomplicated UTIs [8]. 
 
Aminoglycoisdes antibiotics (streptomycin, gentamicin, neomycin, amikacin, 
tobramycin, kanamycin) have been classically associated to congenital nerve 
deafness in animal models. Both vestibular and auditory irreversible 
dysfunction can follow administration of these agents [141]. Some case series 
and case reports associated deafness in children born to women who 
received streptomycin during pregnancy [142, 143]. However, most of the 
evidence issued from observational data in humans did not show a clear 
increase in the risk [33, 144]. The most recent evidence on the subject was 
lead by De Hoog et al. [145], that did not find any association between 
exposure to  tobramycin and vancomycin during pregnancy and the risk of 
hearing loss in neonates.  
      
Tetracyclines are able to cross the placenta and to cause straining of the 
deciduous teeth [146]. Consequently, the risk is apparent only after 4 to 5 
months gestation when the deciduous teeth begin to calcify. It appears that 
the risk of staining teeth is lower for doxycycline [147]. A statistical 
association was found for minor malformations after exposure to tetracycline 
in the first trimester of gestation [148]. A report from the Hungarian 
surveillance group identified 56 malformed infants whose mothers had used 
doxycycline during pregnancy [149]. A case–control study using this 
population showed a significantly increased risk when total malformations 
combined were considered (OR= 1.6, 95% CI: 1.1-2.3).  However, when each 
group of malformation was evaluated separetelly, no risk was detected [149]. 
A more recent case–control study from the same group examining the 
possible teratological effect of oxytetracycline found an increased risk of a 
combination of neural tube defects and cardiovascular malformations (OR= 
12.9; 95% CI 3.8-44.3) [150]. 
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The same Hungarian surveillance group evaluated safety of chloramphenicol 
and metronidazole [151, 152]. These case-control analyses did not show any 
human teratogenic potential of the use of these drugs during the first trimester 
of pregnancy in the different groups of congenital abnormalities. Exposure to 
metronidazole was also evaluated with data from the Israeli Teratogen 
Information Service and no evidence of increased risk of birth defects was 
found [153]. Previous evidence from cohort studies also failed to demonstrate 
evidence of risk after exposure to this drug (RR= 1.2, 95% CI: 0.9-1.6) [154]. 
 
Two recent studies analyzed the risk of major congenital malformation for 
several types of anti-infective drugs at the same time. A retrospective cohort 
study using data from the Tennessee Medicaid program conducted by 
Cooper et al. [155] identified children with fetal exposures to ciprofloxacin, 
azithromycin, doxycycline, amoxicillin and compared their outcomes to 
children exposed to erythromycin during gestation and with infants with no 
fetal exposure to any antibiotics. Overall, 2.9% of children in the cohort had a 
confirmed major congenital malformation (range 2.5% to 3.0%). No increased 
risk was present in multivariable analyses for any malformations and for 
malformations of specific organs. In addition, Crider et al. conducted a case-
control study of women who had pregnancies affected by major birth defects 
[156]. In adjusted models, sulfonamides were associated with anencephaly 
(OR= 3.4, 95% CI: 1.3-8.8), hypoplastic left heart syndrome (OR= 3.2, 95% 
CI: 1.3-7.6), coarctation of the aorta (OR= 2.7, 95% CI: 1.3-5.6), choanal 
atresia (OR= 8.0, 95% CI: 2.7-23.5), transverse limb deficiency (OR= 2.5, 
95% CI: 1.0-5.9), and diaphragmatic hernia (OR= 2.4, 95% CI: 1.1-5.4). In the 
same study, nitrofurantoin was associated with anophthalmia or 
microphthalmos (OR= 3.7, 95% CI: 1.1-12.2), hypoplastic left heart syndrome 
(OR= 4.2, 95% CI: 1.9-9.1), atrial septal defects (OR= 1.9, 95% CI: 1.1-3.4), 
and cleft lip with cleft palate (OR= 2.1, 95% CI: 1.2-3.9).  
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Fluconazole was not associated with an increase in the risk of birth defects in 
a cohort study conducted by Mastroiacovo et al. (RR= 1.07, 95%CI:  0.41-
2.77) [157]. Low statistical power and residual confounding was probable 
responsible for their results, and current consensus is that this drug should be 
used as a last alternative when no other choices are available.  
 
The teratogenic risk of 11 broad-spectrum antibiotics commonly used during 
pregnancy and lactation was summarized in a meta-analysis of one hundred 
twenty-four references [20]. The authors ranged the teratogenic potential for 
humans from "none" (penicillin G and VK) to "unlikely" (amoxicillin, 
chloramphenicol, ciprofloxacin, doxycycline, levofloxacin, and rifampin) to 
"undetermined" (clindamycin, gentamicin, and vancomycin). Assessments of 
risk were based on "good data" (penicillin G and VK), "fair data" (amoxicillin, 
chloramphenicol, ciprofloxacin, doxycycline, levofloxacin, and rifampin), 
"limited data" (clindamycin and gentamicin), and "very limited data" 
(vancomycin).  
 
A summary of these studies is presented in Table 3. 
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Table 3. Summary of the studies on the association between the use of anti-infective drugs during pregnancy and 
the risk of birth defects. 
 
Authors, year 
and country 
Study 
design 
Class or type 
of anti-
infective drug
Number of 
exposed 
subjects 
(prevalence 
of 
outcome) 
Exposure 
window 
Outcome of 
interested 
Measure of 
effect 
(RR, OR or p 
values) 
 
Aminoglycosides 
 
Leroux, 1950, 
France [142] 
Case series – 
Prospective 
cohort 
Streptomycin 01  
(100%) 
Last month 
of 
gestation 
 
Congenital 
nerve 
deafness 
* 
Robinson and 
Combon, 
1964, USA 
[143] 
 
Case series - 
Prospective 
cohort 
Streptomycin 02  
(100%) 
First 
trimester of 
gestation 
 
Congenital 
nerve 
deafness 
* 
Conway and 
Birt, 1965, 
USA [144] 
 
 
 
Case series - 
Prospective 
cohort 
 
Streptomycin 24  
(25%) 
All 
gestation 
 
Congenital 
malformations 
* 
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Beta-Lactams 
 
Czeizel et al., 
2001, Hungary 
[121] 
Case-control 
study – 
Adminis-
trative 
database 
 
Cephalos-
porins 
51 
(5%) 
Second 
and third 
months of 
gestation 
 
Major and 
minor 
congenital 
malformations 
OR= 1.3  
(0.9-1.8) 
Jepsen et al., 
2003, 
Denmark [120] 
Case-control 
study - 
Adminis-
trative 
database 
 
Amoxicillin 401 
(3%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
RR= 1.16  
(0.54- 2.50) 
Berkovitch et 
al., 2004, 
Israel [122] 
Prospective 
cohort study 
Amoxycillin/ 
clavulanic acid
191 
(3%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
RR= 0.62  
(0.15-2.55) 
 
Macrolides 
 
Einarson et al., 
1998, Canada 
[124] 
Prospective 
cohort study 
Clarithromycin 127 
(3%) 
First 
trimester of 
gestation 
Major and 
minor 
congenital 
malformations 
 
P= 0.86 
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Czeizel et al., 
1999, Hungary 
[126] 
Case-control 
study - 
Adminis-
trative 
database 
 
Erythromycin 113 
(4%) 
Second 
and third 
months of 
gestation 
 
Major and 
minor 
congenital 
malformations 
OR= 0.8  
(0.5-1.4) 
Czeizel et al., 
2000, Hungary 
[125] 
Case-control 
study - 
Adminis-
trative 
database 
 
Spiramycin, 
roxithromycin, 
oleandomycin 
and josamycin
31 
(4.5%) 
Second 
and third 
months of 
gestation 
 
Major and 
minor 
congenital 
malformations 
OR= 1.1  
(0.9-1.4) 
Chun et al., 
2006, South-
Koreal [129] 
 
Prospective 
cohort study 
Roxithromycin 20 
(0%) 
First 
trimester of 
gestation 
Major 
congenital 
malformations 
Not available  
Sarkar et al., 
2006, Canada 
[127] 
Prospective 
cohort study 
Azithromycin 123 
(4%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
p= 0.42 
Baz-Oz et al., 
2008, Israel 
[128] 
 
 
 
 
 
 
Case-control 
study - 
Adminis-
trative 
database 
 
Macrolides 161 
(4%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
OR= 1.41 
(0.47-4.23) 
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Quinolones 
 
Berkovitch et 
al., 1994, 
Canada [36] 
Retrospective 
cohort study - 
Adminis-
trative 
database 
Norfloxacin 
and 
ciprofloxacin 
38  
(3%) 
First 
trimester of 
gestation 
Congenital 
malformations 
of the 
muskulo-
skeletical 
system 
P= 0.5 
Schaefer et 
al., 1996, 
Germany [136] 
Prospective 
follow-up 
study 
Quinolones 549  
(4.8%) 
First 
trimester of 
gestation 
Major and 
minor 
congenital 
malformations 
 
Not available 
Loebstein et 
al., 1998, 
Canada [138] 
Prospective 
cohort study 
Quinolones 200 
(3.5%) 
First 
trimester of 
gestation 
Congenital 
malformations 
of the 
muskuloskeleti
cal system 
RR= 0.85  
(0.21-3.49) 
Larsen et al., 
2001, 
Netherlands 
[139] 
 
 
 
 
 
 
Retrospective 
cohort study 
Fluoro-
quinolones 
57 
(3.8%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
RR= 1.30  
(0.30-5.30) 
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Tetracyclines 
 
Czeizel and 
Rockenbauer, 
1997, Hungary 
[149] 
Case-control 
study - 
Adminis-
trative 
database 
 
Doxycycline 56  
(4%) 
All 
gestation 
Major and 
minor 
congenital 
malformations 
 
OR= 1.6  
(1.1-2.3) 
Czeizel and 
Rockenbauer, 
2000, Hungary 
[150] 
Case-control 
study - 
Adminis-
trative 
database 
 
Oxy-
tetracycline 
216 
(4.5%) 
Second 
and third 
months of 
gestation 
 
 
 
 
 
 
Neural-tube 
defects 
OR= 9.7  
(2.0-47.1) 
 
Urinary anti-infectives 
 
Nesbit and 
Young, 1957 
[130] 
Retrospective 
cohort study 
Nitrofurantoin 30  
(4%) 
First 
trimester of 
gestation 
 
Congenital 
malformations 
RR= 1.36  
(0.03-70) 
Hailey et al., 
1983, USA 
[131] 
 
Retrospective 
cohort study 
Nitrofurantoin 
macrocrystals 
29  
(5%) 
First 
trimester of 
gestation 
 
Congenital 
malformations 
RR= 1.98  
(0.11-35.1) 
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Ben David et 
al., 1995, 
Canada [132] 
Meta-
analysis 
Nitrofurantoin 157  
(4%) 
First 
trimester of 
gestation 
Major and 
minor 
congenital 
malformations 
 
OR= 1.29  
(0.25-6.57) 
Czeizel et al., 
2001, Hungary 
[133] 
Case-control 
study 
Nitrofurantoin 1079 
(4.5%) 
Second 
and third 
months of 
gestation 
 
Major and 
minor 
congenital 
malformations 
OR= 1.3  
(1.0-1.7) 
Czeizel et al., 
2001, Hungary 
[140] 
Case-control 
study - 
Adminis-
trative 
database 
 
Nalidixic acid 242 
(4%) 
Third 
trimester of 
gestation 
 
Pyloric 
stenosis 
OR= 11.0  
(1.3-91.4) 
Ratanajamit et 
al., 2003, 
Denmark [135] 
Case-control 
study - 
Adminis-
trative 
database 
 
Sulfamethizole 3484 
(3.5%) 
30 days 
before 
conception
 
Major 
congenital 
malformations 
OR= 1.17  
(0.95-1.43 
Crider et al., 
2009, USA 
[156] 
Case-control 
study - 
Adminis-
trative 
database 
 
 
Sulfonamides 
and 
nitrofurantoin 
13155 Third 
month of 
gestation 
30 selected 
malformations 
Several 
measures of 
effect 
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Metronidazole 
 
Piper et al., 
1993, USA 
[154] 
Retrospective 
cohort study 
Metronidazole 1387  
(3.8%) 
First 
trimester of 
gestation 
Congenital 
malformations 
RR= 1.2 
(0.9-1.6) 
 
Czeizel and 
Rockenbauer, 
1998, Hungary 
[151] 
Case-control 
study - 
Adminis-
trative 
database 
 
Metronidazole 1706 
(4.5%) 
First 
trimester of 
gestation 
Major and 
minor 
congenital 
malformations 
 
OR= 1.14 
(0.89-1.46) 
 
Diav-Citrin et 
al., 2001, 
Israel [153] 
Prospective 
cohort study 
Metronidazole 205 
(3.7%) 
First 
trimester of 
gestation 
 
Major 
congenital 
malformations 
RR= 1.13 
(0.30–4.23) 
 
 
Others 
 
Mastroiacovo 
et al., 1995, 
Italy [157] 
Prospective 
cohort study 
Fluconazole 226 (2.8%) First 
trimester of 
gestation 
 
Any congenital 
malformation 
RR= 1.07  
(0.41-2.77) 
Wilton et al., 
1996, UK [137] 
Prescription-
event 
monitoring 
Quinolones, 
azithromycin 
and cefixime 
307 (4%) Not 
available 
Major and 
minor 
congenital 
malformations 
 
* 
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Czeizel et al., 
2000, Hungary 
[152] 
Case-control 
study - 
Adminis-
trative 
database 
 
Chloram-
phenicol 
52 
(4.0%) 
Second 
and third 
months of 
gestation 
 
Major and 
minor 
congenital 
malformations 
OR= 3.1 
(1.2-7.7) 
Cooper et al., 
2009, USA 
[155] 
Retrospective 
cohort study - 
Adminis-
trative 
database 
Ciprofloxacin, 
azithromycin, 
doxycycline 
and amoxicillin
 
2128 
(4.5%) 
First 
trimester of 
gestation 
Major 
congenital 
malformations 
RR= 1.29  
(0.96-1.73) 
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2.3.2. Use of anti-infective drugs and the risk of preterm birth 
2.3.2.1. Definition of preterm birth 
Preterm birth is defined as childbirth occurring at less than 37 completed 
weeks or 259 days of gestation [158]. Preterm births can be subdivided 
according to gestational age: about 5% of preterm births occur at less than 28 
weeks’ (extreme prematurity), about 15% at 28–31 weeks’ (severe pre 
maturity), about 20% at 32–33 weeks’ (moderate pre maturity), and 60–70% 
at 34–36 weeks’ (near term) [158]. Preterm birth can also be classified in 
spontaneous preterm birth (births that follow spontaneous labour or 
premature rupture of membranes) or medically indicated preterm birth (where 
a medical or obstetrical condition exists that places the mother or the fetus at 
risk) [159]. 
 
2.3.2.2. Epidemiology of preterm birth 
 
Preterm birth rate has been increasing in many countries. In 2005, it was 
estimated that 12.9 million births (9.6% of all births worldwide), were preterm. 
Approximately 85% of these preterm births were concentrated in Africa and 
Asia, while about 0.5 million occurred in Europe and North America and 0.9 
million in Latin America and the Caribbean. The highest rates of preterm birth 
are in Africa and North America (11.9% and 10.6% of all births, respectively), 
and the lowest were in Europe (6.2%) [160]. The incidence of preterm birth in 
Canada increased from 6.6% of live births in 1991, to 7.6% in 2000 [161]. In 
2008, the prevalence of preterm birth in Canada was 8.2% [162]. 
 
About 30–35% of preterm births are indicated, 40–45% follow spontaneous 
preterm labour, and 25–30% follow premature rupture of membranes (PROM) 
[158]. Spontaneous preterm birth is most commonly caused by preterm 
labour in white women, but by PROM in black women [163]. Risk factors for 
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preterm birth are multifactorial and vary by gestational age, geographic and 
ethnic contexts. Predictors for preterm birth include diverse maternal factors 
and clinical diagnoses [159, 161]. The clinical diagnoses that predispose to 
preterm delivery may be obstetrical (pre-eclampsia, placental abruption, 
placenta previa or polyhydramnios) or medical (diabetes and hypertension) 
[161, 164]. A short interpregnancy interval also increases the risk of preterm 
delivery [165-167]. Other maternal factors include low socioeconomic status, 
low body-mass index (BMI), age, stress, smoking, and a history of preterm 
birth, or of induced abortion [159, 164, 168]. In addition, there is increasing 
evidence of the association between maternal infections and preterm delivery 
[169-171]. 
 
2.3.2.3. Consequences of preterm birth 
 
Premature children have higher rates of cerebral palsy, sensory deficits, 
learning disabilities and respiratory illnesses compared with children born at 
term [83]. The morbidity associated with preterm birth often extends to later 
life, resulting in enormous physical, psychological and economic costs [172]. 
Estimates indicate that in 2005 the costs to the United States in terms of 
medical and educational expenditure and lost productivity associated with 
preterm birth were more than US$ 26.2 billion [173]. Of all early neonatal 
deaths (deaths within the first 7 days of life) that are not related to congenital 
malformations, 28% are due to preterm birth [160]. 
 
2.3.2.4. Interventions for preterm birth 
 
Interventions to reduce the morbidity and mortality related to preterm birth can 
be classified as primary (directed to all women before or during pregnancy), 
secondary (aimed to eliminate or reduce the risk in women with known risk 
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factors), or tertiary (initiated after the parturitional process has begun, with a 
goal of preventing delivery or improving outcomes for preterm infants) [174].  
 
Most interventions intended to reduce preterm birth do not show consistent 
benefit when tested rigorously in randomized trials. A recent review has 
highlighted the evidence for interventions directed addressed to the mother 
[175]. Approximately 2000 studies were evaluated, and only 2 specific 
interventions were found to be effective in preventing preterm birth: smoking 
cessation and progesterone therapy for women at higher risk. A recent 
Cochrane review demonstrated that smoking cessation during pregnancy 
reduced preterm birth (RR= 0.86, 95% CI: 0.74-0.98) [176]. An extensive 
review of these interventions is beyond the scope of this thesis. Table 4 
summarizes main interventions for preterm birth [83, 174, 177, 178].  
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Table 4. Interventions for preterm birth. 
 
 
 
Type of intervention Comments 
 
Primary interventions 
 
Pre-conceptional 
primary prevention 
 
• Public educational 
interventions. 
• Public and professional 
policies. 
• Nutritional 
supplementation for 
women planning their 
pregnancy. 
• Smoking cessation 
programs. 
 
• Some authors 
consider these 
strategies attractive 
because many risk 
factors are difficult to 
address during 
pregnancy.  
 
• Primary prevention is 
an increasingly 
compelling strategy 
as the limitations of 
tertiary care become 
evident. 
  
Primary prevention 
during pregnancy 
• Nutritional / multivitamins 
supplements during 
pregnancy. 
• Smoking cessation 
programs adressed for 
pregnant women. 
• Prenatal care. 
• Periodontal care. 
• Screening of low-risk 
women. 
 
 
 
 
 
• Screening for 
asymptomatic 
bacteriuria, 
cervicovaginal fetal 
fibronectin, and 
ultrasonographic 
measurement of 
cervical length. 
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Secondary interventions 
Pre-conceptional 
interventions 
• Obstetric history of 
previous preterm birth. 
 
 
 
 
 
 
 
• These interventions 
are addressed to 
women with evident 
risk of preterm birth 
on the basis of either 
obstetric history or 
present other risk 
factors. 
Post-conceptional 
interventions 
 
 
 
• Secondary prevention of 
indicated preterm birth. 
• Secondary prevention of 
spontaneous preterm birth. 
• Modification of maternal 
activity. 
• Nutritional 
supplementation. 
• Improved care for women 
at risk. 
• Antibiotic treatment. 
• Progesterone treatment. 
• Cervical cerclage. 
 
• There is controversy 
over antibiotic 
treatment in women 
with a previous 
preterm birth who are 
reported to have 
bacterial vaginosis. 
 
Tertiary interventions 
Tertiary interventions for 
women with immediate 
risk of preterm birth 
• Early diagnosis of preterm 
labour. 
• Treatment of women with 
acute risk of preterm birth. 
• Tocolysis. 
• Care after preterm 
premature rupture of the 
fetal membranes. 
• Care after acute treatment 
for preterm labour. 
• Delivery of preterm infants. 
 
• These interventions 
are based n the 
detection of 
conditions proximate 
to preterm birth such 
as uterine 
contractions, rupture 
membranes, and 
vaginal spotting or 
bleeding. 
 
 
Continuation of Table 4 
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2.3.2.5. Role of maternal infections in the genesis of preterm birth 
 
Preterm labour is now thought to be a syndrome initiated by multiple 
mechanisms, including infection or inflammation, uteroplacental ischaemia or 
haemorrhage, uterine overdistension, stress, and other immunologically 
mediated processes [158]. An ascending infection from the lower genital tract 
is thought to be the source of most intrauterine infections [179]. Once bacteria 
are in contact with placental tissues, a pro-inflammatory response can be 
initiated which leads to preterm labour. The inflammatory mediators 
implicated in preterm birth include interleukin-1b, interleukin-6, interleukin-8 
and tumour necrosis factor-alpha [180, 181]. Other important inflammatory 
mediators of infection-induced preterm labor include prostaglandins and 
matrix metalloproteinases, which enhance myometrial contractility and 
weaken the collagen structure of the membranes, respectively [182]. Human 
studies in pregnant women have not adequately clarified a temporal 
relationship between these inflammatory mediators and the onset of preterm 
birth. This would allow the study of the pathophysiology of preterm birth and 
lead to opportunities for preventative and therapeutic discovery [83]. 
 
2.3.2.6. Anti-infective treatment as intervention to prevent preterm birth 
 
During the last 20 years, several trials and observational studies were 
conducted to evaluate the efficacy of the interventions based on the use of 
anti-infective drugs to prevent preterm birth. These interventions can be 
classified as follows: I- Anti-infective treatment for preventing preterm birth 
with intact membranes in women with or without BV and II- Anti-infective 
treatment for preventing preterm birth in pregnant women with preterm 
premature rupture of membranes (PPROM). 
 
 45
In 1989, Newton et al. conducted one of the first studies addressing the use 
of anti-infective agents to prevent preterm birth in pregnant women with intact 
membranes [183]. The authors compared the efficacy of adjunctive therapy 
with intravenous ampicillin plus oral erythromycin in 103 women requiring 
parenteral tocolysis and with intact membranes. Compared with the placebo 
group, the adjunctive antibiotic group had a similar frequency of preterm birth 
(38% versus 44%), time to delivery (34 versus 34 days), and episodes of 
recurrent labor requiring parenteral tocolysis (0.43 versus 0.49). However, no 
significant benefit of this intervention in reducing the risk of preterm birth was 
demonstrated (RR= 0.84, 95%CI: 0.52-1.36).  
 
Use of erythromycin and ampicillin was further evaluated in three different 
trials conducted by Eschenbach et al., [184], Newton et al. [185] and Romero 
et al., [186]. In the first study, pregnant women infected with Ureaplasma 
urealyticum were randomized to receive 333 mg of erythromycin or placebo 
three times daily, starting between 26 and 30 weeks' gestation and continuing 
through 35 completed weeks. There were no significant differences between 
erythromycin and placebo-treated women in gestational age at delivery (RR= 
1.02, 95%CI: 0.70-1.48). Furthermore, there were no significant differences 
between erythromycin and placebo-treated women in infant birth weight, 
frequency of premature rupture of membranes, or neonatal outcome.  
 
Same results were found in the second trial [185]. No differences were noted 
between placebo (n= 43) and study patients (n= 43) in gestational age at 
delivery, term deliveries, or neonatal outcome. Adjunctive ampicillin-
sulbactam with indomethacin did not decrease the risk of preterm birth (RR= 
0.85, 95%CI: 0.59-1.22). The third trial enrolled 277 women with singleton 
pregnancies and preterm labor with intact membranes (24 to 34 weeks), and 
randomly allocated them to receive either antibiotics or placebo (n= 133 for 
antibiotics group vs n= 144 for placebo group). No significant difference 
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between the treatment group and the placebo group was found in maternal 
outcomes, including duration of randomization-to-delivery interval, frequency 
of preterm delivery (< 37 weeks), frequency of preterm premature rupture of 
membranes, clinical chorioamnionitis, endometritis, and number of 
subsequent admissions for preterm labor. The authors concluded that there is 
no support the routine use of antibiotic administration to women in preterm 
labor with intact membranes (RR= 1.02, 95%CI: 0.82-1.29).  
 
Intravenous treatment with another beta-lactam drug, mezlocillin in 
association with and erythromycin was compared to tocolytic treatment in 
women in preterm labor [187]. Women in the antibiotic group had a 
significantly lower incidence of postpartum infections compared with women 
in the placebo group. However, the study did not show antibiotic effect on the 
gestational age at delivery (RR= 0.87, 95%CI: 0.49-1.52).   
 
In a prospective, randomized, double-blinded, placebo-controlled trial, 
Gordon et al. [188] determined the effect of ceftizoxime in the prolongation of 
117 pregnancies receiving tocolysis for preterm labor. The groups consisted 
of women receiving either 2 g of ceftizoxime (n= 58) or a placebo (n= 59) 
every 8 hours. The primary end point of this study was prolongation of 
gestation. The authors found no effect of ceftizoxime on time to delivery or 
duration of pregnancy in women treated for preterm labor (RR= 1.05, 95%CI: 
0.77-1.42).  
 
Cox et al. [189]  assessed the efficacy of ampicillin-sulbactam and amoxicillin-
clavulanic acid in women hospitalized for preterm labor between 24 and 34 
weeks of gestation. Thirty-nine women with preterm labor received 
antimicrobial therapy and 39 received placebos. The mean gestational ages 
at delivery were 34.2 +/- 0.7, for the treatment group and 34.1 +/- 0.6 weeks 
for the placebo group. The authors concluded that treatment with ampicillin-
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sulbactam and amoxicillin-clavulanic acid is ineffective in the prevention of 
preterm birth (RR= 1.05, 95%CI: 0.71-1.53).  
 
The effect of amoxicillin was further investigated in another trial conducted by 
Oyarzún et al. [7].  The authors randomly allocated 196 women with singleton 
pregnancies and preterm labor with intact membranes (22-36 weeks) to 
receive antibiotics or placebo, plus adjunctive parenteral tocolysis. From this 
total, 173 patients (treatment group n= 83 vs. placebo group n= 90) 
completed the treatment. The use of amoxicillin and erythromycin in 
association did not prolong pregnancy in patients with preterm labor and 
intact membranes (RR= 0.92, 95%CI: 0.67-1.25).  
 
The ORACLE II trial, conducted by Kenyon et al., [190], randomly assigned 
6295 women in spontaneous preterm labour with intact membranes to 
receive 250 mg of erythromycin (n= 1611), 325 mg of co-amoxiclav (n= 
1550), both (n= 1565) or placebo (n= 1569) four times daily for 10 days or 
until delivery, whichever occurred first. Intention to treat analysis did not show 
benefit of treatment in the prevention of preterm birth (RR= 1.0, 95%CI: 0.93-
1.08). The previous ORACLE I trial showed a decreased risk of preterm birth 
in women exposed to erythromycin [191]. However, contrary to the 
participants in the ORACLE II, women enrolled in the ORACLE I trials had 
PPROM. At that time, the ORACLE trials and were the largest and most 
ambitious perinatal trials ever funded and results clearly indicated that only 
women with PPROM would benefit from therapy.  
 
In 1994, Norman et al. [192] conducted the first trial showing the benefit of 
treatment with antibiotics to prevent preterm birth in women with intact 
membranes. The study group (n= 43) received ampicillin and metronidazole 
for five days. The control group (n=38) received no antibiotics. In those 
receiving ampicillin and metronidazole the pregnancy was significantly 
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prolonged (median 15 days versus 2.5 days, p= 0.04) with significantly more 
women still pregnant after seven days (63% versus 37%, p= 0.03). In this 
study, the adjuvant use of ampicillin and metronidazole in the management of 
women in preterm labour significantly prolonged duration of pregnancy (RR= 
0.34, 95%CI: 0.13-0.94). In that same year, Morales et al. also showed 
benefit of treatment with 250 mg of metronidazole in 44 women diagnosed 
with BV and with preterm birth in preceding pregnancy (RR= 0.41, 95% CI: 
0.20-0.85) [193]. Compared to the placebo group, patients in the 
metronidazole group had significantly fewer hospital admissions for preterm 
labor (27% versus 78%), preterm births (18% versus 39%) and premature 
rupture of membranes (5% versus 33%). 
 
The potential benefit of metronidazole showed by these studies leaded to the 
conduction of several trials that evaluated the efficacy of this drug during 
gestation. In 1995, Hauth et al. [194] randomized 624 pregnant women with 
BV to receive treatment with metronidazole plus erythromycin (n= 433) or 
placebo (n= 191) during the second trimester of gestation. Twenty-six percent 
of women assigned to metronidazole and erythromycin delivered prematurely, 
as compared with 36% assigned to placebo (p= 0.01). However, the 
association between the study treatment and lower rates of preterm birth was 
observed only among women with BV (RR= 0.72, 95%CI: 0.56-0.93).  
 
Another double-blind controlled trial with 112 women conducted by Svare et 
al., showed the same results when eight days intravenous and oral treatment 
with metronidazole was used in association with ampicillin [195]. When 
compared to placebo, treatment was associated with a significant 
prolongation of pregnancy (admission to delivery 47.5 days versus 27 days, p 
< 0.05), higher gestational age at delivery (37 weeks versus 34 weeks, p < 
0.05, RR= 0.65, 95%CI: 0.46-0.94), and decreased incidence of preterm birth 
(42% versus 65%, p < 0.05). 
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However, more recent trials that evaluated use of metronidazole alone did not 
show evidence of benefit. In 1997, McDonald et al. designed a multicentre, 
randomised, placebo-controlled trial to ascertain whether metronidazole 
treatment (400 mg, twice daily for two days) of 879 women with Gardnerella 
vaginalis during mid-pregnancy would reduce the risk of spontaneous preterm 
birth [196]. Intention-to-treat analysis showed no difference between 
metronidazole and placebo groups in overall preterm birth (7.2% versus 
7.5%) or spontaneous preterm birth (4.7% versus 5.6%). Among 480 women 
with BV, treatment had no effect on spontaneous preterm birth (4.5% versus 
6.3%). In the subgroup of women with a previous preterm birth, the use of 
metronidazole was associated with a significant reduction in spontaneous 
preterm birth (9.1% versus 41.7%, RR= 0.14, 95% CI: 0.01-0.84). A treatment 
effect was also found in compliant women with a previous preterm birth and 
BV. The authors concluded that treatment did not reduce the preterm birth 
rate in women with BV (RR= 0.97, 95%CI: 0.60-1.55). Nevertheless, these 
results suggested that benefit could be obtained with treatment of women 
with a previous preterm birth. 
 
Carey et al. [197] conducted one of the largest trials at that time (n= 1953), 
and showed no evidence of benefit with 2 g metronidazole treatment of 
pregnant women with asymptomatic BV in the reduction of preterm birth rates 
(RR= 0.97, 95%CI: 0.60-1.55). However, BV resolved in 77.8% of women 
who had follow-up Gram's staining in the metronidazole group, and in 37.4% 
of women in the placebo group. The same team also showed in another trial, 
that pregnant women diagnosed with asymptomatic trichomoniasis had an 
80% increase in the risk of preterm birth after use of metronidazole treatment, 
when compared to placebo [198]. The authors randomly assigned 617 
women with asymptomatic trichomoniasis who were 16 to 23 weeks pregnant 
to receive two doses of metronidazole (320 women) or placebo (297 women) 
48 hours apart. The infection resolved in 92% women in the metronidazole 
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group and in 35% of women in the placebo group. However, delivery 
occurred before 37 weeks of gestation in 19% of women in the metronidazole 
group and in 10% of women in the placebo group (RR= 1.8, 95% CI: 1.2 - 
2.7).  
 
Faillure of metronidazole to prevent preterm birth was also demonstrated by 
Odendaal et al. [199]  (RR= 1.64, 95%CI: 1.06-2.53), Andrews et al. [200] 
(RR= 0.99, 95%CI: 0.71-1.38) and Shennan et al., in the PREMET study 
[201]. In this former trial, 900 pregnant women with at least one previous risk 
factor for preterm delivery (including mid-trimester loss or previous preterm 
delivery, uterine abnormality, cervical surgery or cerclage) were screened for 
fetal fibronectin at 24 and 27 weeks of gestation. Positive cases were 
randomised to a week's course of oral metronidazole or placebo. Primary 
outcome was delivery before 30 weeks of gestation. Secondary outcomes 
included delivery before 37 weeks. 21% of women receiving metronidazole 
delivered before 30 weeks compared with 11% taking placebo (RR= 1.9, 95% 
CI: 0.72-5.09). There were significantly more preterm deliveries (before 37 
weeks) in women treated with metronidazole (62%) than women treated with 
placebo (39%) (RR= 1.6, 95% CI: 1.05-2.4).  
 
Topical treatment of BV with clindamycin was evaluated in 8 clinical trials. In 
the first study conducted by McGregor et al. [202] use of clindamycin 
increased the risk of preterm birth, when compared to placebo (RR= 2.07, 
95%CI: 0.73-5.84). Joesoef et al. [109] and Klebanoff et al. [203] also did not 
find any reduction in the risk of preterm birth after the use of this anti-infective 
(RR= 1.11, 95% CI: 0.77-1.61) and (RR= 0.91, 95% CI: 0.64-1.30), 
respectivelly. Vermeulen et al. [111] showed that prophylactic administration 
of clindamycin did not reduce the incidence of spontaneous preterm birth in 
women with an increased risk of recurrence (RR= 1.31, 95% CI: 0.76-.2.24). 
Same results were found by Kurkinen-Räty et al. [204] (OR 2.5, 95% CI: 0.6-
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10), and by Kekki et al. [205] (RR= 1.29, 95%CI: 0.49-3.40). Most recent 
evidence from two larger trials did not corroborate the findings of previous 
studies. In 2003, Lamont et al. showed that 2% clindamycin vaginal cream 
administered to women with abnormal genital tract flora before 20 weeks of 
gestation, can reduce the incidence of preterm birth by 60%, when compared 
with placebo (RR= 0.41, 95% CI: 0.18-0.91) [110]. Benefit was also 
demonstrated by Ugwumadu et al. [206]; asymptomatic women with abnormal 
vaginal flora and BV treated with oral clindamycin early in the second 
trimester of pregnancy, had reduced rates of spontaneous preterm birth (RR= 
0.61, 95%CI: 0.35-1.04). Current consensus is that topical intra-vaginal 
treatment with this agent is not recommended during pregnancy. 
 
Two systematic reviews and meta-analyses concluded that treatment of BV is 
effective in eradicating infections, but there is no evidence to support the use 
of anti-infective treatment for BV or Trichomonas vaginalis in pregnancy to 
reduce the risk of preterm birth or its associated morbidities [107, 207]. The 
review conducted by Okun et al. [207] included results of 14 studies. The 
authors pooled the data from 5 trials and concluded that treatment is effective 
in eradicating infection (RR= 0.32, 95% CI: 0.20-0.52). However, there was 
no difference between the treatment and placebo groups on the risk of 
preterm birth at less than 37 weeks (RR= 0.93, 95% CI: 0.70 –1.22). The 
Cochrane review conducted by McDonald et al. [107] included 15 trials, 
involving 5888 women. Treatment was effective at eradicating BV during 
pregnancy (OR= 0.17, 95% CI: 0.15 - 0.20). Treatment did not reduce the risk 
of preterm birth before 37 weeks (OR= 0.91, 95% CI: 0.78-1.06) 
 
Nevertheless, treatment before 20 weeks’ gestation may reduce the risk of 
preterm birth less than 37 weeks (OR= 0.72, 95% CI: 0.55 - 0.95). The 
authors also showed that in women with a previous preterm birth, treatment 
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did not affect the risk of subsequent outcome (OR= 0.83, 95% CI: 0.59 - 
1.17).  
 
If treatment does not seem to be effective in women with intact membranes or 
BV, King et al. [208] suggested that further research may be justified in order 
to determine if there is a subgroup of women who could experience benefit 
from anti-infective treatment for preterm labour, and to identify which antibiotic 
or combination of antibiotics is the most effective. In 2010, Keynon et al. 
updated the results of a previous Cochrane review and meta-analyses in 
which the authors evaluated the immediate and long-term effects of 
administering anti-infective drugs to a sub-group of women with PROM [209]. 
This review included 22 trials, involving 6800 women and babies. The use of 
anti-infective drugs for PROM was associated with statistically significant 
reductions in chorioamnionitis (RR= 0.66, 95% CI: 0.46-0.96), and a reduction 
in the numbers of babies born within 48 hours (RR= 0.71, 95% CI: 0.58 - 
0.87) and seven days of randomisation (RR= 0.79, 95% CI: 0.71-0.89). 
Therefore, women with PROM clearly benefit from therapy, compared to 
women with intact membranes. Furthermore, the following markers of 
neonatal morbidity were reduced: neonatal infection (RR= 0.67, 95% CI: 0.52-
0.85), use of surfactant (RR= 0.83, 95% CI: 0.72-0.96), oxygen therapy (RR= 
0.88, 95% CI: 0.81-0.96), and abnormal cerebral ultrasound scan prior to 
discharge from hospital (RR= 0.81, 95% CI: 0.68-0.98). However, the use of 
some agents (Co-amoxiclav) was associated with an increased risk of 
neonatal necrotising enterocolitis (RR= 4.72, 95% CI: 1.57-14.23). Given 
these results, the authors conclude that the benefits in some short-term 
outcomes should be balanced against a lack of evidence of benefit for others, 
including perinatal mortality, and longer-term outcomes.  
 
Data from observational studies resulted in the same findings for most of the 
classes of anti-infected investigated in RCTs. In 2001, Larsen et al. 
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conducted a retrospective cohort study of birth outcome following gestational 
exposure to pivmecillinam, using data from the Prescription Database and the 
Birth Registry of Denmark [210]. The authors found no significantly increased 
risks for preterm delivery (OR= 0.91, 95% CI: 0.11-1.86).  
 
The same drug was further evaluated in another cohort study designed by 
Vinther-Skriver et al. [211]. The authors used population-based registries in 
North Jutland County, Denmark of 63 659 women with a live birth, or stillbirth 
after the 28th week of gestation. 2031 women had redeemed prescriptions for 
pivmecillinam any time during pregnancy, 559 in the first trimester and 371 
before delivery. Use of pivmecillinam during pregnancy did not appear to 
increase the risk of preterm delivery (RR= 0.96, 95% CI: 0.79-1.18), which 
corroborates previous data on this agent. However, this study lacked 
statistical power. 
 
Another retrospective cohort study of maternal use of amoxicillin was 
conducted by Jepsen et al. Analyzing data of 401 primiparous women who 
redeemed a prescription for amoxicillin during their pregnancy, the authors 
did not find any increase in the risk of preterm birth after exposure (RR= 0.77, 
95% CI: 0.49-1.21) [120]. Lack of evidence for amoxycillin/clavulanic acid was 
also detected in a cohort study conducted in Israel by Berkovitcz et al. [123]. 
In this study, the exposed group (n= 191) was composed of women treated 
with amoxycillin/clavulanic acid during the first trimester of pregnancy, and 
recruited from two teratogen information centres in Israel. Women were 
matched for age, smoking habits and alcohol consumption with 191 controls 
exposed to amoxycillin only for similar medical indications. Results showed 
that treated women had the same mean gestational age at delivery when 
compared to women exposed to amoxicillin alone (39.4 ± 1.6 weeks versus 
39.6 ± 1.6 weeks, p= 0.294).  
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2.3.2.7. Studies assessing the risk of preterm birth after exposure to 
anti-infective drugs 
 
A population-based follow-up study conducted by Dencker et al., in the 
county of North Jutland, Denmark, analyzed birth outcome of 1886 
pregnancies that redeemed prescriptions for phenoxymethylpenicillin during 
pregnancy. No significantly increased risk of preterm birth was found (RR= 
0.83, 95% CI: 0.66-1.04) [212].  
 
The impact of cefuroxime use during the first trimester of pregnancy on the 
mean gestational age at delivery was evaluated by Berkovitch et al. in a 
prospective cohort study of 106 pregnant women recruited from three 
teratogen information centres in Israel [122]. After matching for age, smoking 
habits and alcohol consumption, no difference was observed between 
exposed and non-exposed group (39 ± 2.8 weeks versus 39 ± 1.7 weeks, p= 
0.6). Use of cefuroxime and amoxycillin/clavulanic acid was further 
investigated by Benyamini et al. in a prospective cohort of 105 pregnant 
women [213]. Results did not indicate any significant difference in mean 
gestational week of birth in a cohort of women (39.79 ± 1.43 weeks for 
women exposed to amoxycillin/clavulanic versus 39.9 ± 1.28 weeks for 
women exposed to cefuroxime).  
 
Sorensen et al., using data from the North Jutland Pharmacoepidemiological 
Prescription Database in Denmark, studied risk of prematurity after exposure 
to fluconazole [214]. The authors analyzed information on birth outcomes of 
165 women who had taken fluconazole just before or during pregnancy. The 
study showed no increased risk of preterm birth in offspring of women who 
had used single dose fluconazole before conception or during pregnancy 
(OR= 1.17, 95% CI: 0.63-2.17). The same agent was studied by 
Mastroiacovo et al. in a prospective cohort study of women who contacted 
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three Italian teratogen information services [157]. Pregnancy outcomes of 226 
women exposed to fluconazole were compared to that of 452 women 
exposed to nonteratogenic agents, and no evidence of risk was detected 
(RR= 1.73, 95%CI: 0.60-4.97). 
 
Safety of itraconazole, another anti-fungal anti-infective, was evaluated by a 
cohort study conducted in Italy by De Santis et al. [215]. The authors found 
no difference in preterm delivery rates between exposed and non-exposed 
groups (6.8% versus 7.9%, p < 0.05). However, in this study, exposure was 
assessed for the first trimester, instead of second or third trimester of 
gestation.  
  
In Denmark, in a prospective cohort, among 87 women who redeemed a 
fluoroquinolone prescription at any time during the pregnancy, Wogelius et al. 
showed that the prevalence ratio of preterm birth was 1.4 (95% CI: 0.6-3.2) 
[216]. Similar results were found for this class in a retrospective cohort of 57 
users of this anti-infective class designed by Larsen et al.  (RR= 1.30, 95% 
CI: 0.30-5.30) [139]. Furthermore, Loebstein et al. [138] enrolled and 
followed-up 200 women exposed to these drugs and found similar results 
(RR= 0.92, 95% CI: 0.42–2.00). In addition, exposure to other quinolones was 
evaluated with data for 116 prospectively documented pregnancies from the 
European Network of Teratology Information Services. No evidence of 
increased risk of prematurity was demonstrated [136]. A recent meta-analysis 
with pooled data of these studies did not show evidence of increased risk of 
preterm birth after exposure to quinolones (OR= 1.15, 95% CI: 0.69–1.91) 
[217]. In an additional analysis including only fluoroquinolones (nalidixic acid 
was removed), the summary odds ratio for major malformations remained 
non-significant (OR= 1.11, 95% CI: 0.57–2.15). 
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The association between use of sulfamethizole and preterm birth was 
investigated in a case-control study conducted by Ratanajamit et al. [135] 
There was no increase in the risk of preterm birth after exposure during 
pregnancy (OR= 1.12, 95%CI: 0.97-1.30). In another study conducted by 
Sarkar et al., [127] gestational exposure to azithromycin was not related to 
preterm birth in a cohort of 123 pregnant women (p= 0.76). Similar results 
were found in a cohort of pregnant women infected with Chlamydia 
trachomatis [218]. In this study, the grouped treated only with azithromycin 
had a non-significant higher incidence of preterm delivery when compared to 
the group exposed to erythromycin (7.5% versus 4%, p=0.54). Similar results 
were found for another macrolide drug: exposure to roxithromycin in a cohort 
of pregnant women was not associated to preterm birth (mean gestational 
age at delivery was 39.2 weeks in the exposed group and 39.4 in non-
exposed women (p= 0.6)). 
 
Sorensen et al. [214] did not show any evidence of an increase in the risk of 
preterm delivery after exposure to metronidazole in a cohort study of 124 
pregnant women using data from the North Jutland Pharmacoepidemiological 
Prescription Database (OR= 0.80, 95%CI: 0.35–1.83). Exposure to 
metronidazole [153]  and mebendazole [219] was evaluated with data from 
the Israeli Teratogen Information Service, and no evidence of increased risk 
of preterm birth was found. 
 
The impact of prenatal antibiotics used in addition to those used to treat 
group B streptococcal bacteriuria was assessed by Anderson et al. using data 
from hospital files [220]. In this study, the frequency of preterm birth was 16% 
among women in the control group, 16% for women with bacteriuria not 
receiving additional antibiotics, and 28% for women with bacteriuria who 
received antibiotics. Among women with bacteriuria, the risk of preterm birth 
was increased (OR= 2.7, 95% CI: 1.2-6.1). 
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A Cochrane review, one meta-analyses and a systematic review summarized 
most of the evidence available from RCTs of interventions for preventing and 
treating preterm birth. The Cochrane review showed a reduction in maternal 
infection with the use of prophylactic antibiotics (RR= 0.74, 95% CI: 0.64-
0.87). However, no clear overall benefit from prophylactic antibiotic treatment 
for preterm labour with intact membranes was obtained (RR= 1.22, 95% CI: 
0.88-1.70) [208]. The meta-analysis conducted by Simcox et al. [221] 
concluded that there was no significant association between antibiotic 
treatment and reduction of preterm birth irrespective of criteria used to assess 
risk, the anti-infective drug used, or gestational age at time of treatment (RR= 
1.03, 95% CI: 0.86-1.24). 
 
In summary, the arguments in favour of anti-infective treatment of women with 
underlying risk factors emphasise the need for clindamycin oral treatment in 
women symptomatic for BV before 20 weeks’ gestation [222]. Support for 
treatment originated from secondary analyses of the trial conducted by Hauth 
et al. in women at risk of preterm birth, in which benefit was limited only to 
women with BV, and from another trial conducted by McDonald et al. in which 
benefit was limited to those women with a diagnosis for BV and with previous 
preterm birth [194, 196]. However, clinicians should be aware that 
intravaginal clindamycin cream might be associated with adverse outcomes if 
used in the latter half of pregnancy [32]. 
 
Arguments against antibiotic treatment are based on the increased incidence 
of preterm birth in women given metronidazole, found by Andrews et al., 
Klebanof et al. and in the PREMET study [200, 201, 203]. In addition, the 
Cochrane review conducted by McDonald et al. corroborates the findings of a 
negative effect of treatment [107]. Although anti-infective treatment can 
eradicate BV in pregnancy, it does not reduce the risk of preterm birth or 
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PROM before 37 weeks’ gestation in all women or in those with a previous 
preterm birth. 
 
There is less controversy when considering the use of antibiotics to reduce 
the risks of adverse feto-maternal outcome following PROM. When compared 
with placebo, antibiotics reduce the rate of delivery within 48 hours and 
delivery within seven days [222, 223]. 
 
A summary of the observational studies and meta-analysis of RCTs, 
assessing anti-infective treatment during pregnancy and the risk of preterm 
birth is presented in Table 5. 
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Table 5. Summary of the studies on the association between the use of anti-infective drugs during pregnancy and 
the risk of preterm birth. 
 
Authors, 
year and 
country 
Study design Class or 
type of anti-
infective 
drug 
Number of 
exposed 
subjects 
(prevalence 
of 
outcome) 
 
Exposure 
window 
Outcome of 
interested 
Measure of 
effect 
(RR, OR or P 
values) 
 
Beta-Lactams 
 
Berkovitch et 
al., 2000, 
Israel [123] 
 
Prospective 
cohort study 
Cefuroxime 109  
(4.3%) 
First 
trimester of 
gestation 
 
Delivery before 
37 weeks of 
gestation 
RR= 0.70 
(0.20-2.39) 
Larsen et al., 
2001, 
Denmark 
[210] 
 
Retrospective 
cohort study- 
Administrative 
database 
Pivmecillinam 411  
(7%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
OR= 0.91  
(0.11-1.86) 
Dencker et 
al., 2002 
[212]  
 
 
Case-control 
study  
Phenoxy-
methyl-
penicillin 
2540  
(5.5%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
OR= 0.83 
(0.66-1.04) 
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Jepsen et al., 
2003, 
Denmark 
[120] 
 
Case-control 
study- 
Administrative 
database 
Amoxicillin 401  
(7.5%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
 
OR= 0.77  
(0.49-1.21) 
Berkovitch et 
al., 2004, 
Israel [122] 
Prospective 
cohort study 
Amoxycillin/ 
clavulanic 
acid 
163  
(3.8%) 
First 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
OR= 1.24  
(0.39-3.97) 
Vinther-
Skriver et al., 
2004, 
Denmark 
[211] 
 
Case-control 
study - 
Administrative 
database 
Pivmecillinam 2031  
(7%) 
First 
trimester of 
gestation 
and 1 month 
before 
delivery 
Delivery before 
37 weeks of 
gestation 
 
OR= 0.96  
(0.79-1.18) 
 
Macrolides 
 
Rahangdale 
et al., 2006, 
USA [218] 
 
Retrospective 
cohort study - 
Administrative 
database 
Azithromycin 221  
(7.5%) 
Exposure 
during the 
third 
trimester of 
gestation 
 
Delivery before 
37 weeks of 
gestation 
 
P= 0.54 
Sarkar et al., 
2006, 
Canada [127] 
 
Retrospective 
cohort study - 
Administrative 
database 
Azithromycin 123 All 
gestational 
period 
Gestational 
age at birth in 
weeks 
P= 0.67 
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Morency and 
Bujold, 2007, 
Canada [224] 
 
Systematic 
review / Meta 
analysis 
Macrolides 1817 Second and 
third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
 
 
 
 
 
 
OR= 0.72 
 (0.56-0.93) 
 
Quinolones 
 
Berkovitch et 
al., 1994, 
Canada [36]  
 
Retrospective 
cohort study - 
Administrative 
database 
 Norfloxacin 
and 
ciprofloxacin 
38  
(19%) 
First 
trimester of 
gestation 
(94% of 
cases) 
 
Delivery before 
37 weeks of 
gestation 
P= 0.7 
Schaefer et 
al., 1996, 
Germany 
[136] 
 
Prospective 
follow-up study
Quinolones 15  
(3.6%) 
First 
trimester of 
gestation 
 
Delivery before 
37 weeks of 
gestation 
Not reported 
Loebstein et 
al., 1998, 
Canada [138] 
 
Prospective 
cohort study - 
Administrative 
database 
Quinolones 200 All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
RR= 0.92 
(0.42–2.00) 
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Larsen et al., 
2001, 
Denmark 
[139] 
 
Retrospective 
cohort study - 
Administrative 
database 
 
Fluoro-
quinolones 
57  
(8.8%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
RR= 1.53 
(0.62-3.80) 
Wogelius et 
al., 2005, 
Denmark 
[216] 
 
Case-control 
study - 
Administrative 
database 
Fluoro-
quinolones 
217  All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
 
OR= 1.4  
(0.6-3.2) 
Bar-Oz et al., 
2009, Israel 
[217] 
Meta-analysis 
of 
Observational 
studies 
 
Quinolones 984  
(27%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
 
OR= 1.05  
(0.90-1.22) 
 
Urinary anti-infectives 
 
Ratanajamit 
et al., 2003, 
Denmark 
[135] 
 
Case-control 
study - 
Administrative 
database 
Sulfa-
methizole 
3484  
(8%) 
30 days 
before 
conception 
 
Delivery before 
37 weeks of 
gestation 
 
OR= 1.12  
(0.97-1.30) 
 
Metronidazole and azoles 
 
Mastroiacovo 
et al., 1995, 
Italy [157] 
Prospective 
cohort study 
Fluconazole 226  First 
trimester of 
gestation 
 
Delivery before 
37 weeks of 
gestation 
RR= 1.73  
(0.60-4.97) 
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Sorensen et 
al., 1999, 
Denmark 
[214] 
Case-control 
study- 
Administrative 
database 
 
Fluconazole 301  
(6.6%) 
All 
gestational 
period 
Delivery before 
37 weeks of 
gestation 
OR= 1.17  
(0.63-2.17) 
Diav-Citrin et 
al., 2001, 
Israel [153] 
  
Retrospective 
cohort study 
Metro-
nidazole 
228  
(6.8%) 
First 
trimester of 
gestation 
 
Delivery before 
37 weeks of 
gestation 
P= 0.58 
Diav-Citrin et 
al., 2003, 
Israel [219] 
Retrospective 
cohort study 
Mebendazole 192 All 
gestational 
period 
Median 
gestational 
week at 
delivery 
 
P= 0.65 
De Santis et 
al., 2009, 
Italy [215] 
Prospective 
cohort study 
Itraconazole 206  
(6.8%) 
First 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
Not disclosed 
(NS) 
 
 
Others 
 
 
King and 
Flenady, 
2002, 
Australia 
[208] 
Systematic 
review / Meta 
analysis of 
RCTs 
 
Prophylactic 
antibiotics for 
inhibiting 
preterm 
labour with 
intact 
membranes 
5204 
(7.6%) 
Last two 
trimesters of 
gestation 
Delivery before 
37 weeks of 
gestation 
OR= 2.7 
 (1.2-6.1) 
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Okun et al., 
2005, 
Canada [207] 
Systematic 
review / Meta 
analysis of 
RCTs 
Antibiotics for 
BV treatment 
3146 
 (13%) 
Second and 
third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
RR= 0.93  
(0.70 –1.22) 
McDonald et 
al., 2007, 
Australia 
[107] 
 
 
 
Systematic 
review / Meta 
analysis of 
RCTs 
Antibiotics for 
BV treatment 
5888  
(12%) 
Second and 
third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
OR= 0.91 
 (0.78 to 1.06) 
Simcox et al., 
2007, UK 
[221] 
 
Systematic 
review / Meta 
analysis of 
RCTs 
 
Clindamycin, 
metro-
nidazole and 
erythromycin 
 
4939  
(14%) 
 
Second and 
third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
RR= 1.03 
(0.86-1.24) 
 
Anderson et 
al., 2008, 
USA [220] 
 
Retrospective 
cohort study 
Additional 
antibiotics for 
women with 
GBS infection
120  
(16%) 
Third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
P= 0.04 
Kenyon et 
al., 2010, UK  
Systematic 
review / Meta 
analysis of 
RCTs 
 
Antibiotics for 
premature 
rupture of 
membranes 
3642  
(13%) 
Second and 
third 
trimester of 
gestation 
Delivery before 
37 weeks of 
gestation 
 
RR= 1.00 
(0.98-1.03) 
 
 
 
 
 65
2.3.3. Use of anti-infective drugs and the risk of infants born small for 
their gestational age 
2.3.3.1. Definition of small for gestational age 
The term small for gestational age (SGA) has been applied to newborns 
having a birth weight and/or a birth length below the 3rd or 10th percentile of 
birth weight for gestational age and sex, based on the distribution in a 
standard population (or below −1.88 or −1.29 standard deviation) [162]. 
Neonates with either low birth weight or length or both for gestational age 
should be considered SGA [225]. Although the definition is somewhat 
arbitrary, the common 10th percentile cut-off point for SGA is the most used 
criteria in the literature [226, 227].  
The terms SGA, intrauterine growth restriction (IUGR) and low birth weight 
are often used interchangeably by obstetric and pediatric clinicians and in the 
literature [228]. Although there is considerable overlap between these 
conditions, these terms are not synonymous [225]. IUGR refers to fetal 
growth retardation and can be observed as a deviation of the intra-uterine 
growth chart. Therefore, IUGR can only be diagnosed when documented by 
two intrauterine growth assessments by ultrasound measurements [229]. Low 
birth weight is defined by the World Health Organization as weight at birth of 
less than 2500 g. However, this is very broad classification for international 
comparison of neonatal and public health, which includes premature infants, 
who though small, have a weight and length that is appropriate for their 
gestational age [230]. 
SGA does not refer to fetal growth but refers to body size at birth. Not all SGA 
infants have suffered from intrauterine growth retardations, as an SGA infant 
may have been small from the beginning of fetal life. Infants born SGA may 
be further classified as SGA-W (low birth weight), SGA-L (low birth length), or 
SGA-WL (low birth weight and length) [225]. 
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2.3.3.2. Epidemiology of small for gestational age 
 
By definition, approximately 10% of all pregnancies will result in newborns 
that are “too small”. Approximately 4% of all live born neonates are born SGA 
when SGA is defined as birth length or birth weight below 2 standard 
deviations of the distribution. There is a lack of data on the incidence of SGA 
births in many countries because birth length and gestational age are 
sometimes not recorded in national databases [225]. However, based on 
available data, it has been estimated that between 2.3% and 10% of all 
infants are born SGA [160, 162, 228], although this may still be an important 
underestimate in international terms [230]. In Canada, previous report 
indicate that the prevalence of SGA is 7.8% [162]. 
 
Risk factors and predictors for SGA should be identified given that underlying 
mechanisms are diverse and may influence prognosis and treatment effects 
[225]. SGA can be caused by demographic, fetal, maternal and placental 
factors [225].  
 
Demographic factors include maternal race, obstetric history, age of the 
mother, height of the mother and father and multiple gestation. Pregnant 
women with more than 35 years have been found in several studies to have 
an elevated risk of SGA [230, 231]. Although the incidence of SGA neonates 
is higher among teenage mothers, it is unclear whether age alone or socio-
economic factors are the cause [232]. Maternal race can also influence fetal 
growth. Studies demonstrate that Afro-American women have more chance to 
bear SGA infants than white American women [233]. Paternal characteristics 
including age, height, birth weight, and low levels of education are also 
associated with SGA [227].  
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Fetal risk factors include genetic and congenital defects, metabolic diseases 
and multiple gestations, and are responsible to 15% to 20% of SGA cases 
[234]. Among genetic defects, some karyotipic abnormalities such as trisomy 
21 (Down syndrome), trisomy 18 (Edward syndrome) and monosomy X 
(Turner syndrome) are responsible for 5 to 7% of all SGA births [86, 225, 229-
231]. Approximately 38% of infants with chromosomal abnormalities are born 
SGA [230]. 
 
Maternal factors can be divided into medical conditions and maternal 
environmental factors. Medical complications include: chronic vascular 
diseases (secondary to conditions such as hypertension, diabetes mellitus or 
renal disorders), conditions associated with low perfusion (such as asthma, 
chronic anemia, sickle cell anemia, cyanotic heart disease, chronic pulmonary 
disease), infections (malaria, toxoplasmosis, trypanosomiasis and particularly 
viral infections such as rubella, cytomegalovirus, human immunodeficiency 
virus and herpes virus), and low pre-pregnancy weight and low pregnancy 
weight with poor weight gain during pregnancy [225, 230]. Environmental 
factors include: use of therapeutic drugs (antimetabolites, anticonvulsants, 
anticoagulants, folic acid antagonists), illicit drug use, alcohol abuse and 
cigarette smoking. Smoking is one of the most common environmental 
causes of SGA birth [226]. Smoking causes fetal oxygen deprivation, which 
can retard fetal growth and result in SGA [225, 226]. About 12% of children 
younger than age 2 whose mothers had smoked while pregnant had been 
SGA births, compared with only 4% whose mothers had not smoked [230].  
 
Placental risk factors involve problems in placental perfusion. As the placenta 
is essential for nutrient and oxygen supply from mother to fetus, any placental 
dysfunction could result in SGA [230].  
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2.3.3.3. Consequences of infants born small for their gestational age 
 
Infants born SGA are at increased risk of morbidity and mortality both in the 
perinatal period and in later life [230]. In the perinatal period, these 
complications include respiratory distress, hypotension, hypoglycemia, 
necrotizing enterocolitis, and neonatal death [235]. Subsequently, infants and 
children born SGA are more susceptible to neurological impairment, delayed 
cognitive development, and poor academic achievement [236, 237]. 
Adolescents and adults born SGA are at increased risk of developing 
cardiovascular disease, obstructive pulmonary disease, type II diabetes, renal 
insufficiency, and impaired reproductive function [238-240]. Failure to achieve 
appropriate catch-up growth after SGA birth results in persistent short stature 
and is associated with higher health risks and psychosocial impairment, 
compared with patients born SGA who achieve their growth potential [241, 
242]. The exact consequences of SGA on the subsequent development of 
these infants depend on the specific cause giving rise to SGA, its time of 
occurrence and the duration of the impairment. As the burden is so 
significant, the detection and management of risk factors are crucial [234].  
 
2.3.3.4. Role of maternal infections in the pathogenesis of small for 
gestational age 
 
Infections are responsible for up to 5-10% of SGA cases [243]. There is 
emerging evidence that subclinical infection and inflammation may lead to 
chorioamnionitis, fetal growth restriction and SGA [244]. The most common 
causes of SGA are toxoplasmosis and cytomegalovirus, and they should be 
the ones most frequently tested for during pregnancy. Cytomegalovirus 
infection is associated with direct fetus cytolysis and loss of functional cells 
[245]. Some authors observed that first episodes of herpes simplex virus 
infection, especially during the third trimester, also may be associated with 
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impaired fetal growth [246]. Rubella causes vascular insufficiency by 
damaging the endothelium of small vessels and also reduces cell division 
[247]. However, due to widespread vaccination, rubella is less of a threat. 
Syphilis is still being diagnosed during in pregnancy both in developed and 
developing countries [244]. The disease results in marked vasculitis, mild 
thrombosis, and villous edema of the placenta. Malaria is the predominant 
infectious cause of SGA in Africa, South-East Asia, and other countries where 
malaria is endemic, accounting for 40% of cases of SGA [248]. The 
pathogenesis of malaria activates immune-mediated inflammatory processes, 
as well as platelets which become deposited in the vascular system and lead 
to vessel obstruction [248].  
 
Some studies suggested that maternal UTIs, chlamydia and mycoplasma 
infections increase the risk of SGA [249]. Furthermore, systemic infection, 
such as advanced tuberculosis, may also be associated with fetal growth 
deficit [250]. Recent findings that maternal periodontal disease may lead to 
preterm and SGA births, indicates that infection is a modifiable etiologic 
factor; its treatment can potentially reduce the frequency of SGA [251, 252]. 
In a prospective longitudinal study, it was shown that pregnant women with 
higher levels of periodontal infection had increased risk of giving birth to low 
birth weight infants (OR= 4.1; 95% CI: 1.3–12.8) after controlling for smoking, 
age, and race [251].  
 
The direct consequences of maternal infections is sub-optimal placental 
perfusion and a dysfunction of the placental microvascularity, which results in 
an inadequate maternal supply of oxygen and nutrients to the fetus and the 
consequent decreased ability of the fetus to use the supply [247]. 
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2.3.3.5. Anti-infective drugs and the risk of small for gestational age 
 
Very few studies assessed the risk of having an infant SGA after exposure to 
anti-infective drugs during pregnancy. Wen et al. conducted one of the most 
recent observational studies assessing maternal exposure to folic acid 
antagonists (such as sulfamethoxazole–trimethoprim) and the risk of SGA 
and other placenta-mediated adverse pregnancy outcomes [13]. Using data 
from health administrative database from Saskatchewan, Canada, the 
authors found that exposure to these drugs significantly increased the risk of 
SGA, when the outcome is defined as birth length smaller than the 3rd 
percentile (OR=1.22, 95% CI: 1.11–1.34), whereas a smaller association was 
found when SGA was defined as birth length smaller than the 10th percentile 
(OR=1.07, 95%CI: 1.01–1.13). Although some methodological flaws in this 
study, such as confounding by indication, the authors put their findings in 
perspective with a very strong biological rational: a placental microvascular 
disease may arise from a maternal folate-homocysteine metabolic defect 
caused by an exposure to these drugs. This could explain how 
sulfamethoxazole–trimethoprim is associated with the development of the 
events that lead to SGA newborns. Other possible related factors are the 
well-documented gastrointestinal adverse effects of this drug (nausea, 
vomiting, diarrhea and stomatitis) that could play a synergic role in preventing 
the fetus from receiving essential micronutrients from the mother. 
 
The vast majority of studies that investigated this issue analyzed the risk of 
having a low birth weight child, instead of directly assessing IUGR or SGA. In 
addition, in most of these studies, low birth weight was not the principal 
outcome of interest, but rather a secondary outcome. A recent Cochrane 
review summarized the evidence of five RCTs with data on weight at birth 
after gestational exposure to anti-infective drugs [208]. After pooling results of 
6628 subjects, the authors found no evidence of effect on birth weight after 
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use of anti-infective during pregnancy (RR= 1.04, 95% CI: 0.95-1.13). Same 
results were found when analysis were done within classes of anti-infective 
drugs; no increase in the risk was detected after use of betalactams 
antibiotics (RR= 1.08, 95% CI: 0.94-1.24), macrolides (RR= 1.05, 95% CI: 
0.90-1.22), association of beta-lactams and macrolides (RR= 1.02, 95% CI: 
0.87-1.20) and antibiotics active against anaerobic bacteria (RR= 0.75, 95% 
CI: 0.56-1.01).  
 
Meta-analysis of two RCTs with data on 4876 pregnant women with PPROM, 
also showed that exposure to anti-infective drugs seems not to be associated 
with low birth weight (RR= 1.00, 95% CI: 0.96-1.04) [209]. Same results were 
found in another Cochrane review four RCTs that with data on 3151 pregnant 
women with a diagnosis of BV (RR= 1.00, 95% CI: 0.79-1.27) [107]. Among 
women with asymptomatic bacteriuria during pregnancy, the use of antibiotics 
was associated with a reduction in the incidence of low birth weight babies 
(OR= 0.60, 95% CI: 0.45 - 0.80) [253, 254]. 
 
A summary of the studies assessing anti-infective treatment during pregnancy 
and the risk of SGA is presented in Table 6. 
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Table 6. Summary of the studies on the association between the use of anti-infective drugs during pregnancy and 
the risk of SGA. 
 
Authors, 
year and 
country 
Study design Class or 
type of anti-
infective 
drug 
Number of 
exposed 
subjects 
(prevalence 
of 
outcome) 
 
Exposure 
window 
Outcome of 
interested 
Measure of 
effect 
(RR, OR or P 
values) 
King and 
Flenady, 
2002, 
Australia 
[208] 
Systematic 
review / Meta 
analysis of 
RCTs 
 
Prophylactic 
antibiotics for 
inhibiting 
preterm 
labour with 
intact 
membranes 
 
4882 Last two 
trimesters of 
gestation 
 
Birthweight < 
2500 g 
RR= 1.04  
(0.95-1.13) 
McDonald et 
al., 2007, 
Australia 
[107] 
 
 
 
Systematic 
review / Meta 
analysis of 
RCTs 
Antibiotics for 
BV treatment 
1568  
(9.3%) 
Last two 
trimesters of 
gestation 
 
Birthweight < 
2500 g 
RR= 1.00 
(0.79-1.27) 
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Smail and 
Vasquez, 
2007, 
Canada [254]  
Systematic 
review / Meta 
analysis of 
RCTs 
 
Antibiotic 
treatment for 
asymptomatic 
bacteriuria 
764  
(8.5%) 
Last two 
trimesters of 
gestation 
 
Birthweight < 
2500 g 
RR= 0.66 
 (0.49 - 0.89) 
Wen et al., 
2008, 
Canada [13] 
 
Retrospective 
cohort study 
Exposure to 
folic acid 
antagonists 
(Sulfa-
methoxazole
–
trimethoprim) 
 
14 982  
(4%) 
1-year 
period 
before 
delivery 
Small-for-
gestational 
age 
(Fetal growth 
restriction < 3rd 
percentile) 
OR= 1.20 
(1.08–1.32) 
Kenyon et 
al., 2010, UK 
[209] 
Systematic 
review / Meta 
analysis of 
RCTs 
 
Antibiotics for 
premature 
rupture of 
membranes 
3614 Last two 
trimesters of 
gestation 
 
Birthweight < 
2500 g 
RR= 1.00 
(0.96-1.04) 
 
 
  
2.4. QUALITY APPRAISAL OF THE STUDIES THAT INVESTIGATED THE 
USE OF ANTI-INFECTIVE DRUGS DURING PREGNANCY AND THE RISK 
OF PRETERM BIRTH AND SGA 
 
A critical appraisal of the studies described in the last sections indicates that, 
despite the amount of data available and the good methodological quality of 
some studies (such as the ORACLE trials [190, 191]), the evidence presented 
is inconclusive for most of the research questions. Due to a variety of factors, 
there is clinical controversy on anti-infective treatment during pregnancy to 
prevent preterm birth and SGA [174]. Trials and observational studies have 
reported conflicting results because of variation in timing, dose, choice of 
treatment and statistical power issues [111, 197, 200, 201].  
 
One possible reason for the lack of benefit of treatment found in most of the 
observational studies and clinical trials, is the inappropriate exposure window 
chosen to evaluate the potential effect of treatment on preterm birth. If 
treatment is evaluated later in gestation, it might not be effective in preventing 
the inflammation of the fetal membranes due to BV or UTIs 
(chorioamnionitis), which leads to preterm delivery [174]. Two trials conducted 
by Goldenberg et al. and Ugwumadu et al. in 2006, reported no difference in 
histological chorioamnionitis between women randomly assigned antibiotics 
versus placebo late in gestation [249, 252]. In addition, this fact could be 
responsible for some reports of an increased risk of preterm birth after 
exposure to anti-infective treatment, which in fact, could be due to 
chorioamnionitis’ severity instead of a real independent effect of treatment.  
 
Another possible reason for treatment failure reported by some studies is that 
host factors, such as smoking habits, diet, and individual variations in 
inflammatory response, might influence the risk of preterm birth and SGA, 
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irrespective of the choice of anti-infective treatment. The observational 
studies reviewed in this thesis, barely had information on the first two host 
factors, whereas clinical trials were not able to control for the variations in 
inflammatory response between subjects. Most of the studies did not have 
information on exposure to other medications, comorbidities and other 
potential confounders, such as the access to health care by the subjects. 
More studies are needed to evaluate the effect of anti-infective drugs on the 
risk of SGA. 
 
Statistical power is by far, the main limitation of the vast majority of trials 
analyzed. The small sample sizes in some trials are problematic when 
attempting to apply the results to the general population. In addition, 
information on exposure to different classes and individual anti-infective drugs 
is lacking in these studies. Furthermore, heterogeneity in pooling of data 
issued from these trials was demonstrated in a number of Cochrane reviews 
and meta-analysis [89, 90, 107, 207-209, 253]. For example, all reviews 
evaluating the effectiveness of anti-infective treatment for BV in pregnancy 
encountered significant heterogeneity.  
 
There is a need of more evidence-based studies determining the independent 
effect of anti-infective drugs on adverse pregnancy outcomes [251], and that 
overcome these methodological drawbacks. 
 
 
 
 
 
 
 
  
Chapter 3  
OBJECTIVES 
_____________________________________________________________ 
 
The objectives of the five manuscripts presented in this thesis are described 
bellow. 
 
3.1. STUDY 1: PREVALENCE AND PREDICTORS OF ANTI-INFECTIVE 
DRUG USE DURING PREGNANCY  
 
The objectives of this study were to: 
• Measure the prevalence of anti-infective drug use before, during, and 
after the end of gestation. 
• Describe the classes, types, and indications for anti-infective use 
during pregnancy. 
• Identify and quantify predictors associated with anti-infective drug use 
during pregnancy. 
 
3.2. STUDY 2: TRENDS IN ANTI-INFECTIVE DRUGS USE DURING 
PREGNANCY – A SHORT COMMUNICATION 
 
The objective of this study was to: 
• Describe trends in the use of general and broad-spectrum anti-infective 
drugs during pregnancy in the province of Quebec, Canada, over a 
period of five years. 
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3.3. STUDY 3: EXPOSURE TO ANTI-INFECTIVE DRUGS DURING 
PREGNANCY AND THE RISK OF PRETERM BIRTH  
 
The objective of this study was to: 
• Determine the association between anti-infective exposure during the 
second and/or third trimester of pregnancy and the risk of preterm 
birth, according to the class and type of anti-infective drug used. 
 
3.4. STUDY 4: EXPOSURE TO ANTI-INFECTIVE DRUGS DURING 
PREGNANCY AND THE RISK OF SMALL-FOR-GESTATIONAL-AGE  
 
The objective of this study was to: 
• Determine the association between anti-infective exposure during the 
second and/or third trimester of pregnancy and the risk of small-for-
gestational-age, according to the class and type of anti-infective drug 
used. 
 
3.5. STUDY 5: RISKS AND BENEFITS OF THE USE OF METRONIDAZOLE 
DURING PREGNANCY: A REVIEW OF THE EVIDENCE  
 
The objective of this study was to a synthesis of the available evidence on the 
association between metronidazole use during pregnancy and the risk of 
preterm delivery and birth defects. 
 
 
 
 
 
 
  
Chapter 4  
METHODS 
_____________________________________________________________ 
 
4.1. DATA SOURCES 
 
Data were obtained from the Quebec Pregnancy Registry, a population-
based cohort of pregnant women built with the linkage of three administrative 
databases: the Régie de l’assurance maladie du Québec (RAMQ) database, 
the Maintenance et exploration des donnés pour l’étude de la clientele 
hospitaliere (Med-Echo) database, and the Fichier des évenements 
démographiques de l’Institut de la statistique du Québec (ISQ).  
 
In Quebec, Canada, the RAMQ is the government body that administers the 
province’s health matters. All healthcare services are recorded in the RAMQ 
administrative databases, which are comprised by a set of claims files. The 
RAMQ database (medical claim file and the pharmaceutical claim file) 
provides information on medical services dispensed to all Quebec residents 
and on prescriptions filled for residents insured by Quebec’s Public Drug 
Insurance Plan. This database prospectively provides collected data on filled 
prescriptions, physician-based diagnoses (International Classification of 
Diseases, ninth revision, ICD-9) [255], therapeutic procedures, characteristics 
of the patient and health care providers, and the costs involved. The RAMQ 
covers the costs for medical services provided to all Quebec residents and 
the drug insurance plan insures approximately 50% of Quebec residents, 
which include persons of 65 years or older, welfare recipients and their 
children, and all workers and their families who do not have access to a 
private drug insurance program (adherents) [256]. Medications prescribed 
during hospitalization are not included in the database. Women insured by 
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the Quebec’s Public Drug Insurance Plan are younger, more likely to be 
immigrant, and have a household income below poverty level. They are also 
less likely to be caucasian, employed, and have a post-secondary education. 
No differences were observed on smoking status and alcohol use during 
pregnancy, when compared to women with private insurance. Access to 
health care services between women covered for their medications by the 
Quebec’s Public Drug Insurance Plan and those covered by private drug 
plans is similar [257]. 
 
Med-Echo is the Quebec hospital discharge database that has been put in 
place since 1980. The Med-Echo database records acute care hospitalization 
data for all Quebec residents (age, sex, admission diagnosis, up to 15 
secondary diagnosis, duration of stay, dates of admission and discharge, type 
of hospital and services received during hospitalization). All diagnoses are 
coded according to ICD-9 system. The database also records gestational age 
for planned abortions, miscarriages and deliveries. Gestational age is defined 
from the first day of the last menstrual period to the end of pregnancy, and 
confirmed by ultrasound around the 18th-20th week of gestation.  
 
The ISQ administers the Fichier des événements démographiques that 
provides data on all births and deaths in Quebec. The following demographic 
information is included: for the mother (date of birth, age, marital status, 
mother-tongue, place of birth, area of residence, number of live births, 
number of deliveries), for the father (date of birth, age, mother-tongue, place 
of birth); and for the baby (gender, type of delivery, weight, gestational age, 
order in the family, date of birth).  
 
The linkage between RAMQ and Med-Echo data was possible using patients’ 
Numéro d’assurance maladie [258], which is a unique identifier for all legal 
residents of Quebec. The mother-child linkage was possible using the unique 
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identifier that links each baby born in Quebec to his/her mother in the RAMQ 
database. The linkage between the RAMQ and ISQ was done using the first 
name, family name and date of birth of both the mother and child.  
 
Data recorded in the RAMQ medication database have been formally 
evaluated and found to be comprehensive and valid [259]. Medical diagnoses 
and pregnancy related data recorded in the ISQ and Med-Echo databases 
have also been evaluated and found to be valid and precise (length of 
gestation, date of last menstruation, date of delivery, maternal age) [260].  
 
The Quebec Pregnancy Registry currently contains data on all pregnancies 
that occurred in Quebec between January 1, 1997 and December 31, 2003 
and were covered by Quebec’s Public Prescription Drug Insurance Plan. The 
Registry cointains data on more than one pregnancy per women, if subjects 
were covered by the Quebec’s Public Prescription Drug Insurance Plan 
during their different gestations. An update of the registry is currently 
underway to include medical, pharmaceutical and hospital data on new 
pregnancies, as well as follow-up data from 2003-2009 on mothers and 
children for pregnancies that are already present in the registry.  
 
The Quebec Pregnancy Registry is a cohort of pregnant women built with the 
linkage of governmental health administrative database. The research team 
of Dr. Anick Berard at the St-Justine Research Centre conceived this cohort. 
It is not a governmental database. The use of the data was approved by the 
CHU Sainte-Justine Hospital Ethics Committee, and by the Commission 
d’accès à l’information du Québec, the provincial agency that grants 
authorization for the use of linked administrative databases. 
 
 
 
 81
4.1.1. Study population 
 
The study population for the four first studies in this thesis was composed of 
all pregnant women that were insured by the Quebec’s Public Drug Insurance 
Plan, and who filled at least one anti-infective prescription between January 
1, 1997 and December 31, 2003. A total of 109 344 pregnant women had 
coverage by the RAMQ drug plane before and during gestation. The 
pregnancies were first identified by a prenatal visit in the RAMQ database or 
by a therapeutic procedure related to pregnancy in the RAMQ or Med-Echo 
files. 
 
4.2. METHODS FOR STUDY 1 AND 2 
 
4.2.1. Study design 
 
For the study on the Prevalence and predictors of anti-infective use during 
pregnancy (Study 1) and Trends in anti-infective drug use (Study 2), a 
retrospective cohort study within the Quebec Pregnancy Registry was 
conceived.  
 
4.2.2. Study population 
 
The study population for these studies was selected from the study 
population described in the section 4.1.1 To be included in these studies, 
women had to meet the following eligibility criteria: (1) be between 15 and 45 
years of age on the date of entry in the Registry, defined as the first day of 
gestation; and (2) continuously insured by the RAMQ drug plan for at least 12 
months prior to the first day of gestation, during pregnancy, and for at least 12 
months after the end of the pregnancy. The end of the pregnancy was 
defined as the calendar date of a planned abortion, miscarriage, or delivery. If 
 82
a woman had more than one pregnancy between 1998 and 2003, the first 
pregnancy meeting eligibility criteria was included for analysis. 
 
4.2.3. Assessment of Exposure 
 
For Study 1, anti-infective drugs were categorized using the 2008 Anatomical 
Therapeutic Chemical (ATC) classification index. Data were collected for oral 
systemic agents in the ATC subgroups J01 (anti-bacterial agents), J02 (anti-
mycotics), and J04 (anti-mycobacterials). 
 
For Study 2, trends in use were assessed for for the following American 
Hospital Formulary Service (AHFS) classes: antifungals (AHFS 8:12:04), 
cephalosporins (AHFS 8:12:06), macrolides (AHFS 8:12:12), penicillins 
(AHFS 8:12:16), quinolones (AHFS 8:12:18), sulfonamides (AHFS 8:12:20), 
tetracyclines (AHFS 8:12:24), other antibacterials (AHFS 8:12:28), 
antimycobacterials (AHFS 8:16), and urinary anti-infectives (AHFS 8:36). We 
also analysed trends for individual drugs (ampicillin, amoxicillin, azithromycin, 
ciprofloxacin, clarithromycin, clindamycin, doxycycline, erythromycin, 
fluconazole, metronidazole, nitrofurantoin, and sulfamethoxazole/trimethoprim 
(SXT)) and for broad spectrum anti-infectives (ampicillin, 
amoxicillin/clavulanate, azithromycin, cefuroxime, cephalexin, ciprofloxacin, 
clarithromycin, clindamycin, doxycycline, erythromycin, fluconazole, 
levofloxacin, metronidazole, minocyclin, moxifloxacin, ofloxacin, 
nitrofurantoin, and SXT). For both studies, data on exposure was obtained in 
the pharmaceutical claims file of the RAMQ databases. The ATC 
classification system is widely used internationally for drug utilization studies, 
such as Study 1 [261]. Given that the RAMQ prescription files classifies drug 
information following the AHFS system, we decided to use this system to 
assess exposure in the Study 2. 
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4.2.4. Assessment of Outcome 
 
In both studies, the prevalence of anti-infective drug use during the 12 
months before pregnancy was calculated by dividing the number of women 
receiving at least one prescription for an anti-infective in this 12-month period 
by the total number of women that met eligibility criteria.  
 
4.2.5. Covariates 
 
The following variables were considered as potential predictors of receiving at 
least one anti-infective drug at the beginning of gestation: maternal age, 
maternal place of residence, maternal RAMQ drug plan status, calendar year 
of the pregnancy, number of different types of medications used other than 
anti-infective, number of different prescribers for all medications, planned 
abortions or miscarriages, number of visits to the physician, visits to the 
emergency department and/or hospitalizations, diabetes, asthma, 
hypertension and infections. 
 
4.2.6. Statistical Analysis 
 
In both studies, descriptive statistics were used to summarize the 
characteristics of the study population and to compare anti-infective use 
during pregnancy according to calendar year. Predictors for anti-infective 
drug use in the beginning of gestation were determined by means of a case-
control analysis, using SAS Unconditional Logistic Regression program, 
adapted for the propose of Study 1. Cases were defined as pregnant women 
that filled at least one prescription for an anti-infective drug within the seven 
days before or after the first day of gestation.  Annual trends in anti-infective 
drug use were analyzed using the Cochran-Armitage test for trend (Study 2). 
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All analyses were two-sided and p ≤ 0.05 was considered significant. SAS 9.1 
(SAS Institute Inc., Cary, NC, USA) was used to conduct analyses. 
 
4.3. METHODS FOR STUDY 3 (EXPOSURE TO ANTI-INFECTIVE DRUGS 
DURING PREGNANCY AND THE RISK OF PRETERM BIRTH) 
 
4.3.1. Study design 
 
A case-control study was designed to determine whether there is an 
association between the use of anti-infective drugs during the last two 
trimesters of pregnancy and the risk of preterm birth. Three independent 
analyses were done: the first assessed the risk of preterm birth for all 
combined anti-infective drugs; the second assessed the risk for the classes of 
anti-infective drugs, and the third assessed the risk for individual types of anti-
infective drugs. 
 
4.3.2. Study population 
 
Within the study population described in section 4.1.1, women meeting the 
following eligibility criteria were included in this study: (1) have between 15 
and 45 years of age on the date of entry in the Registry defined as the first 
day of pregnancy; (2) to be continuously insured by the RAMQ drug plan for 
at least 12 months prior to the first day of gestation and during pregnancy; 
and (3) gave birth to a live born singleton. Given that multiple gestations are 
associated with an increased risk of maternal morbidity and mortality, 
independent of maternal age, we decided to select only singleton gestations 
[262]. The end of the pregnancy was defined as the calendar date of delivery. 
If a woman had more than one pregnancy between 1997 and 2003, the first 
pregnancy meeting eligibility criteria was considered for analysis. 
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4.3.3. Assessment of Exposure 
 
In the three case-control analyses, exposure to anti-infective drugs was 
treated dichotomically. Exposure to at least one anti-infective drug and two or 
more anti-infectives were also assessed. Exposure time window was the 
pregnancy’s second (>14 to ≤ 26 weeks of gestational age) or third trimester 
(>26 weeks until delivery). To be considered as exposed in a particular 
trimester, pregnant women had to have at least one prescription for an anti-
infective drug in the corresponding trimester. 
 
4.3.4. Assessment of Outcome 
 
A case of preterm birth was defined as a delivery occurring before the 37th 
week of gestation. Controls were defined as deliveries occurring ≥ 37th week. 
The index date was the date of delivery and the unity of analysis was the 
pregnant woman. Gestational age was obtained from the Med-Echo files. 
 
4.3.5. Covariates 
 
The following variables were considered as potential confounders of the 
association between exposure and the risk of preterm birth, and were 
measured in the year before and during pregnancy: number of different types 
of medications used other than anti-infective, number of different prescribers 
for all medications, number of visits to the physician, visits to the emergency 
department and/or hospitalizations, diabetes (ICD-9 codes 250-259, 271.4, 
790.2 and the filling of prescriptions for medications for diabetes), asthma 
(ICD-9 codes 493.0, 493.1, 493.9 and the filling of prescriptions for any anti-
asthmatic drugs), hypertension (ICD-9 codes 640-642 and the filling of 
prescriptions for any antihypertensive drugs), infections (ICD-9 codes 001-
136), respiratory tract infections (ICD-9 codes 460-466, 472-487), urinary 
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tract and sexually transmitted infections (ICD-9 codes 590, 599-599.6), 
diseases of the female genital tract (ICD-9 codes 617-619). We also 
determined the following socio-economic variables on the index date: 
maternal age, maternal place of residence, maternal RAMQ drug plan status, 
and calendar year of the pregnancy. Potential confounders were selected 
based in the available literature on the risk factors for the pregnancy 
outcomes of interest. In addition, a variable that modified the point estimate of 
the relationship between anti-infective exposure and adverse pregnancy 
outcome by more than 20% was considered a potential confounder, and was 
included in the multivariate model.  
 
4.3.6. Statistical Analysis 
 
Descriptive statistics, Student’s t-tests, and chi-square tests were used to 
compare cases and controls. Univariate and multivariate unconditional logistic 
regression models were built, adjusting for important confounding factors and 
proxy variables for socio-economic, health service use, and co-morbidities. 
Consistency of the model was evaluated using the Hosmer–Lemeshow 
goodness-of-fit test. The association between anti-infective exposure and the 
risk of preterm birth was quantified by means of adjusted odds ratios (ORs), 
>eng</language></record></Cite></EndNote>[ HYPERLINK \l 
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4.4. METHODS FOR STUDY 4 (EXPOSURE TO ANTI-INFECTIVE DRUGS 
DURING PREGNANCY AND THE RISK OF SMALL-FOR-GESTATIONAL-
AGE) 
 
4.4.1. Study design 
 
A case-control study was conducted to determine if there is an association 
between exposure to anti-infective drugs during the last two trimesters of 
pregnancy and the risk of SGA. Three independent analyses were done: the 
first analysis assessed the risk of SGA for all combined anti-infective drugs; 
the second assessed the risk of SGA for the classes of anti-infective drugs; 
and the third assessed the risk for individual types of anti-infective. 
 
4.4.2. Study population 
 
The same study population described on the section 4.3.2 was used for Study 
4. 
 
4.4.3. Assessment of Exposure 
 
The same criteria for ascertainment of exposure described on the section 
4.3.3 were used for Study 4. 
 
4.4.4. Assessment of Outcome 
 
A case of SGA was defined as a pregnancy resulting with a baby’s weigh 
adjusted for gestational age and gender <10th percentile, according to the 
Canadian gender-specific reference curves [263]. A control was defined as a 
pregnancy resulting with a baby’s weight adjusted for gestational age and 
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gender ≥10th percentile. The index date was defined as the date of delivery. 
Birth weight was obtained from Med-Echo and ISQ files. 
 
4.4.5. Covariates 
 
The following variables were considered as potential confounders of the 
association between exposure to anti-infective drugs and the risk of SGA, and 
were measured in the year before and during pregnancy: number of different 
types of medications used other than anti-infectives, number of different 
prescribers for all medications, number of visits to the physician, visits to the 
emergency department and/or hospitalizations, diabetes (ICD-9 codes 250-
259, 271.4, 790.2 and the filling of at least one prescription for medications 
for diabetes, - AHFS codes 68:20.08, 68:20.20, 68:20.92), asthma (ICD-9 
codes 493.0, 493.1, 493.9 and the filling of at least one prescription for any 
anti-asthmatic drugs), hypertension (ICD-9 codes 640-642 and the filling of at 
least one prescription for any antihypertensive drugs - AHFS class 24:08), 
infections (ICD-9 codes 001-136), respiratory tract infections (ICD-9 codes 
460-466, 472-487), urinary tract and sexually transmitted infections (ICD-9 
codes 590, 599-599.6), pelvic inflammatory disease (ICD-9 codes 614-616), 
pre-term rupture of membranes (ICD-9 codes 658), anemia (ICD-9 codes 
280-285), periodontal disease (ICD-9 codes 521-525), renal disorders (ICD-9 
codes 580-589), depression (ICD-9 codes 296, 309, 311), nutritional 
disorders (ICD-9 codes 260-269), and thyroid disorders (ICD-9 codes 240-
246). In addition, we determined the following socio-economic variables at the 
index date from the RAMQ/ISQ databases: maternal age, maternal place of 
residence (urban versus rural), maternal RAMQ drug plan status (adherent 
versus welfare recipient) and calendar year of pregnancy. 
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4.4.6. Statistical Analysis 
 
The same statistical tests described on the section 4.3.6 were used for Study 
4. 
 
4.5. METHODS FOR STUDY 5 (RISKS AND BENEFITS OF THE USE OF 
METRONIDAZOLE DURING PREGNANCY: A REVIEW OF THE 
EVIDENCE) 
 
Study 5 is a systematic review of the evidence on the use of metronidazole 
during pregnancy. In order to retrieve studies addressing the issue, PubMed 
and EMBASE database were systematically searched to retrieve human 
studies published between 1964 through 2010. Combinations of the following 
MeSH terms were used: “metronidazole” or “prematurity” or “preterm birth” or 
“congenital malformations” or “birth defects” or “anomalies” or “pregnancy” as 
well as “antibiotics” or “bacterial vaginosis” or “tricomoniasis”. Additional 
references were identified from the reference lists of retrieved articles. All 
relevant articles, including prospective and retrospective studies, reviews and 
meta-analysis, published in English or French that examined the association 
between gestational exposure to metronidazole and the risk of adverse 
pregnancy outcomes (having data on preterm birth or birth defects) were 
reviewed. Only etiologic studies with clinical relevant definition of exposure 
were considered (exposure during the last two trimesters of pregnancy for 
studies evaluating prematurity and exposure during the first trimester for birth 
defects). Where the estimates for preterm birth or birth defects was not 
reported by authors, we calculated crude ORs and 95% confidence intervals 
(CI) from the available data in order to compare study results and interpret 
data. Analyses were performed using the SAS System for Windows Version 
9.1.3 (SAS Institute Inc, North Carolina, USA). 
  
Chapter 5  
MANUSCRIPTS 
_____________________________________________________________ 
 
The results of this thesis are presented in the following five manuscripts: 
 
• Prevalence and predictors of anti-infective use during pregnancy. 
Fabiano SANTOS MSc, Driss ORAICHI PhD, Anick BÉRARD PhD. 
Pharmacoepidemiology and drug safety 2010; 19: 418–427. 
 
• Trends in anti-infective drugs use during pregnancy. Fabiano 
SANTOS MSc, Odile SHEEHY MSc, Sylvie PERREAULT PhD, Ema 
FERREIRA PharmD, Anick BÉRARD Ph.D. Submitted to the Journal of 
Population Therapeutics and Clinical Pharmacology 2012. 
 
• Exposure to anti-infective drugs during pregnancy and the risk of 
preterm birth. Fabiano SANTOS MSc, Odile SHEEHY MSc, Sylvie 
PERREAULT PhD, Ema FERREIRA PharmD, Anick BÉRARD Ph.D. 
Int J Antimicrob Agents. 2012 Feb;39(2):177-8. 
 
• Exposure to anti-infective drugs during pregnancy and the risk of 
small-for-gestationalage newborns: a case–control study. Fabiano 
SANTOS MSc, Odile SHEEHY MSc, Sylvie PERREAULT PhD, Ema 
FERREIRA PharmD, Anick BÉRARD Ph.D. British Journal of 
Obstetritics and Gynaecology 2011 Oct;118(11):1374-82. 
 
• Risks and benefits of the use of metronidazole during pregnancy: 
a review of the evidence. Fabiano SANTOS MSc, Ema FERREIRA 
PharmD, Anick BÉRARD Ph.D. Submitted to Drug Safety 2012. 
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Fabiano Santos conducted the studies, performed the analyses, and led the 
writing of the manuscripts. Sylvie Perreault and Ema Ferreira helped to 
interpret the results, and revised the manucripts for important intellectual 
content. Odile Sheehy and Driss Oraichid helped with the statistical methods 
and the interpretation of the results. Anick Berard conceived and supervised 
the studies. All authors read and approved the final version of the article. 
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5.1. PREVALENCE AND PREDICTORS OF ANTI-INFECTIVE USE DURING 
PREGNANCY 
 
Fabiano SANTOS1,2  M.Sc, Driss ORAICHI1,2 Ph.D,  Anick BÉRARD1,2 Ph.D 
 
1Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. 
2Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada. 
 
Manuscript published in Pharmacoepidemiology and drug safety 2010, 19: 
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5.1.1 ABSTRACT 
 
Objectives: (1) Measure the prevalence and trends of anti-infective drug use 
before, during, and after pregnancy; (2) to list the doses, classes, types and 
indications for anti-infective use during pregnancy, and (3) to identify 
predictors associated with anti-infective drug use during pregnancy.   
 
Methods: Retrospective cohort study within the Quebec Pregnancy Registry, 
which was created by the linkage of three administrative databases: RAMQ, 
Méd-Echo, and ISQ. Women were eligible if they were (1) continuously 
insured by the RAMQ drug plan for at least 12 months before the first day of 
gestation, during pregnancy and 12 months after the end of the pregnancy. 
97680 pregnant women met the eligibility criteria. Data were collected for 
systemic agents. Logistic regression models were used to quantify predictors 
of use.  
 
Results: Prevalence of anti-infective use during pregnancy was 24.5%.  
Penicillins use increased compared to others classes. The most frequent 
diagnosed infections were respiratory and urinary tract infections. Predictors 
associated with use at the beginning of gestation were having ≥ 2 different 
prescribers [OR= 3.83 (95% CI: 3.3-4.3)], diagnosis of urinary [OR= 1.50 
(95% CI: 1.3-1.8)] and respiratory tract infection [OR= 1.40 (95% CI: 1.2-1.6)] 
in the year before pregnancy. Visits to an obstetrician/gynecologist were 
protective for use [OR= 0.81 (95% CI: 0.67-0.97)].  
 
Conclusion: Anti-infective use during pregnancy is prevalent. The oldest and 
safest agents are preferred.  
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5.1.2. INTRODUCTION  
 
Despite the fact that anti-infective drugs are among the most frequently used 
medications during pregnancy, there is still no agreement regarding the risks 
and benefits for the pregnant woman and the fetus (1). Thus far, only a few 
classes of antimicrobial compounds have been shown to be safe when used 
during gestation. Hence, essential anti-infective drugs used for the treatment 
of maternal infections are sometimes avoided, and this may contribute to the 
progression of intrauterine infections and their adverse consequences (2).  
 
The prescription of an anti-infective drug for a given condition may change in 
response to the bacterial resistance profile. Therefore, pregnant women may 
be exposed to different anti-infective drugs/classes for the same infection, if 
the etiologic agent is resistant to the first therapy chosen (3). It is possible to 
describe a situation where a physician may be in the dilemma of prescribing a 
non-recommended drug, as a second choice, if the first recommended choice 
does not treat the infection. Nevertheless, the risk factors for use presented 
by the pregnant woman may be the same. In order to better address this 
issue, population-based data on the prevalence and trends of anti-infective 
drug use during pregnancy are needed. Identifying characteristics of anti-
infective use during pregnancy will increase appropriate of use and therefore, 
improve mother’s health (4,5).  
 
Thus far, drug utilization reviews focusing specifically on anti-infective drug 
use during gestation have been scarce and were based on retrospective 
maternal recall of drug exposure (6-8). Given that a recent cross-sectional 
study conducted in a teratology information service in Canada showed that 
gestational exposure to antibiotics was the third most frequently inquired 
class of medication by health professionals, there is a need to better assess 
prevalence, trends and indication for their use during pregnancy (9). 
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Therefore, the objectives of this study were (I) to determine the prevalence 
and trends of anti-infective drug use before, during, and after pregnancy; 
[264] to list the doses, classes, types and indications for anti-infective use 
during pregnancy, and (III) to identify predictors associated with anti-infective 
drug use during pregnancy. 
 
5.1.3. METHODS  
 
5.1.3.1. Data sources 
 
Data were obtained from the Quebec Pregnancy Registry, which contains 
data on all pregnancies occurring in Quebec between January 1st 1997 and 
December 31 2003. This registry was built from the linkage of three 
administrative databases: 1) the Régie de l’assurance maladie du Québec 
(RAMQ), 2) Med-Echo database, and 3) the Institut de la statistique du 
Québec (ISQ). The linkage between RAMQ and Med-Echo data was done 
using patients’ ‘Numéro d’assurance maladie’ [258], which is a unique 
identifier for all legal residents of Quebec. The mother-child linkage was 
possible using this unique identifier that links each baby born in Quebec to 
his/her mother in the RAMQ database. The linkage between the RAMQ and 
ISQ was done using the first name, family name and date of birth of both 
mother and child. The final Quebec Pregnancy Registry contains the following 
variables from each database: 
 
1) The RAMQ database provides prospectively collected data on filled 
prescriptions, physician-based diagnoses (according to the International 
Classification of Diseases, ninth revision, ICD-9) (10), physician and 
emergency department visits, procedures and hospitalizations, health care 
providers and patient characteristics, and costs. The RAMQ covers costs of 
medical services for all Quebec residents and the RAMQ drug prescription 
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plan insures approximately 50% of all residents (11), which includes persons 
of 65 years or older, welfare recipients and their children, and all workers and 
their families who do not have access to a private drug insurance program. 
Pharmacists in Quebec are not allowed to substitute one drug for another 
different drug, even if the two drugs belong to same therapeutic class. 
However, pharmacists are given the privilege of substituting trademark drugs 
by their generic equivalent. It is estimated that 30% of women between 15 
and 45 years of age in Quebec are covered by the RAMQ drug plan for their 
medications. Access to health care services between women covered for their 
medications by the RAMQ drug plan and those covered by private drug plan 
is similar (12). 
 
2) The Med-Echo database provides acute care hospitalization data for all 
Quebec residents; it also records gestational age for planned abortions, 
miscarriages and deliveries. Gestational age is defined from the first day of 
the last menstrual period to the end of pregnancy, and confirmed by 
ultrasound around the 18th-20th week of gestation. 
 
3) The ISQ provides demographic data on all births and deaths in Quebec. 
The ISQ contains demographic information on the mother (date of birth, age, 
marital status, mother-tongue, place of birth, area of residence, number of live 
births, number of deliveries), on the father (date of birth, age, mother-tongue, 
place of birth) and on the baby (gender, type of delivery, weight, gestational 
age, order in the family, date of birth).  
 
Pregnancies are identifiable in the RAMQ database by a prenatal visit, an 
ICD-9 diagnostic code or a procedure code related to pregnancy such as an 
ultrasound or amniocentesis; and in the Med-Echo database by a procedure 
code related to pregnancy including a planned or spontaneous abortions or a 
delivery (liveborn or stillbirth). Given that the majority of pregnancies in 
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Quebec deliver in a hospital setting, and that all abortions (planned or 
spontaneous) are performed in subsidized clinics, we feel confident that we 
are capturing the great majority of all pregnancies. Only pregnancies that are 
not detected by the mother (before the pregnancy becomes diagnosed) are 
not captured in our registry. 
 
Data recorded in the RAMQ, Med-Echo and ISQ database have been 
formally evaluated and found to be comprehensive and valid (13,14,15). 
RAMQ and Med-Echo databases have often been used in the past for 
epidemiological research leading to scientific articles published in peer-
reviewed medical journals (16-18).  
 
The final Quebec Pregnancy Registry has often been used to assess the 
risks and benefits of drug use during pregnancy (16,19, 20). 
 
5.1.3.2. Study Population 
 
Within the Registry, women meeting the following eligibility criteria were 
included in this study: they had to be (1) between 15 and 45 years of age on 
the date of entry in the registry defined as the first day of gestation and (2) 
continuously insured by the RAMQ drug plan for at least 12 months prior to 
the first day of gestation, during pregnancy, and for at least 12 months 
following pregnancy. The end of pregnancy was defined as the calendar date 
of a planned abortion, miscarriage, or delivery. If a woman had more than one 
pregnancy between 1998 and 2003, the first pregnancy meeting eligibility 
criteria was included for analysis. 
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5.1.3.3. Outcome measures 
 
Anti-infective drugs were categorized using the 2008 Anatomical Therapeutic 
Chemical (ATC) classification index. Data were collected for oral systemic 
agents in the ATC subgroups J01 (antibacterial agents), J02 (antimycotics), 
and J04 (antimycobacterials). The ATC classification and guidelines are 
updated regularly and the system is widely used internationally for drug 
utilization studies (21).     
 
The prevalence of anti-infective drug use during the 12 months before 
pregnancy was calculated by dividing the number of women receiving at least 
one prescription for an anti-infective in this 12-month period by the total 
number of women that met eligibility criteria. In addition, the prevalence of 
anti-infective drug use in the first trimester (≤14 weeks of gestational age), 
second trimester (>14 to ≤ 26 weeks of gestational age), and third trimester 
(>26 weeks of gestational age) of pregnancy was calculated by dividing the 
number of women filling at least one anti-infective prescription in the 
respective trimester by the number of women in the study during that time 
(depending on the outcome of the pregnancy - abortions, miscarriages or 
delivery - some women were counted in the denominator only in the first or 
second trimester). To be considered as exposed in a particular trimester, 
pregnant women had to have at least one prescription for an anti-infective 
drug in the corresponding trimester. For the five most frequently dispensed 
anti-infective in each period, the mean daily dosage and the mean duration of 
use were calculated. 
 
Women were considered exposed on the first day of gestation and at the end 
of the second trimester of pregnancy if they filled a prescription for an anti-
infective or if the duration of the prescription overlapped these periods. We 
allowed a 7-day grace period between consecutive prescriptions and thus, 
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women were considered exposed if the first day of gestation or the end of the 
second trimester of pregnancy fell during this grace period. 
 
The following variables were considered as potential predictors of receiving at 
least one anti-infective drug at the beginning of gestation and were measured 
at this time: maternal age, maternal place of residence (urban versus rural), 
maternal RAMQ drug plan status (adherent versus welfare recipient), and 
calendar year of the pregnancy. The following variables were also considered 
as potential predictors of receiving at least one anti-infective drug at the 
beginning of gestation and were measured in the year before pregnancy: 
number of different types of medications used other than anti-infective, 
number of different prescribers for all medications, planned abortions or 
miscarriages, number of visits to the physician, visits to the emergency 
department and/or hospitalizations, diabetes, asthma, hypertension, 
infections, respiratory tract infections, human immunodeficiency virus (HIV) 
infection, gastro-intestinal infections, tuberculosis, urinary tract [7] and 
sexually transmitted infections (STI), fungal infections, parasitical infections, 
pelvic inflammatory disease (PID), and viral infections (Table 1).  
 
The use of the data was approved by the CHU Sainte-Justine’s ethics 
committee, and the ‘Commission d’Accès à l’Information du Québec’ (CAI). 
 
5.1.3.4. Statistical analysis 
 
We chose to collect data on the first pregnancy meeting eligibility criteria to 
avoid having dependent units of analyses. Furthermore, the potential risk 
factors can change over time, conditional on the history of pregnancy.  
 
Descriptive statistics were used to summarize the characteristic of the study 
population and to compare anti-invectives’ users to non-users according to 
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trimester of exposure. Chi-square statistics and Student t-tests were used to 
compare proportions and means, respectively. Univariate and multivariate 
unconditional logistic regression models were built, adjusting for important 
confounders and proxy variables for socioeconomic, health services utilization 
and co-morbidities. A variable that modified the point estimate of the 
relationship between anti-infective exposure at the first day of gestational age 
and at the end of the second trimester by more than 20% was considered a 
predictor, and was included in the multivariate model. Consistency of the 
model was evaluated by Hosmer-Lemeshow goodness of fit test. Adjusted 
odds ratios (OR) along with 95% confidence intervals (95% CI) were 
estimated. All analyses were two-sided and p ≤ 0.05 was considered 
significant. SAS version 8.2 (SAS Institute, Cary, NC) was used to conduct 
the analyses. 
 
5.1.4. RESULTS 
 
5.1.4.1. Study population, prevalence, indications for use and types of 
anti-infective used 
 
A total of 97 680 pregnant women within the Quebec Pregnancy Registry met 
eligibility criteria and were thus, included in this study. The mean age of the 
cohort was 27.4 years, 35% of women were welfare recipients and 80% were 
living in an urban area on the beginning of gestation. The overall prevalence 
of anti-infective drug use during pregnancy was 24.5%. The prevalence of 
anti-infective drug use during the 12 months before gestation and during the 
12 months after the end of pregnancy was 40.6% and 45.5%, respectively (p 
< 0.01, Table 2). Anti-infective drug use decreased during the first trimester 
compared to the year before pregnancy (15.3% versus 40.6%, p < 0.01) and 
continued to decrease during the second (10.0%) and third trimester (10.6%) 
(Table 2). 
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The most prevalent indications for anti-infective use are presented in Table 3. 
The most frequent indication for anti-infective use in all study periods in our 
cohort was respiratory tract infections with a peak of 65.7% of all indications 
for anti-infective use in the first trimester of pregnancy. PID was the second 
most diagnosed condition in all periods followed by UTI and STIs.  
 
Table 4 lists the most prevalent anti-infective used stratified by ATC classes 
for each period. Penicillins use increased over time, whereas use of other 
anti-infective classes such as macrolides, quinolones, antimycotics, and 
sulfonamides decreased within the same period. Tetracycline was the least 
used class through all periods.  
 
Amoxicillin was the most used individual drug in all periods, with highest 
frequency of use in the third trimester of pregnancy.  
Phenoxymethylpenicilline had an inversed time-trend tendency (highest 
prevalence in the first trimester and lowest prevalence in the third trimester). 
Two macrolides were among the most used drugs in all periods: 
clarithromycin before pregnancy and in the first trimester, and erythromycin in 
the second and in the third trimester. 
 
Our data showed that ciprofloxacin was the fourth most frequently used anti-
infective drug in the twelve months before pregnancy (7.4%) and in the first 
trimester (6.1%). Antimycotic drugs was the fourth most prevalent class of 
anti-infective used before (8.4%) and showed decreasing proportions of use 
during pregnancy. 
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5.1.4.2. Predictors of anti-infective use 
 
Predictors of anti-infective drug use on the first day of gestation and at the 
end of the second trimester are summarized in Table 5 and Table 6, 
respectively. In multivariate analysis, predictors significantly associated with 
anti-infective drugs use at the beginning of gestation were being on welfare, 
having at least two different prescribers in the year before pregnancy, at least 
six visits to a physician in the year before pregnancy, having a diagnosis of 
infection, tuberculosis, UTI and STIs and respiratory tract infection in the year 
before pregnancy. Being on welfare on the last day of the second trimester 
and having at least six visits to a physician in the twelve months before 
pregnancy were associated with anti-infective use at the end of the second 
trimester of gestation. In contrast, having a visit to an obstetrician or 
gynecologist between the first day of gestation and the last day of the second 
trimester decreased the chance of taking an anti-infective drug at the end of 
the second trimester.  
 
5.1.5. DISCUSSION 
 
5.1.5.1. Trends and predictors of anti-infective drug use during 
pregnancy 
 
To our knowledge, this is the first study that considers in an exhaustive way, 
the trends and predictors of anti-infective drugs use during pregnancy, and 
relevant clinical variables as predictors of use. 
 
The frequency of anti-infective use during pregnancy in our cohort decreased 
progressively from the period before pregnancy through the end of 
pregnancy. The analysis was repeated for the nine months before and the 
nine months after the end of pregnancy, and results remained unchanged. 
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These findings may indicate that physicians are reluctant in prescribing anti-
infective drugs once pregnancy is diagnosed. Studies about the utilization of 
anti-infective drugs during pregnancy in other countries show variable 
proportions of anti-infective drug use. In Hungary, a study showed that 17.0% 
of pregnant women were treated with antibiotics at some point during 
gestation (22). In Germany, 20.0% of pregnant women received antibiotics 
during pregnancy (1). In Denmark, 44.0% of pregnant women received 
prescriptions for at least one drug and the majority of prescriptions were for 
anti-infectives (28.7%) (23). High prevalence of anti-infective use in 
pregnancy was also reported in Australia (24) and in the USA (25, 26). 
 
5.1.5.2. Indications for anti-infective use 
 
In all study periods, respiratory tract infections were the most prevalent 
infections diagnosed in the cohort, followed by PID, UTI and STIs, 
gastrointestinal infections, fungal infections, parasitical infections and 
tuberculosis. 
 
Acute respiratory infections are among the most frequent maternal infections 
during pregnancy, affecting about 10.0% of pregnant women (27). Our results 
may be viewed in light of what could be expected for a nordic country with 
long and rigorous winters. The physiological changes during pregnancy that 
makes pregnant women more susceptible to respiratory tract pathogens may 
also help explain this finding (28). In addition, pregnant women are often in 
contact with young children, so they are at greater risk of developing upper 
respiratory tract infections (29).  
 
UTI and STIs are positively associated with a higher incidence of PID, which 
in turn is related to a increased risk for adverse pregnancy outcomes (30, 31). 
It was estimated that approximately 30-50% of PID diagnosed in Canada is 
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attributable to UTI and STIs (32). In our study, PID and UTI were the second 
and third most prevalent types of diagnosed infections during all periods, 
respectively. Our finding of a high prevalence of PID in third trimester of 
pregnancy is noteworthy. This may indicate that UTI and STIs diagnosed in 
the first and second trimester of pregnancy may be sub-optimally treated, and 
this would potentially be a risk factor for PID development in the third 
trimester.    
 
5.1.5.3. Types of anti-infective drugs used 
 
The most notable finding was the increasing frequency of penicillins use 
throughout all periods considered in our analysis. Other classes of anti-
infective drugs like macrolides, quinolones, antimycotics and sulfonamides 
showed a contrary tendency with decreasing frequency of use. This analysis 
shows a shift in prescription to older anti-infective drugs once pregnancy is 
diagnosed. Similar trends were observed in others studies (1).  
 
In our study, 66.0% of the anti-infective drugs used in the first trimester are 
considered safe – these drugs are not known to be associated with the risk of 
adverse pregnancy outcomes (4). This number rises to 77.0% in the second, 
and to 86.0% in the third trimester of pregnancy. This is a good indication that 
physicians are concerned in not to expose pregnant women to potentially 
harmful anti-infective drugs. However, the use of drugs of uncertain safety 
profiles such as ciprofloxacin and fluconazole in the first trimester, 
doxyciclyne in the second, and nitrofurantoin in the second and third 
trimesters, may also indicate the need for more studies on the risk-benefit 
ratio for the use of these drugs. The exposure to a potentially harmful anti-
infective drug in the first trimester of gestation may be explained by the fact 
that 50.0% of all pregnancies in North America are unplanned (33). The 
pregnant woman and her doctor may not be aware of the existence of the 
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new fetus. The use of less secure and less effective anti-infectives once 
pregnancy is diagnosed may reflect an inappropriate prescribing practice 
among physicians.  
 
5.1.5.4. Predictors for anti-infective use  
 
Our results show that women who were welfare recipients at the beginning of 
gestation were slightly more at risk of use an anti-infective drug at the end of 
second trimester of pregnancy. Older pregnant women were less likely to use 
an anti-infective drug at the beginning of gestation than younger ones. This 
result is corroborated by the fact that infections in younger women are more 
prevalent (1).  
 
Predictors related with a poor health status were among the factors 
associated with exposure of at least one anti-infective drug at the beginning 
of gestation and at the second trimester. These findings may indicate that the 
immune response before and during early pregnancy may play an important 
role in the likeliness of obtaining a prescription for an anti-infective drug 
during gestation. Several factors are responsible for a deficient immune 
response during early pregnancy (28,34,35) and it is important for physicians 
to be aware of underlying conditions that can lead to immunodeficiency 
states. Furthermore, having two or more prescribers in the year before 
pregnancy increased the risk of having a prescription for an anti-infective on 
the first day of gestation. This finding can be explained by the fact that the 
more physicians one consults, the more likely they are of receiving a 
prescription for a drug. The care management can be suboptimal when many 
physicians are consulted without prior knowledge on history of comorbidity 
and drug use. Visits to an obstetrician or gynecologist were protective for use 
of an anti-infective drug at the end of the second trimester. Pregnant women 
who visit their physicians may receive more appropriate treatment and 
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consequently, avoid conditions that predispose them to use of anti-infective 
drugs.  
 
5.1.5.5. Strengths and limitations 
 
This study was conducted on prospectively collected information obtained 
from administrative databases, and thus, we were able to assess a large 
number of potential variables and predictors related to anti-infective drug use 
during pregnancy. Nevertheless, this study has some limitations. The 
prevalence of anti-infective drug use was calculated on the basis of the drugs 
dispensed to study subjects and does not reflect the actual intake. On the 
other hand, the provincial drug plan requires that the beneficiary pay a portion 
of the costs of the prescription medications. This increases the likelihood that 
prescriptions that are filled are in fact consumed. We did not address 
appropriateness of anti-infective prescriptions according to the patterns of the 
most prevalent infections for each period, and we did not evaluate the 
switches between classes according to infections because we do not have 
data on the specific bacterial agent related to the infection. 
 
Furthermore, multiple testing could explain in part some of our findings. Data 
were not available for pregnant women who are not covered by the RAMQ 
drug plan for their medications, nor on anti-infective use for more severe 
infections in hospital setting. This will likely underestimate the prevalence of 
anti-infective use for certain classes of drugs. Given the free universal 
healthcare system in Quebec, we do not believe that this would confound our 
results. Indeed, Bérard and Lacasse have shown that this could affect the 
generalizability of some findings that are more strongly associated with socio-
demographic factors, but this will not affect internal validity (12). 
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5.1.6. CONCLUSION 
 
The use of anti-infective drugs during pregnancy is prevalent and prescribers 
seem to be concerned about the choice of older and well-known safety-profile 
anti-infective drugs.  However, the use of potentially harmful anti-infectives in 
critical periods raises the question of whether the anti-infective prescribing 
practice and use are really appropriate. Health care professionals must 
consider the risk profiles of anti-infective agents in making prescribing 
decisions during pregnancy. Predictors related with lower social/health status 
before and during the first two trimesters of pregnancy increased the 
likelihood of using at least one anti-infective drug.  
 
We highlight the need for evidence-based studies that evaluate the risks and 
benefits of anti-infective drug use during pregnancy adjusting for indication for 
use. 
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Table 1. Type of infections, comorbidities and ICD-9/AHFS assessment code. 
 
Type of infection ICD-9 and AHFS code 
Diabetes ICD-9 codes 250-259, 271.4, 790.2 and the 
filling of prescriptions for medications for 
diabetes, - American Hospital Formulary 
Service (AHFS) 68:20.08, 68:20.20, 68:20.92 
 
Asthma ICD-9 codes 493.0, 493.1, 493.9 and the filling 
of prescriptions for any anti-asthmatic drugs 
Hypertension ICD-9 codes 640-642 and the filling of 
prescriptions for any antihypertensive drugs - 
AHFS class 24:08 
Infections ICD-9 codes 001-136 
Respiratory tract infections ICD-9 codes 460-466, 472-487 
HIV infection ICD-9 codes 042-044 
Gastro-intestinal infections ICD-9 codes 001-009), 
Tuberculosis ICD-9 codes 010-018 
UT/STI ICD-9 codes 590, 599-599.6 
Fungal infections ICD-9 codes 110-118 
Parasitical infections ICD-9 codes 120-136 
PID ICD-9 codes 614-616 
Viral infections ICD9 codes 045-066 
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Table 2. Prevalence of anti-infective drug use before, during, and after 
pregnancy. 
 
Period Number of anti-
infective drug 
users 
Total number 
of women* 
Percentage 
(95% 
Confidence 
interval - CI) 
During the 12 months 
before pregnancy 
39724 97680 40.6 (40.3 – 40.9) 
During pregnancy 23913 97680 24.5 (24.2 – 24.7) 
During the first trimester of 
pregnancy  
(≤14 weeks of gestational 
age) 
14990 97680 15.3 (15.1 – 15.5) 
During the second 
trimester of pregnancy  
(>14 to ≤ 26 weeks of 
gestational age) 
8074 80164 10.0 (9.8 – 10.2) 
During the third trimester of 
pregnancy 
(>26 weeks of gestational 
age) 
6005 56578 10.6 (10.3 – 10.8) 
During the 12 months after 
the end of pregnancy** 
44499 97680 45.5 (45.2 – 45.8) 
 
*Depending on the pregnancy outcome (abortion, miscarriage or delivery), some women were not included in the 
denominators for the prevalence of use in the second or third trimester; 
 
**The end of pregnancy was defined as a planned abortion, a miscarriage, or a delivery, whichever occurred. 
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Table 3. Most prevalent diagnosed infections treated with anti-infectives, 
before, during and after pregnancy. 
 
Type of 
infection, n 
(%)* 
During the 
12 months 
before 
gestation 
(n=97680)**
During the 
first 
trimester 
of 
pregnancy 
(≤14 weeks 
of 
gestational 
age) 
(n=97680)**
During the 
second 
trimester 
of 
pregnancy 
(>14 to ≤ 
26 weeks 
of 
gestational 
age) 
(n=80164)**
During the 
third 
trimester 
of 
pregnancy 
(>26 weeks 
of 
gestational 
age) 
(n=56578)** 
During the 
12 months 
after the 
end of the 
pregnancy** 
(n=97680)** 
Respiratory 
tract infections 
52708 
(62.0) 
12255 
(65.7) 
5640 
(63.5) 
4514 
(42.2) 
45284 
(57.5) 
Pelvic 
Inflammatory 
disease 
16420 
(19.3) 
3873 
(20.7) 
1318 
(14.8) 
2611 
(24.4) 
17606 
(22.4) 
Urinary tract 
and sexually 
transmitted 
8128 (9.5) 659 (3.5) 852 (9.6) 783 (7.3) 7133 (9.0) 
Gastro-
intestinal 
infections 
2113 (2.5) 680 (3.6) 336 (3.8) 302 (2.8) 2133 (2.7) 
Fungal 
infections 
1733 (2.0) 350 (1.9) 153 (1.7) 193 (1.8) 2027 (2.5) 
Parasitical 
Infections 
1153 (1.3) 252 (1.3) 169 (1.9) 150 (1.4) 1199 (1.5) 
Tuberculosis  670 (0.8) 97 (0.5) 94 (1.0) 52 (0.4) 738 (0.9) 
 
Others 2066 (2.4) 466 (2.5) 312 (3.5) 2093 
(19.5) 
2595 (3.3) 
Total of 
Infections 
84991 
(100.0) 
18632 
(100.0) 
8874 
(100.0) 
10689 
(100.0) 
78715 
(100.0) 
 
* Number and percent of all infections during each period 
**Number of women included in the analysis in each period. Depending on the pregnancy outcome (abortion, 
miscarriage or delivery), some women were not included in the denominators for the prevalence of use in the second 
or third trimester. 
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Table 4. Prevalence of anti-infective use before pregnancy, during the first, 
second and third trimester, stratified by drug class. 
 
Class of Anti-
infectives  
(Percentages may not add 
up to 100% due to rounding. 
Groups are not mutually 
exclusive since a woman 
could have received more 
than one class of anti-
infective.  
 
* Were excluded for this 
analyses the ATC/WHO 
subgroups J05 (antivirals for 
systemic use), J06 (immune 
sera and immunoglobulins) 
and J07 (vaccines).  
 
** Number of women who 
received at least one 
antibiotic during the first, 
second, or third trimester, 
respectively. 
 
Number of 
prescriptions 
and percent 
 
12 months 
before 
pregnancy 
(n=39724)** 
Number of 
prescriptions 
and percent 
 
First 
trimester 
(≤14 weeks of 
gestational 
age) 
(n=14990)** 
Number of 
prescriptions 
and percent 
 
Second 
trimester 
(>14 to ≤ 26 
weeks of 
gestational 
age) 
(n=8074)** 
Number of 
prescriptions 
and percent 
 
Third 
trimester 
(>26 weeks of 
gestational 
age) 
(n=6005)** 
Penicillins  23481 (37.7) 7306 (40.8) 4971 (54.3) 4255 (62.0) 
Macrolides, 
lincosamides and 
streptogramins  
12706 (20.4) 3519 (19.6) 1518 (16.6) 1097 (16.0) 
Quinolones 5881 (9.4) 1396 (7.8) 183(2.0) 59 (0.8) 
Antifongiques  5257 (8.4) 1217 (6.8) 192 (2.1) 110 (1.6) 
Sulfonamides  3980 (6.4) 860 (4.8) 202 (2.2) 82 (1.2) 
Cephalosporins  3927 (6.3) 1074 (6.0) 622 (6.8) 600 (8.7) 
Others 
antibacterials  
3304 (5.3) 1253 (7.0) 933 (10.2) 603 (8.8) 
Tetracyclines  3117 (5.0) 1110 (6.2) 490 (5.3) 21 (0.3) 
Others 685 (1.1) 165 (0.9) 36 (0.4) 27 (0.4) 
Total 62338 (100.0) 17901 (100.0) 9147 (100.0) 6854 (100.0) 
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Table 5. Predictors of anti-infective drug use at the beginning of gestation 
 
 
Users on the 
first day of 
gestation 
(n=1840) 
Non-users on 
the first day of 
gestation 
(n=95 840) 
Crude  OR 
(95% CI) 
Adjusted 
OR* (95% 
CI) 
On the first day of gestation 
 
Maternal age, years 
(mean, SD) 
 
26.7 (6.1) 27.4 (6.1) 0.98  
(0.97-0.98) 
0.98 
 (0.98-0.99) 
Urban living, n (%) 
 
No 355 (19.3) 19248 (20.0) 1.00 1.00 
Yes 1485 (80.7) 76592 (80.0) 1.05 
(0.93-1.18) 
1.00 
(0.90-1.13) 
Welfare recipient, n (%) 
 
No 1065 (57.8) 60279 (65.2) 1.00 1.00 
Yes 775 (42.1) 32233 (34.8) 1.36 
(1.24-1.50) 
1.12 
(1.02-1.24) 
During the 12 months before the first day of gestation 
 
Number of different prescribers, n (%) 
 
1 283 (15.4) 50083 (52.2) 1.00 1.00 
≥ 2 1557 (84.6) 45757 (47.7) 6.02 
(5.30-6.80) 
3.83 
(3.30-4.30) 
 
Number of different medications used other than anti-infectives, n (%) 
 
0-2 927 (50.4) 69581 (72.6) 1.00 1.00 
3-5 556 (30.2) 19648 (20.5) 2.12 
(1.91-2.36) 
0.87 
(0.78-1.0) 
≥ 6 357 (19.4) 6611 (6.9) 4.05 
(3.57-4.60) 
1.37 
(1.18-1.50) 
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Number of visits to a physician, n (%) 
 
0-2 228 (12.4) 30783 (32.1) 1.00 1.00 
3-5 394 (21.4) 23245 (24.2) 2.28 
(1.95-2.70) 
1.26 
(1.06-1.50) 
≥ 6 1218 (66.2) 41812 (43.6) 3.94 
(3.14-4.53) 
1.37 
(1.161.62) 
 
 
 
Emergency department visit/hospitalization n (%) 
 
No 1494 (81.2) 81785 (85.3) 1.00 1.00 
Yes 346 (18.8) 14055 (14.7) 1.35 
(1.19-1.51) 
0.9 
(0.80-1.0) 
 
Diabetes, n (%) 
No 1805 (98.1) 94845 (98.9) 1.00 1.00 
Yes 35 (1.9) 995 (1.1) 1.85 
(1.31-2.6) 
1.00 
(0.7-1.5) 
 
Hypertension, n (%) 
 
No 1808 (98.3) 94680 (98.8) 1.00 1.00 
Yes 32 (1.7) 1160 (1.2) 1.45 
(1.00-2.00) 
0.86 
(0.60-1.20) 
Asthma, n (%) 
 
No 1433 (77.9) 83493 (87.2) 1.00 1.00 
Yes 407 (22.1) 12347 (12.8) 1.92 
(1.71-2.14) 
1.13 
(1.00-1.20) 
 
 
Continuation of Table 5 
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Infections, n (%) 
 
No 518 (28.15) 53520 (55.84) 1.00 1.00 
Yes 1,322 (71.8) 42320 (44.2) 3.20 
(2.91-3.50) 
1.30 
(1.11-1.50) 
 
HIV, n (%) 
 
No 1837 (99.84) 95803 (99.96) 1.00 1.00 
Yes 3 (0.16) 37 (0.04) 4.30 
(1.3-13.7) 
2.00 
(0.61-6.00) 
Gastro intestinal infections, n (%) 
 
No 1801 (97.8) 94547 (98.65) 1.00 1.00 
Yes 39 (2.1) 1293 (1.35) 1.60 
(1.15 – 2.18) 
0.90 
(0.60-1.23) 
 
Tuberculosis, n (%) 
 
No 1817 (98.75) 95654 (99.8) 1.00 1.00 
Yes 23 (1.25) 186 (0.2) 6.50 
(4.20 – 10.0) 
4.50 
(2.80-7.10) 
 
 
Urinary tract and sexually transmitted infections, n (%) 
 
No 1627 (88.4) 91221 (95.2) 1.00 1.00 
Yes 213 (11.6) 4619 (4.8) 2.60 
(2.20 – 2.90) 
1.5 
(1.30-1.81) 
 
Fungal infection, n (%) 
 
No 1759 (95.6) 93961 (98.04) 1.00 1.00 
 
     
Continuation of Table 5 
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Yes 81 (4.4) 1879 (1.96) 2.30 
(1.80 – 2.90) 
1.30 
(1.01-1.80) 
 
Parasitical infection, n (%) 
 
No 1803 (97.9) 94886 (99.0) 1.00 1.00 
Yes 37 (2) 954  (1) 2.00 
(1.50-2.80) 
1.10 
(0.70-1.50) 
 
Viral infection, n (%) 
 
No 1670 (90.8) 90242 (94.1) 1.00 1.00 
Yes 170 (9.2) 5598 (5.84) 1.65 
(1.40-1.92) 
1.04 
(0.87-1.22) 
 
Respiratory tract infection, n (%) 
 
No 849 (46.2) 66649 (69.6) 1.00 1.00 
Yes 991 (53.8) 29191 (30.4) 2.60 
(2.40 – 2.92) 
1.40 
(1.20-1.60) 
 
Pelvic inflammatory disease, n (%) 
 
No 1495 (81.2) 85766 (89.5) 1.00 1.00 
Yes 
345 (18.7) 10074 (10.5) 1.90 
(1.70-2.20) 
1.14 
(1.00-1.30) 
 
Percentages may not add up to 100% due to rounding.  
*Adjusted for the covariates in the table and calendar year of pregnancy. 
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Table 6. Predictors of anti-infective drug use at the end of the second 
trimester 
Predictor 
Users on 
the last day 
of second 
trimester of 
gestation 
(n= 685) 
Non-users on 
last day of 
second 
trimester of 
gestation 
(n=55956) 
Crude OR (95% 
CI) 
Adjusted 
OR* (95% 
CI) 
At the end of the second trimester of gestation 
 
Maternal age, years 
(mean, standard 
deviation) 
26.7 (5.5) 27.4 (5.6) 0.97 
(0.96-0.98) 
0.99 
(0.97-1.0) 
Urban inhabitants, n (%) 
 
No 170 (24.8) 13117 (23.5) 1.00 1.00 
Yes 515 (75.2) 42839 (76.5) 0.92 
(0.8-1.1) 
0.86 
(0.7-1.0) 
Welfare, n (%) 
 
No 387 (56.5) 36576 (67.9) 1.00 1.00 
Yes 298 (43.5) 17268 (32.1) 1.63 
(1.4-1.9) 
1.21 
(1.03-1.4) 
During the 12 months before the first day of gestation 
 
Number of visits to a physician, n (%) 
 
0-2 136 (19.8) 18200 (32.5) 1.00 1.00 
3-5 138 (20.15) 13587 (24.2) 1.36  
(1.07-1.72) 
0.98  
(0.76-.26) 
≥ 6 411 (60.0) 24169 (43.1) 2.27 
(1.87-2.7) 
1.00  
(0.78-1.2) 
 
Diagnosis of infections,n (%) 
 
No 275 (40.2) 31719 (56.7) 1.00 1.00 
Yes 410 (59.8) 24237 (43.3) 1.90 
(1.7-2.2) 
1.32 
(1-1.8) 
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Between the first day of gestation and the end of second trimester of gestation 
 
Number of different prescribers, n(%) 
 
1 236 (34.4) 43301 (77.4) 1.00 1.00 
≥ 2 449 (65.5) 12655 (22.6) 6.51 
(5.55-7.63) 
4.25 
(3.5-5.1) 
Asthma, n (%) 
 
No 549 (80.1) 52033 (92.9) 1.00 1.00 
Yes 136 (20.0) 3923 (7.0) 3.30 
(2.7-4.00) 
1.68 
(1.3-2.01) 
 
Infections, n (%) 
 
No 312 (45.5) 43086 (77.0) 1.00 1.00 
Yes 373 (54.4) 12870 (23.0) 4.01 
(3.4-4.6) 
1.43 
(1.00-2.00) 
 
 
Respiratory tract infection, n (%) 
 
No 391 (57.0) 47574 (85.0) 1.00 1.00 
Yes 294 (43.0) 8382 (15.0) 4.26 
(3.6-5) 
1.95 
(1.41-2.7) 
Visit to an Obstetrician or Gynecologist, n (%) 
 
No 163 (23.2) 12174 (21.8) 1.00 1.00 
Yes 522 (76.2) 43782 (78.2) 0.90 
(0.75-1.06) 
0.81 
(0.67-0.97) 
 
Percentages may not add up to 100% due to rounding.  
*Adjusted for the covariates in the table, table 5 and calendar year of the pregnancy. 
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5.2.1. ABSTRACT 
 
Background: Development of knowledge in understanding the use of 
antibiotics during pregnancy has been limited by difficulties in testing 
medications in pregnant women and lack of good evidence-based data. 
Overuse of broad spectra antibiotics is associated with development and 
spread of bacterial resistance, a problem that is faced as a significant threat 
to the public health.  
 
Objectives: To describe trends in use of general and broad spectrum anti-
infective drugs during pregnancy. 
 
Methods: We used the Quebec Pregnancy Registry to analyse trends for use 
of oral anti-infectives dispensed during pregnancy for the five-year period 
comprised between January 1998 and December 2002. Trends in use were 
assessed for classes of anti-infectives and for broad-spectrum drugs. 
Descriptive statistics were used to summarize the characteristics of the study 
population. Annual trends for anti-infective use were analyzed using the 
Cochran-Armitage test. 
 
Results: The use of anti-infective drugs and broad spectrum agents during 
pregnancy decreased from 1998 to 2002 (p ≤ 0.05 for trends). The classes 
that showed increasing trend for use were: macrolides, quinolones, 
tetracyclines, urinary anti-infective drugs and antimycotics. Use of penicillins 
and sulfonamides decreased. Azithromycin showed a remarkable increase in 
its use: 0.04% of all anti-infective prescriptions in 1998, compared to 10.16% 
in 2002. 
 
Conclusions: Decrease of broad-spectrum anti-infective drugs use may have 
been caused by a positive impact of data issue from evidence in everyday life 
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clinical practice. More data are needed to evaluate the impact of the 
knowledge transfer from evidence-base studies on prescription’s trends 
during pregnancy. 
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5.2.2. INTRODUCTION 
 
Physicians and health care providers face on a daily basis the question of 
whether to prescribe or not anti-infective drugs to pregnant women. Healthy 
pregnant women are no more susceptible to most infections than their non-
pregnant counterparts. However, when an infection occurs during pregnancy, 
it can be associated with obstetric complications, and physicians can be 
reluctant to prescribe anti-infectives since some antibiotics (e.g., 
tetracyclines) are known to be teratogens or may have a post-natal toxic 
effect on the newborn (e.g., nitrofurantoin) (1,2). On the other hand, the use 
of antibiotics in pregnancy has been cited as one of the main causes of 
decrease in maternal and perinatal mortality in industrialized countries (3).  
 
An important issue related to the use of such drugs during pregnancy is the 
choice of an effective therapeutic regimen in situations where resistant 
infections are life-threatening. In Canada, the Canadian Committee on 
Antibiotic Resistance (CCAR) encourages health care professionals to 
prescribe fewer antibiotics in an effort to decrease resistance (4). However, 
the development of knowledge in understanding the use of broad spectrum 
antibiotics during pregnancy has been in stalemate in comparison to other 
areas of therapeutics, due mainly to difficulties in testing medications in 
pregnant women and lack of good evidence-based data (5). Use and overuse 
of broad spectra antibiotics is associated with development and spread of 
bacterial resistance, a problem that is faced by health care organizations as a 
significant threat to the public health.  
 
In this study, we describe trends in prescription of general and broad-
spectrum anti-infective drugs during pregnancy in the province of Quebec, 
Canada, over a period of five years.  
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5.2.3. METHODS  
 
5.2.3.1. Data sources 
 
The study was conducted using the Quebec Pregnancy Registry, which 
contains data on all pregnancies with drug plan coverage occurring in 
Quebec between January 1st 1998 and December 31 2002. This registry was 
built from the linkage of three administrative databases: 1) the Régie de 
l’assurance maladie du Québec (RAMQ), 2) Med-Echo database, and 3) the 
Institut de la statistique du Québec (ISQ). The final Quebec Pregnancy 
Registry contains the following variables from each database: 
 
1) The RAMQ database provides prospectively collected data on filled 
prescriptions, physician-based diagnoses (according to the International 
Classification of Diseases, ninth revision, ICD-9) (6), physician and 
emergency department visits, procedures and hospitalizations, health care 
providers and patient characteristics. The RAMQ covers costs of medical 
services for all Quebec residents and the RAMQ drug prescription plan 
insures approximately 50% of all residents, which includes persons of 65 
years or older, welfare recipients and their children, and all workers and their 
families who do not have access to a private drug insurance program (7). The 
maternal use of prescribed anti-infective drugs was identified from the RAMQ 
pharmacy files.  
 
2) The Med-Echo database provides acute care hospitalization data for all 
Quebec residents; it also records gestational age for planned abortions, 
miscarriages and deliveries.  
 
 3) The ISQ provides demographic data on all births and deaths in Quebec.  
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In order to form the Registry, the linkage between RAMQ and Med-Echo was 
done using patients’ Numéro d’assurance maladie [258], which is a unique 
identifier for all legal residents of Quebec. The mother-child linkage was 
possible using the unique identifier that links each baby born in Quebec to 
his/her mother in the RAMQ database. The linkage between the RAMQ and 
ISQ was done using the first name, family name and date of birth of both the 
mother and child. Pregnancies are identifiable in the RAMQ database by a 
prenatal visit, an ICD-9 diagnostic code or a procedure code related to 
pregnancy such as an ultrasound or amniocentesis. MedEcho database 
furnish procedure codes related to pregnancy, including a planned or 
spontaneous abortions or deliveries (live births or stillbirth).  
 
Data recorded in the RAMQ, Med-Echo and ISQ database have been 
formally evaluated and found to be comprehensive and valid (8). RAMQ and 
Med-Echo databases have often been used in the past for epidemiological 
research leading to scientific articles published in peer-reviewed medical 
journals (9). The final Quebec Pregnancy Registry has often been used to 
assess the risks and benefits of drug use during pregnancy (10). The used of 
data from the Registry was approved by the CHU Sainte-Justine’s ethics 
committee, and the ‘Commission d’Accès à l’Information du Québec’ (CAI). 
 
5.2.3.2. Study Population 
 
Anti-infective use was analysed for pregnant women meeting the following 
criteria: (1) have between 15 and 45 years of age on the date of entry in the 
registry defined as the first day of gestation and (2) continuously insured by 
the RAMQ drug plan for at least 12 months prior to the first day of gestation, 
during pregnancy, and for at least 12 months following pregnancy. 
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5.2.3.3. Trends in anti-infective drugs use 
 
We analysed trends for new prescriptions of oral systemic anti-infectives 
dispensed during pregnancy for the five-year period comprised between 
January 1st 1998 and December 31st 2002. Each year was considered 
separately. Trends in use were assessed for overall exposure (exposed 
versus non-exposed) and for the following American Hospital Formulary 
Service (AHFS) classes: antifungals (AHFS 8:12:04), cephalosporins (AHFS 
8:12:06), macrolides (AHFS 8:12:12), penicillins (AHFS 8:12:16), quinolones 
(AHFS 8:12:18), sulfonamides (AHFS 8:12:20), tetracyclines (AHFS 8:12:24), 
other antibacterials (AHFS 8:12:28), antimycobacterials (AHFS 8:16), and 
urinary anti-infectives (AHFS 8:36). We also analysed trends for individual 
drugs (ampicillin, amoxicillin, azithromycin, ciprofloxacin, clarithromycin, 
clindamycin, doxycycline, erythromycin, fluconazole, metronidazole, 
nitrofurantoin, and sulfamethoxazole/trimethoprim (SXT)) and for broad 
spectrum anti-infectives (ampicillin, amoxicillin/clavulanate, azithromycin, 
cefuroxime, cephalexin, ciprofloxacin, clarithromycin, clindamycin, 
doxycycline, erythromycin, fluconazole, levofloxacin, metronidazole, 
minocyclin, moxifloxacin, ofloxacin, nitrofurantoin, and SXT).     
 
5.2.3.4. Statistical analysis 
 
Descriptive statistics were used to summarize the characteristics of the study 
population and to compare anti-infective use during pregnancy according to 
calendar year. Prevalence of anti-infective drug use during pregnancy for 
each year was calculated by dividing the number of women filling at least one 
prescription for an anti-infective drug in each 12-month period by the total 
number of women that met eligibility criteria for that year. Prevalence of use 
for each class and individual molecule was calculated by dividing the total 
number of new prescriptions for each class/type of anti-infective by the total 
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number of filled prescriptions for a giving period. Annual trends in anti-
infective prescriptions were analyzed using the Cochran-Armitage test for 
trend. All analyses were two-sided and p ≤ 0.05 was considered significant. 
SAS version 9.1 (SAS Institute, Cary, NC) was used to conduct the analyses. 
 
5.2.4. RESULTS 
 
97 680 pregnant women within the Quebec Pregnancy Registry met eligibility 
criteria and were included in the study. From this total, 23913 (24.5%) were 
exposed at least once to an anti-infective. There were 34753 filled 
prescriptions for anti-infective drugs during the five-year period considered: 
33510 were new filled prescriptions (3.57% were refill prescriptions).  
 
The overall use of anti-infective drugs during pregnancy decreased from 1998 
to 2002 (p ≤ 0.05 for trends, Table 1). The same result was found when the 
analysis considered the use of broad spectrum agents; for this class, the 
highest prevalence of use was observed in 2000: 38.9% of all anti-infectives 
prescribed in that year were broad spectrum agents. 
 
The classes that showed increasing trend for use were: macrolides, 
quinolones, tetracyclines, urinary anti-infective drugs and antimycotics. Use of 
penicillins and sulfonamides decreased, while cephalosporins, anti-protozoals 
and antimycobacterials showed no trend.  
 
Increased use of azithromycin, nitrofurantoin and fluconazole was observed 
from 1998 to 2002. Azithromycin showed a remarkable increase in its use: 
0.04% of all anti-infective prescriptions in 1998, compared to 10.16% in 2002.  
Drugs like amoxicillin, erythromycin, doxycyclin and SXT showed decrease in 
their use during the same period. These results and the effectives for each 
year are summarized in Table 1.  
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5.2.5. DISCUSSION 
 
The gradual decrease in the use of anti-infective drugs (all confounded) and 
broad spectrum agents during pregnancy observed in our cohort may indicate 
that physicians are concerned about prescribing anti-infective drugs once 
pregnancy is diagnosed. These results may be a sign that Canadian 
clinicians are compliant with the recommendations of the CCAR.  The use of 
narrow-spectrum anti-infective is preferred over those with a broad spectrum 
for the treatment of well-established infection. Studies about the use of broad-
spectrum anti-infectives in other clinical contexts showed increased trends in 
prescription (11).  Prevalence of use of these drugs during pregnancy in other 
countries varies (12). 
 
Several recent studies were published reporting an increased risk of 
congenital malformations after exposure to SXT (13). Even if this drug is 
prescribed for infectious diseases of the urinary, respiratory, and 
gastrointestinal tract, the impact of these studies may have caused physicians 
to decrease prescription of this drug during pregnancy, as observed in our 
cohort. This reduction is probably related to the increase in the use of 
nitrofurantoin, as a SXT substitute. Physicians may feel more confident 
prescribing nitrofurantoin for indications that this switch is justified; 
nitrofurantoin is one of the most used urinary anti-infective drugs during 
pregnancy, mainly because of its well-known safety profile and efficacy14. 
However, increasing nitrofurantoin resistance complicates this choice for 
empiric regimens.  
 
The tapering in the use of SXT and penicillins may partially explain the 
increase in the use of ciprofloxacin, a quinolone antibiotic commonly 
prescribed for the treatment of urinary tract infections. Quinolones, as a class 
also showed increased trends in prescription. Despite the theoretical risk of 
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foetotoxicty after exposure to quinolones, the use of ciprofloxacin has not 
been associated with the risk of congenital malformations (13). We believe 
that, in our study, women were exposed to this drug in the first trimester of 
pregnancy, before being aware of their condition. Exposure to a potentially 
harmful anti-infective drug in the first trimester of gestation may be explained 
by the fact that 50% of all pregnancies in North America are unplanned (1). 
This fact may also be responsible for the augmentation of the use of 
doxycycline and fluconazole. Furthermore, oral fluconzaole became more 
popular than topical azoles for treatment of vaginal candidiasis (13). 
Doxycycline is commonly prescribed after a surgical abortion, and its use is 
related to the raise in these procedures in Quebec during the study period 
(15). 
 
Finally, we observed that macrolides showed increase trends in its use. 
Azithromycin was the individual drug responsible for this effect. Bacterial 
resistance associated with penicillins and the convenience of the short 
treatment course and once daily regimen of azithromycin might have 
contributed to its popularity. Azithromycin and erythromycin have a similar 
mechanism of action. However, azithromycin has advantages over 
erythromycin: better efficacy, broader spectra, and better tolerability. Its main 
indications for use include treatment of mild to moderate infections of the 
respiratory tract and chlamydial cervicitis when administered as a single one-
gram dose. The single oral dose administration increases compliance when 
compared to the standard erythromycin or amoxicillin 7-day regimen (16). 
Growing evidence on the safety and efficacy of azithromycin during 
pregnancy may have played a role in the raise in its use found in our cohort. 
Again, prescription practice seems to be related to the evidence of safety and 
efficacy of medications during pregnancy. Nevertheless, there is controversy 
on diagnosis of pregnancy infections in the absence of bacterial culture data; 
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emergency physicians are usually required to choose empiric therapy without 
such information (17).  
 
This study was conducted on prospectively collected information obtained 
from administrative databases, and hence it has some limitations. Prevalence 
and trends of anti-infective drug use were calculated on the basis of the drugs 
dispensed to study subjects and do not reflect the actual intake. However, the 
provincial drug plan requires that the beneficiary pay a portion of the costs of 
the prescription medications. This increases the likelihood that prescriptions 
that are filled are in fact consumed.  
 
5.2.6. CONCLUSION 
 
In conclusion, physicians seem to be concerned in rationalizing anti-infective 
prescription practice during pregnancy. Decrease of broad-spectrum anti-
infective drugs use may have been caused by a positive impact of data issue 
from evidence in everyday life clinical practice. More data are needed to 
evaluate the impact of the knowledge transfer from evidence-base studies on 
prescription’s trends during pregnancy. 
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Table 1. Trends in anti-infective drug use during pregnancy 
 
Anti-infective 
drugs  
(n, %) 
Number of pregnant women by year 
Total 
Cochran-
Armitage 
Test 
(p value) 
 1998 
(n=25705) 
1999 
(n=22617)
2000 
(n=19093) 
2001 
(n=17338)
2002 
(n=12927) 
 
  
Pregnant women taking an anti-infective* 
 
Yes 6436 
(25.0%) 
5524 
(24.4%) 
4794 
(25.1%) 
4171 
(24.0%) 
2988 
(23.1%) 
23913 
(24.4%) 
0.0002 – 
decrease 
 
No 19269 
(74.9%) 
17093 
(75.8%) 
14299 
(74.8%) 
13167 
(75.9%) 
9939 
(76.9%) 
73767 
(75.5%) 
 
 
      97680 
(100%) 
 
 
Prescriptions filled for anti-infectives* 
 
New 
prescriptions 
9062 
(97.2%) 
7758 
(96.5%) 
6770 
(96.9%) 
5788 
(95.0%) 
4132 
(95.4%) 
33510 
(96.4%) 
 
 
 
 
Refill 
prescriptions 
254 
(2.7%) 
280 
(3.4%) 
214 
(3.0%) 
299 
(4.9%) 196 (4.5%) 
1243 
(3.7%) 
 
 
Spectrum of Anti-infective drug used** 
 
Broad 
spectrum 
3529 
(38.9%) 
2726 
(35.1%) 
2075 
(30.6%) 
1679 
(29.0%) 
1137 
(24.5%) 
11146 
(33.2%) 
 
<.0001 - 
decrease 
Narrow 
spectrum 
5533 
(61.0%) 
5032 
(64.8%) 
4695 
(69.3%) 
4109 
(70.9%) 
2995 
(72.4%) 
22364 
(66.7%) 
 
 
      33510 
(100%) 
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Classes of anti-infective drugs used** 
 
Penicillins 
4980 
(54.9%) 
4132 
(53.2%) 
3154 
(46.5%) 
2553 
(44.1%) 
1712 
(41.4%) 
16531 
(49.3%) 
<.0001 – 
decrease 
 
Macrolides 
1362 
(15.0%) 
1129 
(14.5%) 
1209 
(17.8%) 
1152 
(19.9%) 
814 
(19.7%) 
5666 
(16.9%) 
<.0001 - 
increase 
 
Quinolones 
 
305 
(3.3%) 
 
348 
(4.4%) 
 
359 
(5.3%) 
 
337 
(5.8%) 
 
293  
(7.0%) 
 
1642 
(4.9%) 
 
<.0001 - 
increase 
 
Cephalos-
porins 
437 
(4.8%) 
399 
(5.1%) 
348 
(5.1%) 
258 
(4.4%) 172 (4.1%) 
1614 
(4.8%) 0.0579 
 
Tetracyclines 
294 
(3.2%) 
256 
(3.3%) 
288 
(4.2%) 
402  
(6.9%) 
275  
(6.6%) 
1515 
(4.5%) 
<.0001 - 
increase 
 
UTI 
341  
(3.76 %) 
308 
(3.7%) 
312 
(4.6%) 
301 
(5.2%) 
218  
(5.2%) 
1480 
(4.4%) 
<.0001 - 
increase 
Antimycotics 
307 
(3.3%) 
298 
(3.8%) 
293 
(4.3%) 
244 
 (4.2%) 
208  
(5.0%) 
1350 
(4.0%) 
<.0001 - 
increase 
 
Anti-
protozoals 
342 
(3.7%) 
289 
(3.7%) 
273 
(4.0%) 
121 
(2.0%) 
208  
(5.0%) 
1233 
(3.6%) 0.9878 
Others 
 
270 
(2.9%) 
 
252 
(3.2%) 
 
271 
(4.0%) 
 
239 
(4.1%) 
 
135  
(3.2%) 
 
1167 
(3.4%) 
 
0.005 
 
Sulfonamides 
383 
(4.2%) 
291 
(3.7%) 
202 
(2.9%) 
151 
(2.1%) 
77 
 (1.6%) 
1104 
(3.2%) 
<.0001 - 
decrease 
Antimyco-
bacterials 
41  
(0.4%) 
56 
 (0.7%) 
61 
(0.9%) 
30 
 (0.5%) 
20 
 (0.4%) 
208 
(0.6%) 0.7815 
 
Type of anti-infective drugs used** 
  
Amoxicillin 
3529 
(38.9%) 
2726 
(35.1%) 
2075 
(30.6%) 
1679 
(29.0%) 
1137 
(27.5%) 
11146 
(33.2%) 
<.0001 - 
decrease 
Phenoxy-
methyl-
penicillin 
 
799 
(8.8%) 
 
848 
(10.9%) 
 
626 
(9.2%) 
 
549 
(9.4%) 
 
349 (8.4%) 
 
3171 
(9.4%) 
 
0.2756 
Erythromycin 
 
663 
(7.3%) 
 
419 
(5.4%) 
 
286 
(4.2%) 
 
178 
(3.0%) 
 
103 (2.4%) 
 
1649 
(4.9%) 
 
<.0001 - 
decrease 
 
Azithromycin 
4 
 (0.04%) 
138 
(1.7%) 
436 
(6.4%) 
558 
(9.6%) 
420 
(10.1%) 
1556 
(4.6%) 
<.0001 - 
increase 
Continuation of Table 1 
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Clarithromycin 
 
 
418 
(4.6%) 
330 
(4.2%) 
308 
(4.5%) 
267 
(4.61%) 
177  
(4.2  %) 
1500 
(4.4 %) 0.7643 
Ciprofloxacin 
288 
(3.1%) 
272 
(3.5%) 
260 
(3.8%) 
249 
(4.3%) 
229 
 (5.5%) 
1298 
(3.8%) 
<.0001 - 
increase 
 
Nitrofurantoin 
272 
(3.0%) 
256 
(3.3%) 
270 
(3.9%) 
265 
(4.5%) 
191 
 (4.6%) 
1254 
(3.7%) 
<.0001 - 
increase 
 
Metronidazole 
340 
(3.7%) 
286 
(3.6%) 
272 
(4.0%) 
116 
(2.0%) 
207 
 (5.0%) 
1221 
(3.6%) 0.9156  
 
Doxycycline 
233 
(2.5%) 
164 
(2.1%) 
213 
(3.1%) 
321 
(5.5%) 
217 
 (5.2%) 
1148 
(3.4%) 
<.0001 - 
decrease 
 
Fluconazole 
242 
(2.6%) 
250 
(3.2%) 
249 
(3.6%) 
209 
(3.6%) 
176  
(4.2%) 
1126 
(3.3%) 
<.0001 - 
increase 
 
Trimethoprime
-sufame-
toxazole 
381 
(4.2%) 
290 
(3.7%) 
202 
(2.8%) 
150 
(2.5%) 
75 
 (1.8%) 
1098 
(3.2%) 
<.0001 - 
decrease 
 
Clindamycine 
242 
(2.6%) 
229 
(2.9%) 
246 
(3.6%) 
204 
(3.5%) 115 (2.7%) 
1036 
(3.0%) 0.0444 
 
 
*Based on the number of pregnant women per year. 
** Based on the number of new filled prescriptions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuation of Table 1 
 139
5.3. EXPOSURE TO ANTI-INFECTIVE DRUGS DURING PREGNANCY 
AND THE RISK OF PRETERM BIRTH  
 
Fabiano SANTOS1,2 M.Sc,  Odile SHEEHY2 M.Sc, Sylvie PERREAULT1 
Ph.D, Ema FERREIRA1,2 Ph.D,  Anick BÉRARD1,2 Ph.D 
 
1Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. 
2Research Center, CHU Sainte-Justine, Montreal, Quebec, Canada. 
 
Manuscript published in Int J Antimicrob Agents. 2012 Feb;39(2):177-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 140
5.3.1. ABSTRACT 
 
Objectives: Genitourinary infections during gestation are known risk factors 
for preterm birth.  However, there is still controversy regarding the use of anti-
infective drugs for the management of infections related to this condition. The 
objective of this study was to determine the association between anti-infective 
exposure during the last two trimesters of pregnancy and the risk of preterm 
birth.   
 
Methods: We conducted a case-control study within the Quebec Pregnancy 
Registry. Analyses were done on prospectively collected data on 64618 
pregnant women that met eligibility criteria for the study. Use of oral anti-
infective drugs during the last two trimesters of pregnancy was the main 
exposure definition. A case of preterm birth was defined as a delivery 
occurring before the 37th week of gestation. Controls were defined as 
deliveries occurring ≥ 37th week. The index date was the date of delivery and 
the unity of analysis was the pregnant woman. Unconditional logistic 
regression models were used to generate Odds ratio (OR) along with 95% 
confidence intervals (95%CI).  
 
Results: The prevalence of preterm birth in the study population was 7.2%.  
Exposure to all combined anti-infective drugs was associated with a 
decreased risk of preterm birth (OR=0.78, 95% CI: 0.70-0.88). Use of 
macrolides was associated with a decreased risk (OR=0.65, 95% CI: 0.50-
0.85), whereas the use of metronidazole increased the risk (OR=1.81, 95% 
CI: 1.30-2.54]). Azithromycin was responsible for a protective effect in women 
with premature rupture of membranes (OR=0.31, 95% CI: 0.10-0.93).  
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Conclusion: Physicians must consider therapeutic alternatives to 
metronidazole in the management of infections that predispose to preterm 
birth. 
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5.3.2. INTRODUCTION 
 
Urinary tract infections [7] and bacterial vaginosis (BV) are common during 
pregnancy, with an incidence of 8% for UTIs and 9% to 20% for BV (1,2). 
They have been shown to produce both vaginal and systemic immune 
response and are themselves associated with a high incidence of pelvic 
inflammatory disease (PID), premature rupture of membranes (PROM), and 
preterm birth (3). Although the rate of preterm birth has increased in recent 
years and represents the primary reason for prenatal morbidity and mortality 
in industrialized countries (4), there is still some controversy regarding the 
role of anti-infective drugs in the management of infections related to this 
condition (5). Some studies suggest that a prophylactic anti-infective 
treatment for inhibiting preterm birth is effective only in women with PROM (6) 
although there is no consensus as to which would be the best therapeutic 
choice (7). A Cochrane review concluded that antibiotics routinely 
administrated during the second or third trimester of pregnancy reduce the 
risk of preterm birth (8). However, for pregnant women with intact 
membranes, treatment does not seem to be useful (9). It has also been 
hypothesised that the type of anti-infective may be important. Commonly 
recommended bactericidal drugs could cause the release of a 
microorganism’s metabolic products into the genital-urinary internal 
environment. This effect could trigger the inflammatory pathway leading to 
preterm birth (10,11). Drugs with a bacteriostatic mechanism of action would 
have theoretical advantages over bactericidal anti-infective drugs when 
dealing with infections to avoid preterm birth (12). Several anti-infective 
classes and administration routes were used in these studies, rendering the 
application of these findings difficult in the development of specific guidelines. 
This issue remains controversial (13).  
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Therefore, the objective of this study was to determine the association 
between anti-infective exposure during the second and/or third trimester of 
pregnancy and the risk of preterm birth according to the class and type of 
anti-infective drug.  
 
5.3.3. METHODS  
 
5.3.3.1. Data Source 
 
We used the Quebec Pregnancy Registry (QPR), built from the linkage of 
three administrative databases: the Régie de l’assurance maladie du Québec 
(RAMQ), Med-Echo, and the Institut de la statistique du Québec (ISQ).  
 
The RAMQ database provides information on medical services dispensed to 
all residents of Quebec and on prescriptions filled for residents insured by 
Quebec’s Public Prescription Drug Insurance Plan. This database 
prospectively provides collected data on filled prescriptions, physician-based 
diagnoses (International Classification of Diseases, ICD-9) (14), therapeutic 
procedures and the type of institution where the medical procedures were 
performed, the characteristics of the patient and health care providers, and 
the costs involved. The RAMQ covers costs for medical services to all 
Quebec residents and the RAMQ Prescription Drug Plan covers 
approximately 50% of residents (15), which include persons 65 years and 
older, welfare recipients and their children, and all workers and their families 
who do not have access to a private drug insurance program. It is estimated 
that the medication for 30% of women between 15 and 45 years of age is 
covered by the RAMQ’s drug plan. Access to healthcare services between 
women covered for their medications by the RAMQ’s drug plan and those 
covered by a private drug plan is similar (16). 
 144
The Med-Echo database is a provincial database that records acute care 
hospitalization data for all Quebec residents, including gestational age. 
Gestational age is defined from the first day of the last menstrual period to the 
end of the pregnancy and it is confirmed by ultra-sound around the 18-20th 
week of gestation.  
 
The ISQ administers the Fichier des événements démographiques that 
provides data on all births and deaths in Quebec. The ISQ database contains 
demographic information for the mother (date of birth, age, marital status, 
mother-tongue, place of birth, area of residence, number of live births, 
number of deliveries), the father (date of birth, age, mother-tongue, place of 
birth), and the baby (gender, type of delivery, weight, gestational age, order in 
the family, date of birth).  
 
The linkage between RAMQ and Med-Echo was done using patients’ Numéro 
d’assurance maladie, which is a unique identifier for all legal residents in 
Quebec. The mother-child linkage was possible using the unique identifier 
that links each baby born to his/her mother in the RAMQ database. The 
linkage between the RAMQ and ISQ was done using the first name, family 
name and date of birth of both mother and child.  
 
The Registry contains information on all pregnancies that occurred in Quebec 
between January 1, 1998 and December 31, 2003. The RAMQ and Med-
Echo databases have often been used for epidemiological research leading 
to articles published in peer-reviewed medical journals (17-19). Data recorded 
in the RAMQ medication database and in the Med-Echo database have been 
formally evaluated and found to be comprehensive and valid (20). Medical 
diagnoses and data recorded in the ISQ databases have also been evaluated 
and found to be valid and precise (21, 22).  The Quebec Pregnancy Registry 
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has often been used to assess the risks and benefits of drug use during 
pregnancy (23, 24). 
 
This study was approved by the Sainte-Justine Hospital Ethics Committee, 
and by the Commission d’accès à l’information du Québec, the provincial 
agency that grants authorization for the use of linked administrative 
databases (protocol reference #1740). 
 
5.3.3.2. Study Population 
 
Within the Registry, women meeting the following eligibility criteria were 
included in this study: (1) have between 15 and 45 years of age on the date 
of entry in the Registry defined as the first day of pregnancy (the first day of 
last menstrual period); (2) to be continuously insured by the RAMQ drug plan 
for at least 12 months prior to the first day of gestation and during pregnancy; 
and (3) gave birth to a live born singleton. The end of the pregnancy was 
defined as the calendar date of the delivery. If a woman had more than one 
pregnancy between 1998 and 2003, the first pregnancy meeting eligibility 
criteria was considered for analysis. 
 
5.3.3.3. Study Design  
 
Within the study population, we conducted a case-control study. Three 
independent analyses were done: the first assessed the risk of preterm birth 
for all combined anti-infective drugs; the second assessed the risk for the 
classes of anti-infective drugs, and the third assessed the risk for individual 
types of anti-infective drugs.  
 
A case of preterm birth was defined as a delivery occurring before the 37th 
week of gestation. Controls were defined as deliveries occurring ≥ 37th week. 
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The index date was the date of delivery and the unity of analysis was the 
pregnant woman. 
 
5.3.3.4. Assessment of Exposure 
 
In all analyses, exposure to anti-infective drugs was treated dichotomically. 
We also assessed exposure to at least one anti-infective drug and two or 
more anti-infectives. Exposure window was the pregnancy’s second (>14 to ≤ 
26 weeks of gestational age) or third trimester (>26 weeks until delivery). To 
be considered as exposed in a particular trimester, pregnant women had to 
have at least one prescription for an anti-infective drug in the corresponding 
trimester. 
 
For the first analysis, overall exposure to at least one anti-infective drug (all 
combined) was compared to no exposure. For the second analysis, anti-
infective drugs were grouped in the following American Hospital Formulary 
Service (AHFS) classes: antifongicals (AHFS 8:12:04), cephalosporins (AHFS 
8:12:06), macrolides (AHFS 8:12:12), penicillins (AHFS 8:12:16), quinolones 
(AHFS 8:12:18), sulfonamides (AHFS 8:12:20), tetracyclines (AHFS 8:12:24), 
other antibacterials (AHFS 8:12:28), antimycobacterials (AHFS 8:16), and 
urinary anti-infective drugs (AHFS 8:36). The reference category was 
pregnant women using penicillins (AHFS 8:12:16). For the third analyses, 
data were collected for the following individual drugs: ampicillin, amoxicillin, 
azithromycin, ciprofloxacin, clindamycin, doxycycline, erythromycin, 
fluconazole, metronidazole, nitrofurantoin, and sulfamethoxazole/trimethoprim 
(SXT).   
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5.3.3.5. Covariates 
 
The following variables were considered as potential confounders of the 
association between exposure and the risk of preterm birth, and were 
measured in the year before and during pregnancy: number of different types 
of medications used other than anti-infective, number of different prescribers 
for all medications, number of visits to the physician, visits to the emergency 
department and/or hospitalizations, diabetes (ICD-9 codes 250-259, 271.4, 
790.2 and the filling of prescriptions for medications for diabetes), asthma 
(ICD-9 codes 493.0, 493.1, 493.9 and the filling of prescriptions for any anti-
asthmatic drugs), hypertension (ICD-9 codes 640-642 and the filling of 
prescriptions for any antihypertensive drugs), infections (ICD-9 codes 001-
136), respiratory tract infections (ICD-9 codes 460-466, 472-487), urinary 
tract and sexually transmitted infections ((UT and STI) ICD-9 codes 590, 599-
599.6), PID (ICD-9 codes 614-616), diseases of the female genital tract (ICD-
9 codes 617-619). We also determined the following socio-economic 
variables on index date: maternal age, maternal place of residence (urban 
versus rural), maternal RAMQ drug plan status (adherent versus welfare 
recipient), and calendar year of the pregnancy. 
 
5.3.3.6. Statistical and Sensitivity Analysis 
 
Descriptive statistics were used to compare cases and controls. Student t-
tests and Chi-square tests were used to examine the differences between the 
two groups for continuous and categorical data, respectively. Some women 
may have been diagnosed with an infection after recognition of a pregnancy 
complication such as PROM and treated in the hospital just prior to giving 
birth. Since we relied on outpatient pharmacy records to ascertain exposure, 
such a group of women would have erroneously been considered as non-
exposed. To counter this potential bias, we repeated the three analyses for 
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the group of women with a diagnosis of UT/STI and PROM. Univariate and 
multivariable unconditional logistic regression models were built, adjusting for 
important confounders and proxy variables for socioeconomic, health services 
utilization and co-morbidities. Consistency of the model was evaluated by 
Hosmer-Lemeshow goodness of fit test. Results were expressed in adjusted 
odds ratios (OR) along with 95% confidence intervals (95% CI). SAS version 
9.1 (SAS Institute, Cary, NC) was used to conduct all analyses. 
 
5.3.4. RESULTS 
 
5.3.4.1. Characteristics of the Study Population 
 
64618 pregnant women within the Quebec Pregnancy Registry met the 
eligibility criteria. The mean age of the study population was 27.4 (standard 
deviation 5.9 years), 35% of women were welfare recipients and 80% lived in 
an urban area on the index date. The prevalence of preterm birth was 7.2%. 
Cases were 28% more likely to be welfare recipients at the index date when 
compared to controls (Table 1).  
 
5.3.4.2. Exposure to an Anti-infective Drug and the Risk for Preterm birth 
 
The use of anti-infective drugs during the second or third trimesters of 
pregnancy was slightly higher among controls (18.7%) than among cases 
(17.8%). Exposure to all combined anti-infective drugs during these periods 
was a protective factor for preterm birth (adjusted OR=0.78 [95%CI: 0.70, 
0.88]) (Table 2). 
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5.3.4.3. Classes and Types of Anti-infective Drugs and the Risk of 
Preterm birth 
 
Penicillins and macrolides were significantly associated with a decreased risk 
of preterm birth (adjusted OR=0.65 [95%CI: 0.53, 0.82] and adjusted 
OR=0.65 [95%CI: 0.50, 0.85], respectively, Table 3 and 4). Amoxicillin 
(adjusted OR=0.78 [95%CI: 0.70, 0.87]) and erythromycin (adjusted OR=0.76 
[95%CI: 0.61, 0.95]) both reduced the risk of preterm birth when the reference 
group had no exposure to such drugs, while metronidazole was associated 
with an 81% increase in the risk (adjusted OR=1.81 [95%CI: 1.30, 2.54], 
Table 5). 
 
5.3.4.5. Analysis in the Subgroup of Women with a Diagnosis for UT/STI 
and PROM 
 
We identified 17052 women with a diagnosis of UT/STI (prevalence of 
preterm birth: 9.75%) and 9325 women with a diagnosis of PROM 
(prevalence of preterm birth: 18.25%, Table 6). In the UT/STI subgroup, 
exposure to penicillins was protective for preterm birth (adjusted OR=0.84 
[95%CI: 0.72, 0.99]), whereas metronidazole was associated with an almost 
three-fold increase in the risk (adjusted OR=2.80 [95%CI: 1.65, 4.71]). 
Women with a diagnosis of PROM and who were exposed to macrolides were 
more protected against preterm birth (adjusted OR=0.61 [95%CI: 0.41, 0.90]). 
Azithromycin was responsible for this protective effect (adjusted OR=0.31 
[95%CI: 0.10, 0.93], Table 6). 
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5.3.5. DISCUSSION 
 
The prevalence of preterm birth in our study population is lower than the 
proportion in the Canadian population (8.2%) (25), and in the USA (12.8%) 
(26), and is similar to the proportion reported in Europe (5-9%) (27). In spite 
of medical advances in the area of prenatal care, the annual rate of preterm 
birth is increasing (28). Some explanations for this trend include the use of 
obstetric interventions, increasing rates of multiplicity (29), and older maternal 
age. Our data suggest that factors related to a lower socio-economic and 
health status in the year before and during pregnancy, may be targets for 
preventive interventions in the course of pregnancy. Our findings are 
corroborated by other studies (4,26,30,31). 
 
Maternal infections are related to 40% of the cases of preterm birth (32). 
However, there is some controversy when considering anti-infective drugs to 
reduce the risk of preterm birth with respect to the best therapeutic choice (5). 
Our data suggest that women treated with anti-infective drugs during the 
second or third trimester of pregnancy have a 22% decrease in the risk of 
having a preterm delivery. The decrease in the risk was more evident for 
women taking at least two anti-infectives. Two meta-analyses of randomized 
clinical trials (RCTs) that compared all combined antibiotics with placebo or 
no treatment, failed to demonstrate a significant reduction in the risk of 
preterm birth (8;33). In spite of the overall quality of RCTs included in these 
studies, these meta-analyses could have lacked power to assess a random 
protective effect of several classes of anti-infective drugs combined together. 
As different anti-infective drugs act trough different action mechanisms, this 
could have influenced these results.  
 
In our study, macrolides and penicillins were significantly associated with a 
35% reduction in the risk of preterm birth. Results from others studies 
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corroborate our findings of a beneficial effect of treatment with amoxicillin or 
erythromycin in the management of infections that predispose to preterm 
birth. However, the results of a recent RCT (34) provide evidence against 
antibiotic treatment of asymptomatic women: there was an increase in the risk 
of cerebral palsy in children of women with intact membranes who received 
amoxicillin or erythromycin to avoid preterm birth. Others studies have 
showed the benefits of erythromycin in reducing the risk of preterm birth 
compared to placebo (6,13) and the combination of this drug with clindamycin 
has already been proposed (13,35,36), although the literature concerning this 
regimen is conflicting (33).  
 
Macrolides appears to be more protective in reducing preterm birth, 
compared to penicillins. We believe that the principal reason for this 
difference is the mechanism of action. Macrolides are bacteriostatic, whereas 
penicillins are bactericidals. Treatment of infections with bactericidal drugs is 
associated with the release of endotoxins from bacteriolysis, causing a local 
vaginal inflammatory response and possibly, resulting in preterm birth (13). 
Our analysis shows bacteriostatic drugs to be protective for preterm birth, 
after adjustment for others variables. However, the 95% confidence intervals 
of the point estimate for each class tend to overlap. Further research is 
required to address this question. 
 
Another finding in favor to the bacteriostatic hypothesis is that our results 
showed an increased risk of preterm birth after use of metronidazole. Several 
studies are in agreement with this result (13, 37-39). Furthermore, others 
studies were unable to demonstrate a clear benefit of metronidazole in 
preventing preterm birth (33,40). Despite the evidence against the use of 
metronidazole to treat women at risk for preterm birth, this drug is currently 
indicated for the treatment of bacterial vaginosis (41). Metronidazole is able to 
promote artificial selection of lactobacilli in the vaginal environment, allowing 
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a non-competitive growth of harmful microorganisms, ascending infection, 
stimulation of a local inflammatory process, and early delivery (42).  
 
Finally, a noteworthy finding was the effect of azithromycin in women with a 
diagnosis of UT/STI and PROM. This drug was associated with a reduction of 
70% in the risk of preterm birth in the PROM subgroup. This result indicates 
that azithromycin can be an effective alternative candidate to erythromycin in 
women with PROM. Erythromycin became the preferred choice for women 
with PROM, after the evidence linking amoxicillin/clavulanate (formerly the 
first choice for this condition) with neonatal necrotising enterocolitis (43). 
Since then, the widespread use of erythromycin has been responsible for an 
increase in bacterial resistance and resulting reduction in its efficacy (44). 
Both drugs have a similar mechanism of action, thought azithromycin has 
some advantages over erythromycin: better efficacy, broader spectra, and 
better tolerability (45). However, to date, there are no sound studies that have 
evaluated the risk of azithromycin on adverse pregnancy outcomes. To our 
knowledge, this is the first study that relates azithromycin to a significant 
decrease in the risk of preterm birth. Our results may encourage physicians to 
consider the use of this drug as an alternative in the management of 
infections that predispose to preterm birth.  
 
This study was conducted on a large sample of pregnant women obtained 
from administrative databases and thus, we were able to adjust for several 
variables related to anti-infective drug use and the risk of preterm birth. The 
assessment of exposure in studies using administrative databases offers the 
advantage of avoiding recall bias, a major source of potential bias in 
observational research. We were able to obtain information on classes and 
types of anti-infective drugs according to prescriptions.  
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Dispensing of a prescription does not mean that a patient actually took the 
medication or was completely compliant with treatment. However, the 
provincial drug plan requires that the beneficiary pay a portion of the costs for 
medications. This increases the likelihood that prescriptions that are filled are 
in fact consumed. Data were not available for pregnant women who did not 
use the public healthcare system. However, given the free universal system in 
Québec, we do not believe that this would confound our results, but this could 
affect the generalizability of some findings that may be more strongly 
associated with socio-demographic factors that could act as an effect modifier 
(16). Similarly, data are not available for anti-infective exposure for more 
severe infections in hospital setting. Furthermore, multiple testing could 
partially explain some of our findings. 
 
5.3.6. CONCLUSION 
 
In conclusion, our study showed that the use of anti-infective drugs during the 
second or third trimester of pregnancy was significantly associated with a 
reduced risk of preterm birth. Drugs with a bacteriostatic mechanism of action 
seem to be more effective in avoiding preterm birth, although more data are 
required to clarify this issue. Treatment with metronidazole should be revised 
in women with a higher risk of preterm birth. Azithromycin may be an efficient 
choice in the management of infections that predispose to preterm birth. 
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Table 1.  Characteristics and health status of the study population. 
 
Variables Cases*
(n=4650) 
(7.2%) 
Controls** 
(n=59968) 
(92.8%) 
Crude OR 
[95% CI] 
Adjusted 
ORb 
[95% CI] 
 
Maternal characteristics at the index date 
 
Maternal age 27.4 
(5.9) 
27.3 
(5.5) 
1.00 
[0.99, 1.00] 
1.01 
[0.99, 1.02] 
 
Place of birth 
 
Rural 1053 
(22.6) 
14050 
(23.4) 
1.00 
(reference) 
1.00 
(reference) 
 
Urban 3597 
(77.3) 
45918 
(76.5) 
1.04 
[0.97, 1.12] 
0.99 
[0.91, 1.06] 
 
RAMQ Insurance Status 
 
Adherents 2803 (62.2) 39842 (69.0) 1.00 
(reference) 
1.00 
(reference) 
 
Welfare 
recipients 
1704 (37.8) 17831 (30.9) 1.36 
[1.27, 1.44] 
1.28 
[1.19, 1.36] 
 
 
Health Status and medication use before pregnancy 
 
 
Number of different medications used 
 
0-2 3162 
(68.0) 
44028 
(73.4) 
1.00 
(reference) 
1.00 
(reference) 
 
3-5 1072 
(23.0) 
12170 
(20.3) 
1.23 
[1.14, 1.31] 
1.21 
[1.10, 1.33] 
 
≥ 6 416 
(8.9) 
3770 
(6.2) 
1.53 
[1.38, 1.71] 
1.31 
[1.12, 1.52] 
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Number of different prescribers before pregnancy 
 
0-2 3239 
(69.6) 
43595 
(72.7) 
1.00 
(reference) 
1.00 
(reference) 
≥ 3 1411 
(30.3) 
16373 
(27.3) 
1.16 
[1.08, 1.23] 
0.94 
[0.85, 1.04] 
 
Emergency department visit/hospitalization 
 
No 3888 
(83.6) 
51365 
(85.6) 
1.00 
(reference) 
1.00 
(reference) 
Yes 762 
(16.4) 
8603 
(14.3) 
1.16 
[1.10, 1.22] 
1.02 
[0.93, 1.12] 
 
Physician visits before pregnancy 
 
0-2 125 
(2.7) 
997 
(1.6) 
1.00 
(reference) 
1.00 
(reference) 
 
3-5 258 
(5.5) 
2044 
(3.4) 
1.00 
[0.80, 1.26] 
0.92 
[0.72, 1.17] 
 
≥6 4267 
(91.7) 
56927 
(94.9) 
0.60 
[0.49, 0.72] 
0.41 
[0.33, 0.50] 
 
Comorbidities 
 
Infections 566 
(12.1) 
6556 
(10.9) 
1.13 
[1.03, 1.23] 
1.08 
[0.97, 1.19] 
 
Respiratory 
tract 
infections 
1053 
(22.5) 
14236 
(23.7) 
0.94 
[0.87, 1.01] 
0.92 
[0.85, 1.00] 
 
Urinary tract 
and sexually 
transmitted 
infections 
344 
(7.4) 
3572 
(5.9) 
1.26 
[1.12, 1.41] 
1.12 
[0.99, 1.27] 
 
 
Pelvic 
inflammatory 
disease 
 
519 
(11.6) 
6090 
(10.1) 
1.11 
[1.01, 1.22] 
1.07 
[0.97, 1.18] 
Diseases of 
the female 
genital tract 
1011 
(21.7) 
11583 
(19.3) 
1.16 
[1.08, 1.25] 
1.07 
[0.99, 1.16] 
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Asthma 673 
(14.4) 
7510 
(12.5) 
1.18 
[1.08, 1.30] 
0.99 
[0.90, 1.09] 
 
Diabetes 85 
(1.8) 
551 
(0.9) 
2.00 
[1.60, 2.52] 
1.40 
[1.08, 1.81] 
 
Hypertension 97 
(2) 
695 
(1.1) 
1.82 
[1.46, 2.25] 
1.02 
[0.80, 1.30] 
 
 
Health Status and medication use during pregnancy 
 
 
Number of different medications used 
 
0-2 3720 
(80.0) 
50302 
(83.8) 
1.00 
(reference) 
1.00 
(reference) 
 
3-5 682 
(14.6) 7804 
(13.0) 
1.18 
[1.08, 1.30] 
1.00 
[0.90, 1.12] 
≥ 6 248 
(5.3) 
1862 
(3.1) 
1.80 
[1.57, 2.06] 
1.14 
[0.94, 1.37] 
 
 
Number of different prescribers 
 
0-2 3826 
(82.3) 
51110 
(85.2) 
1.00 
(reference) 
1.00 
(reference) 
 
≥ 3 824 
(17.7) 
8858 
(14.7) 
1.24 
[1.15, 1.34] 
0.98 
[0.87, 1.09] 
 
 
Emergency department visit/hospitalisation 
 
No 152 
(3.2) 
7588 
(12.6) 
1.00 
(reference) 
1.00 
(reference) 
 
Yes 4498 
(96.7) 
52380 
(87.3) 
1.90 
[1.81, 1.98] 
4.58 
[3.86, 5.43] 
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Comorbidities 
 
Infections 539 
(11.6) 
6458 
(10.7) 
1.08 
[0.98, 1.19] 
0.95 
[0.85, 1.05] 
 
Respiratory 
tract 
infections 
647 
(13.9) 
9036 
(15.0) 
0.91 
[0.83, 0.99] 
0.92 
[0.85, 1.02] 
 
Urinary tract 
and sexually 
transmitted 
infections 
 
 
1665 
(35.8) 
 
15387 
(25.6) 
1.61 
[1.52, 1.72] 
1.50 
[1.40, 1.60] 
Pelvic 
inflammatory 
disease 
 
299 
(6.4) 
4514 
(7.5) 
0.84 
[0.75, 0.95] 
1.12 
[0.58, 2.18] 
Diseases of 
the female 
genital tract 
 
996 
(21.4) 
11518 
(19.2) 
1.15 
[1.06, 1.23] 
1.08 
[1.00, 1.17] 
Asthma 825 
(17.4) 
7101 
(11.8) 
1.60 
[1.48, 1.73] 
1.24 
[1.13, 1.36] 
 
Diabetes 320 
(6.8) 
3099 
(5.1) 
1.35 
[1.20, 1.53] 
1.02 
[0.89, 1.17] 
 
Hypertension 617 
(13.2) 
3119 
(5.2) 
2.80 
[2.54, 3.05] 
2.37 
[2.14, 2.62] 
 
 
Visit to an Obstetrician or Gynecologist, n (%) 
 
No 518 
(11.2) 
13569 
(22.6) 
1.00 
(reference) 
1.00 
(reference) 
 
Yes 4132 
(88.8) 
46399 
(77.3) 
2.33 
[2.12, 2.56] 
2.03 
[1.85, 2.25] 
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Number of prenatal visits, n (%) 
 
0-5 
 
 
 
 
1522 
(32.7) 
11273 (18.8) 
1.00 
(reference) 
1.00 
(reference) 
 
 
6-11 2652 
(57) 
33045 
(55.1) 
0.60 
[0.55, 0.63] 
0.50 
[0.45, 0.53] 
 
≥12 476 
(10.2) 
15650 
(26.1) 
0.22 
[0.20, 0.25] 
0.16 
[0.15, 0.18] 
 
 
*Percentages may not add up to 100% due to rounding.  
**Adjusted for calendar year of pregnancy 
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Table 2.  Exposure to anti-infective drugs and the risk of preterm birth 
 
Variables Cases* 
(n=4650) 
(7.2%) 
Controls* 
(n=59 968) 
(92.8%) 
 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
Anti-infective Drug use 
 
Anti-infective use during the second and/or the third trimesters of pregnancy 
 
No 3823  
(82.2) 
48759  
(81.3) 
1.00  
(reference) 
1.00  
(reference) 
Yes 827  
(17.8) 
11209  
(18.7) 
0.94  
[0.87, 1.01] 
0.78  
[0.70, 0.88] 
At least 1 anti-
infective drug 
666  
(14.3) 
9043  
(15) 
0.93  
[0.86, 1.02] 
0.86  
[0.79, 0.95] 
2 or more anti-
infective drugs 
161  
(3.3) 
2166  
(3.6) 
0.90  
[0.76, 1.07] 
0.79  
[0.66, 0.95] 
 
Anti-infective use before pregnancy 
 
No 2788  
(60.0) 
36487  
(60.8) 
1.00  
(reference) 
1.00  
(reference) 
Yes 1862  
(40.0) 
23481  
(39.1) 
1.03  
[0.97, 1.10] 
0.95  
[0.88, 1.03] 
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Anti-infective use any point during pregnancy 
 
No 3366  
(72.4) 
43753  
(72.9) 
1.00  
(reference) 
1.00  
(reference) 
Yes 1284  
(27.6) 
16215  
(27.0) 
1.02  
[0.96, 1.10] 
1.08  
[0.97, 1.20] 
 
Anti-infective use during the first trimester of pregnancy 
 
No 3935  
(84.6) 
52130 
(86.9) 
1.00  
(reference) 
1.00  
(reference) 
Yes 715  
(15.3) 
7838  
(13) 
1.20  
[1.11, 1.31] 
1.13 
[1.03, 1.24] 
 
*Percentages may not add up to 100% due to rounding. 
**Analysis adjusted for all the variables present in Table 1, and calendar date. 
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Table 3. Exposure to anti-infective drugs and the risk of preterm birth – 
analysis by class. 
 
Variables Cases* 
(n=4650) 
(7.2%) 
 
Controls* 
(n=59968) 
(92.8%) 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
 
 
Anti-infective Drugs use by Pharmacological Class – 2nd or 3rd trimester 
 
 
Antimycobacterials 
 
No 4645 (99.8) 59963 (99.9) 1.00 (reference) 1.00 (reference) 
 
Yes 5 (0.11) 32 (0.1) 2.01 [0.78, 5.17] 1.64 [0.62, 4.32]
 
Antimycotics 
 
No 4630 (99.5) 59786 (99.7) 1.00 (reference) 1.00 (reference) 
 
Yes 20 (0.5) 182 (0.3) 1.42 [0.90, 2.25] 1.33 [0.82, 2.15]
 
Cephalosporins 
 
No 4560 (98.1) 58894 (99.2) 1.00 (reference) 1.00 (reference) 
 
Yes 90 (1.9) 1074 (1.8) 1.08 [0.87, 1.34] 0.93 [0.74, 1.17]
 
Macrolides 
 
No 4538 (97.6) 58241 (99.8) 1.00 (reference) 1.00 (reference) 
 
Yes 112 (2.4) 1727 (2.8) 0.83 [0.68, 1.01] 0.65 [0.50, 0.85]
 
Penicillins 
 
No 4119 (88.5) 52161 (87.0) 1.00 (reference) 1.00 (reference) 
 
Yes 531 (11.4) 7807 (13.0) 0.86 [0.78, 0.94] 0.65 [0.53, 0.82]
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Quinolones 
No 4631 (99.5) 59650 (99.5) 1.00 (reference) 1.00 (reference) 
 
Yes 19 (0.5) 318 (0.5) 0.77 [0.5, 1.22] 0.97 [0.46, 2.05]
 
 
Sulfonamides 
No 4639 (99.8) 59750 (99.6) 1.00 (reference) 1.00 (reference) 
 
Yes 11 (0.2) 218 (0.4) 0.65 [0.35, 1.19] 0.60 [0.22, 1.55]
 
Tetracyclines 
 
No 4649 (99.9) 59920 (99.9) 1.00 (reference) 1.00 (reference) 
 
Yes 1 (0.1) 48 (0.1) 0.27 [0.04, 1.95] 0.36 [0.05, 2.64]
Urinary anti-infectives 
 
No 4563 (98.1) 59068 (98.5) 1.00 (reference) 1.00 (reference) 
 
Yes 87 (1.9) 900 (1.5) 1.25 [1.00, 1.56] 0.95 [0.73, 1.25]
 
Others 
 
No 4610 (99.1) 59552 (99.3) 1.00 (reference) 1.00 (reference) 
 
Yes 40 (0.8) 416 (0.7) 1.24 [0.90, 1.72] 1.17 [0.84, 1.63]
 
 
*Percentages may not add up to 100% due to rounding. 
**Analysis adjusted for all the variables present in Table 1, and calendar date. 
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Table 4. Exposure to anti-infective drugs and the risk of preterm birth – class 
analysis, reference: penicillin 
 
Variables Cases* 
(n=4650) 
(7.2%) 
Controls* 
(n=59968) 
(92.8%) 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
Classes 
Antimycobacterials 5 (0.11) 20 (0.03) 3.73 [1.40, 9.98] 2.63 [0.94, 7.40]
 
Antimycotics 8 (0.17) 94 (0.16) 1.27 [0.61, 2.62] 1.25 [0.58, 2.66]
 
Cephalosporins 49 (1.05) 573 (0.96) 1.27 [0.93, 1.73] 1.22 [0.88, 1.67]
 
Macrolides 80 (1.72) 1204 (2.01) 0.99 [0.77, 1.26] 0.92 [0.72, 1.19]
 
Penicillins 455 (9.7) 6777 (11.3) 1.00 (reference) 1.00 (reference) 
 
Quinolones 4 (0.09) 40 (0.07) 1.50 [0.53, 4.20] 1.61 [0.55, 4.71]
 
Tetracyclines 1 (0.02) 31 (0.05) 0.48 [0.06, 3.52] 0.50 [0.06, 3.70]
 
Urinary anti-
infectives 
 
52 (1.12) 551 (0.92) 1.40 [1.04, 1.90] 1.30 [0.95, 1.77]
 
Others 27 (0.60) 267 (0.40) 1.50 [1.00, 2.26] 1.41 [0.92, 2.15]
 
*Percentages may not add up to 100% due to rounding. 
**Analysis adjusted for all the variables present in Table 1, and calendar date. 
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Table 5. Exposure to anti-infective drugs and the risk of preterm birth – 
individual drugs analysis. 
*Percentages may not add up to 100% due to rounding. **Analysis adjusted for all the 
variables present in Table 1, and calendar date. 
 
 
 
 
 
 
Effect of individual drugs Cases* 
(n=4650) 
(7.2%) 
Controls* 
(n=59968) 
(92.8%) 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
Ampicillin 11 (0.24) 113 (0.2) 1.25 [0.67, 2.33] 1.17 [0.62, 2.19]
 
Amoxicillin 435 (9.35) 6391 (10.6) 0.86 [0.78, 0.95] 0.78 [0.70, 0.87]
 
Azithromycin 26 (0.56) 392 (0.65) 0.85 [0.57, 1.27] 0.79 [0.52, 1.18]
 
Ciprofloxacin 8 (0.17) 84 (0.14) 1.23 [0.56, 2.54] 1.15 [0.54, 2.44]
 
Clindamicin 35 (0.75) 328 (0.5) 1.38 [0.97, 1.95] 1.27 [0.90, 1.82]
 
Doxyciclin 1 (0.02) 21 (0.04) 0.61 [0.08, 4.56] 0.80 [0.10, 6.40]
 
Erythromycin 90 (1.95) 1374 (2.3) 0.84 [0.68, 1.04] 0.76 [0.61, 0.95]
 
Fluconazole 13 (0.28) 109 (0.2) 1.55 [0.87, 2.74] 1.40 [0.76, 2.52]
 
Metronidazole 41 (0.88) 287 (0.5) 1.85 [1.33, 2.57] 1.81 [1.30, 2.54]
 
Nitrofurantoin 87 (1.9) 900 (1.5) 1.25 [1.00, 1.56] 1.06 [0.84, 1.33]
 
Trimethoprim/ 
Sulfamethoxazole 
 
 
11 (0.24) 
 
213 (0.36) 
0.66 [0.36, 1.22] 0.60 [0.32, 1.10]
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Table 6. Exposure to anti-infective drugs and the risk of preterm birth - UTI 
and PROM subgroup analysis. 
 
Variables 
 
UTI/STI 
(n=17 052, cases=9.75%)* 
PROM 
(n=9 325, cases=18.25%)* 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
Crude OR 
[95% CI] 
Adjusted OR** 
[95% CI] 
 
Anti-infective Drugs use by Pharmacological Class – 2nd or 3rd trimester 
(reference: no exposure to the respective class) 
 
Anti-infective use 
during the 
second and/or the 
third trimesters of 
pregnancy 
 
0.96 [0.85, 1.10] 1.10 [0.85, 1.43] 0.98 [0.86, 1.13] 0.90 [0.76, 1.05]
Anti-
mycobacterials 
 
1.23 [0.28, 5.40] 1.47 [0.32, 6.73] 2.25 [0.20, 24.7] 2.35 [0.19, 28.3]
Antimycotics 
 
1.52 [0.82, 2.81] 1.57 [0.81, 3.06] 1.80 [0.80, 4.08] 1.65 [0.66, 4.08]
Cephalosporins 
 
1.19 [0.90, 1.60] 1.14 [0.83, 1.55] 1.07 [0.71, 1.61] 1.04 [0.67, 1.62]
Macrolides 
 
0.90 [0.67, 1.20] 0.84 [0.62, 1.15] 0.70 [0.48, 1.02] 0.61 [0.41, 0.90]
Penicillins 
 
0.84 [0.73, 0.98] 0.84 [0.72, 0.99] 0.98 [0.83, 1.16] 0.91 [0.76, 1.10]
Quinolones 
 
0.70 [0.35, 1.27] 0.93  [0.35, 2.50] 0.62 [0.24, 1.58] 1.20 [0.32, 4.56]
Sulfonamides 
 
0.48 [0.19, 1.19] 0.42 [0.11, 1.63] 0.35 [0.08, 1.50] 0.25 [0.03, 1.80]
Tetracyclines 
 
0.77 [0.10, 6.0] 0.84 [0.09, 7.88] 2.25 [0.20, 24.7] 1.35 [0.10, 17.6]
Urinary anti-
infectives 
 
1.12 [0.85, 1.50] 1.23 [0.91, 1.66] 1.05 [0.69, 1.60] 0.99 [0.63, 1.55]
Others 
 
0.85 [0.50, 1.51] 0.73 [0.40, 1.32] 1.18 [0.65, 2.13] 1.07 [0.58, 2.00]
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Anti-infective Drugs use by Pharmacological Class – 2nd or 3rd trimester 
(reference: exposure to penicillins) 
 
Anti-
mycobacterials 
 
1.80 [0.21, 15.0] 1.80 [0.16, 19.8] 4.61 [0.28, 74.1] 3.75 [0.22, 64.2]
Antimycotics 
 
1.85 [0.76, 4.45] 1.84 [0.72, 4.66] 0.77 [0.17, 3.46] 1.26 [0.26, 6.10]
Cephalosporins 
 
1.65 [1.10, 2.49] 1.40 [0.90, 2.16] 1.12 [0.63, 1.98] 1.10 [0.60, 2.01]
Macrolides 
 
2.15 [0.47, 9.9] 2.14 [0.44, 10.4] 0.50 [0.29, 0.85] 0.46 [0.26, 0.81]
Penicillins 
 
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Quinolones 
 
0.83 [0.10, 6.37] 0.67 [0.08, 5.42] 1.15 [0.12, 10.4] 1.39 [0.14, 13.7]
Sulfonamides*** 
 
1.25 [0.87, 1.80] 1.14 [0.78, 1.67] *** *** 
Tetracyclines 
 
1.54 [0.18, 12.6] 2.13 [0.23, 19.4] 2.30 [0.20, 25.5] 1.47 [0.11, 19.7]
Urinary anti-
infectives 
 
1.24 [0.82, 1.86] 1.24 [0.80, 1.90] 0.85 [0.48, 1.52] 0.80 [0.44, 1.47]
Others 1.02 [0.49, 2.15] 0.88 [0.40, 1.91] 1.21 [0.60, 2.48] 1.30 [0.62, 2.76]
Anti-infective Drugs use by Individual drug – 2nd or 3rd trimester 
 
Amoxicillin 
 
0.88 [0.76, 1.03] 0.90 [0.75, 1.06] 0.95 [0.80, 1.14] 0.87 [0.70, 1.08]
Ampicillin 
 
0.72 [0.26, 2.00] 1.03 [0.35, 2.97] 1.72 [0.61, 4.84] 2.97 [0.93, 9.48]
Azithromycin 
 
0.95 [0.55, 1.65] 0.88 [0.50, 1.60] 0.71 [0.35, 1.45] 0.31 [0.10, 0.93]
Ciprofloxacin 
 
1.12 [0.44, 2.85] 1.00 [0.36, 2.77] 1.50 [0.40, 5.51] 1.40 [0.13, 14.7]
Clindamycin 
 
0.94 [0.50, 1.75] 0.77 [0.40, 1.48] 1.11 [0.57, 2.17] 1.19 [0.55, 2.58]
Doxyciclin*** 
 
1.54 [0.18, 12.8] 1.12[0.09, 13.9] *** *** 
Erythromycin 
 
0.92 [0.66, 1.27] 0.88 [0.62, 1.25] 0.67 [0.44, 1.03] 0.61 [0.36, 1.04]
Fluconazole*** 
 
1.70 [0.83, 3.47] 1.64 [0.75, 3.56] *** *** 
Metronidazole 2.7 [1.67, 4.35] 2.80 [1.65, 4.71] 2.45 [1.37, 4.36] 1.87 [0.97, 3.62]
Continuation of Table 6 
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Nitrofurantoin 
 
1.12 [0.85, 1.50] 1.21 [0.90, 1.64] 1.05 [0.69, 1.60] 0.73 [0.42, 1.29]
Trimethoprim- 
sulfamethoxazole 
 
0.50 [0.20, 1.23] 0.42 [0.16, 1.09] 0.37 [0.08, 1.57] 0.52 [0.11, 2.36]
 
*Percentages may not add up to 100% due to rounding.  
**Analysis adjusted for all the variables present in Table 1, and calendar date. 
***No data available for the PROM subgroup. 
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5.4.1. ABSTRACT 
 
Objective: To determine the association between anti-infective exposure 
during the last two trimesters of pregnancy and the risk of small-for-
gestational-age (SGA) newborns.   
 
Study Design: Case-control study within the Quebec Pregnancy Registry. 
 
Setting: Province of Quebec, Canada. 
 
Study population: Analyses were done on prospectively collected data of 
63338 pregnant women that met eligibility criteria for the study (8192 cases 
and 55146 controls). 
 
Methods: Unconditional logistic regression models were used to quantify the 
association between exposure to anti-infective drugs and the risk of SGA.  
 
Main outcome measures: A case of SGA was defined as a pregnancy 
resulting in a baby’s weigh adjusted for gestational age and gender <10th 
percentile, according to the Canadian gender-specific reference curves. A 
control was defined as a pregnancy resulting in a baby’s weight adjusted for 
gestational age and gender ≥10th percentile.  
 
Results: Exposure to all combined anti-infective drugs was not associated 
with the risk of SGA (OR= 0.97, 95%CI: 0.91-1.04). Use of 
sulfamethoxazole/trimethoprim was associated with SGA (OR= 1.61, 95%CI: 
1.16-2.23), whereas the use of urinary anti-infective drugs decreased the risk 
(OR= 0.80, 95%CI: 0.65-0.97).  
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Conclusions: Exposure to sulfamethoxazole/trimethoprim during the last two 
trimesters of pregnancy was associated with SGA. Further research is 
needed to address the use of other therapeutic alternatives in the 
management of infections that predispose to SGA infants in pregnant women 
with other risk factors for this condition.  
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5.4.2. INTRODUCTION 
 
Intrauterine growth restriction (IUGR) is an important and often under-
diagnosed condition during pregnancy that may cause important implications 
on the health of an infant and on his on-going health (1). Small-for-
gestational-age (SGA) is often taken as a good proxy for IUGR. Although the 
definition is somewhat arbitrary, a common cut-off point for SGA is the 10th 
percentile of birth weight for gestational age and sex, based on the 
distribution in the standard population. This is the one most often used 
definition in published clinical studies dealing with risk factors for IUGR (2). 
SGA babies are at increased risk of long-term morbidity, including neurologic 
and behavior problems, delayed growth during childhood, short stature, 
hypertension, obesity, and type II diabetes in adulthood (3,4). The exact 
consequences of SGA on the subsequent development of these infants 
depend on the specific cause giving rise to the IUGR, its time of occurrence 
and the duration of the impairment (5). As the burden is so significant, the 
detection and management of risk factors are crucial (6). Among the putative 
risk factors for SGA, common maternal infections have been positively 
associated with a sub-optimal placental perfusion and a dysfunction of the 
placental microvascularity, which results in an inadequate maternal supply of 
oxygen and nutrients to the fetus and the consequent decreased ability of the 
fetus to use the supply (1,7,8).   
 
The use of anti-infective drugs seems to be the natural choice to treat 
maternal infections, thus preventing SGA and other infection-related adverse 
pregnancy outcomes. Despite the very frequent usage of anti-infective drugs 
during pregnancy (9), there is still some controversy regarding the risks and 
benefits of such usage on the pregnant woman and her unborn child. Only a 
few classes of antimicrobial compounds have been shown to be fetus-safe 
when used during gestation, such as older beta-lactams. Furthermore, the 
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association between these drugs and the risk of SGA has not been 
extensively assessed. Some studies have tested the hypothesis that maternal 
exposure to some antibiotics, such as sulfonamides and tetracyclines, could 
cause adverse pregnancy outcomes that share a placenta-mediated pathway, 
as in the cases for IUGR (10). Since randomized trials on therapeutic harm 
are rarely ethical and practical during pregnancy, this issue would be better 
addressed by large population-based studies derived from evidence-based 
data. A better understanding of the possible role of maternal anti-infective 
drug usage on fetal growth could eventually lead to interventions such as the 
identification of an effective treatment for women at higher risk of having SGA 
newborns. 
 
Therefore, the objective of this study was to determine the association 
between anti-infective exposure during the second or third trimester of 
pregnancy and the risk of SGA, according to the class and type of anti-
infective used.  
 
5.4.2. METHODS  
 
5.4.2.1. Data sources 
 
We used the Quebec Pregnancy Registry, built from the linkage of three 
administrative databases: the Régie de l’assurance maladie du Québec 
(RAMQ), Med-Echo, and the Institut de la statistique du Québec (ISQ).  
 
RAMQ database provides information on medical services dispensed to all 
Quebec residents and on prescriptions filled for residents insured by 
Quebec’s Public Drug Insurance Plan. This database prospectively provides 
collected data on filled prescriptions, physician-based diagnoses 
(International Classification of Diseases, ninth revision, ICD-9) (11), 
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therapeutic procedures, characteristics of the patient and health care 
providers, and the costs involved. The RAMQ covers the costs for medical 
services provided to all Quebec residents and the drug insurance plan 
insures approximately 50% of Quebec residents, which include persons of 65 
years or older, welfare recipients and their children, and all workers and their 
families who do not have access to a private drug insurance program (12). 
Access to health care services between women covered for their medications 
by the RAMQ’s drug plan and those covered by private drug plans is similar 
(13). 
 
The Med-Echo database records acute care hospitalization data for all 
Quebec residents; it also records gestational age for planned abortions, 
miscarriages and deliveries. Gestational age is defined from the first day of 
the last menstrual period to the end of pregnancy, and confirmed by 
ultrasound around the 18th-20th week of gestation.  
 
The ISQ administers the Fichier des événements démographiques that 
provides data on all births and deaths in Quebec. The following demographic 
information is included: for the mother (date of birth, age, marital status, 
mother-tongue, place of birth, area of residence, number of live births, 
number of deliveries), for the father (date of birth, age, mother-tongue, place 
of birth); and for the baby (gender, type of delivery, weight, gestational age, 
order in the family, date of birth).  
 
The linkage between RAMQ and Med-Echo data was done using patients’ 
Numéro d’assurance maladie [258], which is a unique identifier for all legal 
residents of Quebec. The mother-child linkage was possible using the unique 
identifier that links each baby born in Quebec to his/her mother in the RAMQ 
database. The linkage between the RAMQ and ISQ was done using the first 
name, family name and date of birth of both the mother and child.  
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The RAMQ and Med-Echo databases have often been used for 
epidemiological research leading to scientific articles published in peer-
reviewed medical journals (14-16). Data recorded in the RAMQ medication 
database and in the Med-Echo database have been formally evaluated and 
found to be comprehensive and valid (17). Medical diagnoses and data 
recorded in the ISQ databases have also been evaluated and found to be 
valid and precise (18,19). The Registry has often been used to assess the 
risks and benefits of drug use during pregnancy (20,21). 
 
This study was approved by the Sainte-Justine Hospital Ethics Committee 
and by the Commission d’accès à l’information du Québec, the provincial 
agency that grants authorization for the use of linked administrative 
databases. 
 
5.4.2.2. Study Population 
 
Within the Registry, women meeting the following eligibility criteria were 
included in this study: (1) have between 15 and 45 years of age on the date 
of entry in the Registry defined as the first day of pregnancy (the first day of 
last menstrual period); (2) to be continuously insured by the RAMQ drug plan 
for at least 12 months prior to the first day of gestation and during pregnancy; 
and (3) gave birth to a live born singleton. The end of the pregnancy was 
defined as the calendar date of the delivery. If a woman had more than one 
pregnancy between 1998 and 2003, the first pregnancy meeting eligibility 
criteria was considered for analysis. 
 
5.4.2.3. Study Design and Outcome Definition 
 
We conducted a case-control study. Three independent analyses were done: 
the first analysis assessed the risk of SGA for all combined anti-infective 
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drugs; the second assessed the risk of SGA for the classes of anti-infective 
drugs; and the third assessed the risk for individual types of anti-infective.  
 
A case of SGA was defined as a pregnancy resulting with a baby’s weigh 
adjusted for gestational age and gender <10th percentile, according to the 
Canadian gender-specific reference curves (22). A control was defined as a 
pregnancy resulting with a baby’s weight adjusted for gestational age and 
gender ≥10th percentile. The index date was defined as the date of delivery. 
 
5.4.2.4. Exposure to Anti-infective Drugs 
 
In all analyses, the exposure to anti-infective drugs was treated 
dichotomously. The exposure window was the pregnancy’s second (>14 to ≤ 
26 weeks of gestational age) or third trimester (>26 weeks of gestational 
age). To be considered as exposed in a particular trimester, pregnant women 
had to have filled at least one prescription for an anti-infective drug in the 
corresponding trimester, or if the duration of a prescription overlapped the 
corresponding trimester. 
 
For the first analysis, overall exposure to at least one anti-infective drug (all 
combined) was compared to no exposure (reference category). For the 
second analysis, anti-infective drugs were grouped in the following American 
Hospital Formulary Service (AHFS) classes: cephalosporins (AHFS 8:12:06), 
macrolides (AHFS 8:12:12), penicillins (AHFS 8:12:16), sulfonamides (AHFS 
8:12:20), urinary anti-infectives (AHFS 8:36) and other antibacterials (AHFS 
8:12:28). For the third analysis, data were analyzed for the following 
individual drugs: ampicillin, amoxicillin, azithromycin, ciprofloxacin, 
clindamycin, doxycycline, erythromycin, fluconazole, metronidazole, 
nitrofurantoin, and sulfamethoxazole/ trimethoprim (SXT).   
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5.4.2.5. Covariates 
 
The following variables were considered as potential confounders of the 
association between exposure to anti-infective drugs and the risk of SGA, and 
were measured in the year before and during pregnancy: number of different 
types of medications used other than anti-infectives, number of different 
prescribers for all medications, number of visits to the physician, visits to the 
emergency department and/or hospitalizations, diabetes (ICD-9 codes 250-
259, 271.4, 790.2 and the filling of at least one prescription for medications 
for diabetes, - AHFS codes 68:20.08, 68:20.20, 68:20.92), asthma (ICD-9 
codes 493.0, 493.1, 493.9 and the filling of at least one prescription for any 
anti-asthmatic drugs), hypertension (ICD-9 codes 640-642 and the filling of at 
least one prescription for any antihypertensive drugs - AHFS class 24:08), 
infections (ICD-9 codes 001-136), respiratory tract infections (ICD-9 codes 
460-466, 472-487), urinary tract and sexually transmitted infections (UT and 
STI) ICD-9 codes 590, 599-599.6), pelvic inflammatory disease (ICD-9 codes 
614-616), pre-term rupture of membranes (ICD-9 codes 658), anemia (ICD-9 
codes 280-285), periodontal disease (ICD-9 codes 521-525), renal disorders 
(ICD-9 codes 580-589), depression (ICD-9 codes 296, 309, 311), nutritional 
disorders (ICD-9 codes 260-269), and thyroid disorders (ICD-9 codes 240-
246). Diagnosis for hypertension and diabetes covers the entire study period. 
Diagnostic codes related to renal disorders refer to acute renal conditions. 
Women counted for these variables during the last year before pregnancy are 
not likely to be the same women with a code for this variable during 
pregnancy. In addition, we determined the following socio-economic variables 
at the index date from the RAMQ/ISQ databases: maternal age, maternal 
place of residence (urban versus rural), maternal RAMQ drug plan status 
(adherent versus welfare recipient) and calendar year of pregnancy. 
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5.4.2.6. Statistical Analysis 
 
Descriptive statistics, Student t-tests and Chi-square test were used to 
compare cases and controls. Univariate and multivariate unconditional logistic 
regression models were built, adjusting for important confounders and proxy 
variables for socioeconomic, health services utilization and co-morbidities. 
Consistency of the model was evaluated by Hosmer-Lemeshow goodness of 
fit test. Sensitivity analysis was done using a cut-off point of <3rd percentile of 
birth weight for gestational age and sex, as definition for SGA. The 
association between anti-infective exposure and the risk of SGA was 
quantified by means of adjusted odds ratios (OR) along with 95% confidence 
intervals (95% CI). SAS version 9.1 (SAS Institute Inc. North Caroline, USA) 
was used to conduct analyses. 
 
5.4.3. RESULTS 
 
5.4.3.1. Characteristics of the Study Population 
 
A total of 63 338 pregnant women within the registry met the eligibility criteria 
and were included in this study. The mean age of the cohort was 27.1 years 
(standard deviation: 5.6 years), 35% of women were welfare recipients and 
80% were living in an urban area on the index date. The mean gestational 
age at delivery was 39.1 weeks for cases (median: 40 weeks, standard 
deviation: 1.7) and 38.8 weeks for controls (median: 39 weeks, standard 
deviation: 2.1). The prevalence of SGA in our study population was 13% (n= 
8192 cases). Cases were more likely to be welfare recipients at the index 
date compared to controls (OR= 1.38, 95% CI: 1.31-1.45) (Table 1). 
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5.4.3.2. Exposure to Anti-infectives and the Risk of SGA 
 
We found that anti-infective drugs used during the second or third trimester of 
pregnancy were higher in cases (20.1%) compared to controls (18.4%). Our 
data showed that exposure to anti-infective drugs (all combined) during this 
period was not associated with SGA (OR= 0.97, 95%CI: 0.91-1.04) (Table 1). 
 
5.4.3.3. Classes and Types of Anti-infective and the Risk of SGA 
 
Exposure to sulfonamides during the second or third trimester of pregnancy 
was significantly associated with SGA, when analyses were done using no 
exposure to sulfonamides as the reference group (OR= 1.66, 95%CI: 1.20-
2.30, Table 2), and when the reference group was formed by women exposed 
to penicillins (OR= 1.91, 95%CI: 1.23-2.95, Table 3). SXT was the individual 
sulfonamide drug associated with SGA (OR= 1.61, 95%CI: 1.16-2.23, Table 
4) 
 
The use of urinary anti-infectives during the same period decreased the 
frequency of SGA (OR= 0.80, 95%CI: 0.65-0.97, Table 2). Nitrofurantoin 
seems to be the responsible for this effect (OR= 0.80, 95%CI: 0.66-0.98, 
Table 4). Amoxicillin was another individual drug associated with a decreased 
frequency of SGA (OR =0.92, 95%CI: 0.85-0.99, Table 4). 
 
There was no qualitative difference when the analyses were done using a 
cut-off point of <3rd percentile of birth weight for gestational age and sex, as 
definition for SGA. 
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5.4.4. DISCUSSION 
 
The prevalence of SGA in our study population (13%) was higher than the 
one previously reported for the Canadian population (7.8%) (23). This can be 
due to the fact that our population is formed by women with a lower socio-
economic status, which is a known risk factor for SGA (6). Furthermore, SGA 
is a relative measure and varies according to the standard used for 
calculation. There is still controversy as to what is the optimal method to 
assess newborn infant size in identifying SGA babies (24-26). The standard 
used for this study is the population-based Canadian reference for birth 
weight for gestational age (22).   
 
Our results showed that in multivariate adjusted models, exposure to 
sulfonamides during the second or third trimester of pregnancy increases the 
probability of having a SGA newborn. These drugs are the first-line agent for 
the treatment of urinary tract infections among women allergic to penicillins 
(27). SXT is a folic acid antagonist that inhibits deoxyribonucleic acid 
synthesis by interfering with the production of folic acid. This combination is 
highly specific for bacterial DNA (28). However, recent evidence suggests 
that there is an association between exposure to SXT and adverse pregnancy 
outcomes, such as congenital malformations and placenta-mediated events 
like preeclampsia (10,29). In one of these studies, exposure to folic acid 
antagonists, for which SXT was the most prevalent, was associated with an 
increased risk of fetal growth restriction and fetal death (10). Although some 
methodological flaws in this study, the authors put their findings in 
perspective with a very strong biological rational: a placental microvascular 
disease may arise from a maternal folate-homocysteine metabolic defect 
caused by an exposure to these drugs. In the absence of confounding by 
indication, this can explain how SXT is associated with the development of 
the events that lead to SGA newborns. Other possible related factors are the 
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well documented SXT gastrointestinal adverse effects (nausea, vomiting, 
diarrhea and stomatitis) that could play a synergic role in preventing the fetus 
from receiving essential micronutrients from the mother (28). 
 
Given the scarcity of sulfonamides exposure in our study population, it is 
unlikely that the population attributable risk for SGA due to such exposure is 
high enough to justify the SXT suspension from clinical practice. However, 
our findings bring attention to unsuspicious non-antibiotic properties of old 
and well known anti-infective drugs and the clinical implications of these 
properties. In fact, there is increasing evidence that some other anti-
infectives, may show different biological actions in the modulation of the 
inflammatory pathway, apoptosis inhibition, regulation of bone metabolism 
and angiogenesis (30). Further research is needed to address this issue. 
 
Nitrofurantoin and amoxicillin were associated with a reduction in the risk of 
SGA, although the clinical significance of the amoxicillin risk reduction is 
questionable. Nitrofurantoin is one of the oldest urinary anti-infective drugs 
available and it can be safely used by pregnant woman in any given trimester 
(29). The choice of SXT, nitrofurantoin or other drug as appropriate regimens 
for the management of urinary tract infections, is based upon the results from 
susceptibility testing (27). Nitrofurantoin can be an efficient candidate in the 
treatment of urinary tract infections in women with other SGA-related risk 
factors. Nevertheless, increasing nitrofurantoin resistance complicates the 
choice of empiric regimens.  
 
To our knowledge, this is the first population-based study assessing the 
association between SGA and the use of anti-infective drugs in a large 
population of pregnant women. Furthermore, it has the largest sample size of 
all studies that addressed IUGR related outcomes. We were able to adjust for 
a large number of potential variables and predictors related to anti-infective 
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use and the risk of SGA. The assessments of exposures in studies using 
administrative databases offer the advantage of not being influenced by recall 
bias. We were also able to get accurate information on several classes and 
types of anti-infectives according to prescriptions.  
 
This study had some limitations inherent to the use of administrative 
databases. We were unable to measure some risk factors for SGA such as 
smoking, illicit substances, alcohol and caffeine intake. Data on maternal 
height and weight are missing in the Quebec Pregnancy Registry. Indeed, 
these variables are associated with SGA.  In the other hand, it is not clear if 
maternal height and weight are independently associated with anti-infective 
drugs use during gestation. However, residual confounding can be present. 
The dispensing of a prescription does not mean that a patient actually took 
the medication or was completely compliant with treatment. Nevertheless, the 
provincial drug plan requires that the beneficiary pay a portion of the costs of 
the prescription medications. This increases the likelihood that filled 
prescriptions are in fact consumed.   
 
Multiple testing could partially explain some of our findings. Data were not 
available for pregnant women who did not use the public healthcare system. 
Given that Quebec’s health insurance plan is free, we do not believe that this 
would confound our results, but rather affect the generalizability of some 
findings that may be more strongly associated with socio-demographic factors 
that could act as an effect modifier (13). Similarly, data are not available for 
anti-infective exposure in more severe hospital infections nor for over-the-
counter drugs. However, all systemic anti-infective drugs available in Quebec 
are dispended by a pharmacist under the filling of a prescription, so this can 
reduce the probability of bias. 
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5.4.5. CONCLUSION 
 
Exposure to sulfonamides and SXT during the last two trimesters of 
pregnancy was associated with an increased frequency of SGA. Use of 
nitrofurantoin and amoxicillin decreased the risk.  Physicians should consider 
the use of other therapeutic alternatives to sulfonamides in the management 
of infections that predispose to SGA children in pregnant women with other 
risk factors for this condition. 
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Table 1. Exposure to anti-infective drugs during pregnancy and the risk of 
SGA and characteristics of the study population* 
 
Variables 
 
Cases 
(n, %) 
(n=8192) 
(13%) 
Controls 
(n, %) 
(n=55146) 
(87%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Anti-infective Drug use 
 
Anti-infective use during the second and/or the third trimesters of pregnancy 
 
No 6540 (79.8) 44982 (81.5) 1.00 
(reference) 
1.00 (reference) 
Yes 1652 (20.1) 10164 (18.4) 1.11  
(1.05-1.18) 
0.97  
(0.91-1.04) 
 
Maternal characteristics at the index date 
 
Maternal age  
(mean, SD) 
 26.9 (5.8) 27.3 (5.5) 
0.98  
(0.98-0.99) 0.99 (0.99-1.00) 
Gestational age 
(mean, SD) 
 39.1 (1.7) 38.8 (2.1) ** ** 
 
Place of birth 
Rural  1924 (23.5) 12924 (23.4) 
1.00 
(reference) 1.00 (reference) 
Urban    6268 (76.5) 42222 (76.6) 
0.99  
(0.94-1.05) 0.96 (0.90-1.01) 
 
RAMQ Insurance Status 
Adherents 4907 (61.7) 36950 (69.7) 
1.00 
(reference) 1.00 (reference) 
Welfare recipients    3045 (38.3) 16075 (30.3) 
1.42  
(1.36-1.49) 1.38 (1.31-1.45) 
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Health Status and medication use before pregnancy 
 
 
Number of different medications used 
 
0-2 5688 (69.4) 40549 (73.5) 1.00 
(reference) 
1.00 (reference) 
3-5 1848 (22.5) 11157 (20.2) 1.18  
(1.11-1.24) 
1.06 (0.99-1.14) 
≥ 6 656 (8.0) 3440 (6.2) 1.36  
(1.24-1.48) 
1.03 (0.92-1.16) 
 
Number of different prescribers before pregnancy 
 
0-2 5691 (69.5) 40188 (72.9) 1.00 
(reference) 
1.00 (reference) 
≥ 3 2501 (30.5) 14958 (27.1) 1.18  
(1.12-1.24) 
0.97 (0.90-1.05) 
 
Emergency department visit/hospitalization 
 
No 6909 (84.3) 47215 (85.6) 1.00 
(reference) 
1.00 (reference) 
Yes 1283 (15.7) 7931 (14.4) 1.10 (1.03-
1.17) 
1.00 (0.94-1.08) 
 
Physician visits before pregnancy 
 
0-2 2499 (30.5) 17789 (32.2) 1.00 
(reference) 
1.00 (reference) 
3-5 1901 (23.2) 13564 (24.6) 0.99  
(0.93-1.06) 
0.96 (0.90-1.03) 
≥6 3792 (46.3) 23793 (43.1) 1.13  
(1.07-1.12) 
0.98 (0.92-1.06) 
Comorbidities 
 
Infections 982 (11.9) 6009 (10.9) 1.11  
(1.04-1.19) 
1.03 (0.95-1.11) 
Respiratory tract 
infections 
1965 (23.9) 13041 (23.6) 1.02 
(0.96-1.07) 
0.95 (0.89-1.00) 
Urinary tract and  
 sexually transmitted 
infections 
564 (6.8) 3276 (5.9) 1.17  
(1.06-1.28) 
1.06 (0.96-1.17) 
Continuation of Table 1 
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Pelvic inflammatory 
disease 
914 (11.1) 5571 (10.1) 1.12  
(1.04-1.20) 
1.04 (0.96-1.12) 
Diseases of female 
genital tract 
1709 (20.8) 10629 (19.2) 1.10  
(1.04-1.16) 
1.01 (0.95-1.08) 
Asthma 1189 (14.5) 6840 (12.4) 1.20  
(1.12-1.28) 
1.04 (0.97-1.12) 
Diabetes*** 538 (6.5) 3866 (7.0) 0.93  
(0.85-1.02) 
0.80 (0.72-0.88) 
Hypertension*** 719 (8.8) 3502 (6.3) 1.42  
(1.30-1.54) 
1.35 (1.24-1.48) 
Anemia 123 (1.5) 776 (1.4) 1.07  
(0.88-1.29) 
0.95 (0.78-1.16) 
Periodontal disease 38 (0.4) 157 (0.2) 1.63  
(1.14-2.33) 
1.55 (1.07-2.22) 
Renal disorders 20 (0.2) 79 (0.1) 1.71  
(1.05-2.8) 
1.19 (0.70-2.02) 
Depression 426 (5.2) 2472 (4.5) 1.17  
(1.05-1.23) 
0.96 (0.86-1.08) 
Nutritional disorders 6 (0.07) 30 (0.05) 1.34  
(0.56-3.23) 
1.35 (0.55-3.33) 
Thyroid disorders 202 (2.5) 1350 (2.45) 1.00  
(0.86-1.17) 
0.94 (0.80-1.11) 
 
Health Status and medication use during pregnancy 
 
 
Number of different medications used 
 
0-2 6589 (80.4) 46375 (84.1) 1.00 
(reference) 
1.00 (reference) 
3-5 1230 (15.0) 7078 (12.8) 1.22 
 (1.14-1.30) 
1.05 (0.97-1.14) 
≥ 6 373 (4.5) 1693 (3.0) 1.55  
(1.38-1.74) 
1.22 (1.05-1.41) 
 
Number of different prescribers during pregnancy 
 
0-2 6715 (82.0) 47145 (85.5) 1.00 
(reference) 
1.00 (reference) 
≥ 3 1477 (18.0) 8001 (14.5) 1.30  
(1.22-1.37) 
1.05 (0.97-1.15) 
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Emergency department visit/hospitalization 
 
No 1517 (18.5) 5592 (10.1) 1.00 
(reference) 
1.00 (reference) 
Yes 6675 (81.5) 49554 (89.9) 0.50  
(0.46-0.52) 
0.48 (0.45-0.51) 
 
Physician visits during pregnancy 
 
0-2 117 (1.4) 865 (1.5) 1.00 
(reference) 
1.00 (reference) 
3-5 287 (3.5) 1824 (3.3) 1.16 (0.92-
1.46) 
1.15 (0.90-1.46) 
≥6 7788 (95.0) 52457 (95.1) 1.10 (0.90-
1.33) 
1.16 (0.94-1.43) 
 
Comorbidities 
 
Infections 913 (11.1) 5965 (10.8) 1.03  
(0.96-1.11) 
0.99 (0.92-1.08) 
Respiratory tract 
infections 
1269 (15.5) 8235 (14.9) 1.04  
(0.97-1.11) 
0.96 (0.90-1.03) 
Urinary tract and  
sexually transmitted 
infections 
2261 (27.6) 14482 (26.2) 1.07  
(1.01-1.12) 
1.06 (1.00-1.12) 
Pelvic inflammatory 
disease 
616 (7.5) 4125 (7.5) 1.00  
(0.92-1.09) 
0.96 (0.87-1.05) 
Diseases of female 
genital tract 
1702 (20.8) 10491 (19.0) 1.11  
(1.05-1.18) 
1.10 (1.03-1.16) 
Asthma 1225 (14.9) 6555 (11.9) 1.30  
(1.22-1.39) 
1.14 (1.06-1.23) 
Diabetes*** 538 (6.6) 3866 (7.0) 0.93  
(0.85-1.02) 
0.80 (0.72-0.88) 
Hypertension*** 719 (8.8) 3502 (6.3) 1.42  
(1.30-1.54) 
1.36 (1.24-1.48) 
Anemia 172 (2.1) 964 (1.7) 1.20  
(1.02-1.42) 
1.17 (0.98-1.38) 
Periodontal disease 21 (0.3) 64 (0.12) 2.21  
(1.35-3.62) 
1.97 (1.19-3.26) 
Renal disorders 30 (0.4) 90 (0.16) 2.25  
(1.48-3.40) 
1.70 (1.09-2.67) 
Depression 
 
 
207 (2.5) 1036 (1.9) 1.35  
(1.16-1.57) 
1.17 (0.99-1.38) 
Continuation of Table 1 
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Nutritional disorders 10 (0.12) 36 (0.07) 1.87  
(0.92-3.77) 
1.79 (0.87-3.70) 
Thyroid disorders 188 (2.3) 1124 (2.0) 1.13  
(0.96-1.32) 
1.16 (0.97-1.38) 
Pprom 1147 (14.0) 8043 (14.6) 0.95  
(0.89-1.02) 
1.04 (0.97-1.12) 
Cesarian section 483 (5.9) 4127 (7.5) 0.77 
 (0.70-0.85) 
0.82 (0.74-0.91) 
 
* Analysis adjusted for calendar year of pregnancy. 
** Given that SGA is a composite measure that takes into account gestational age at 
delivery, there is no need to adjust for GA at delivery in the analysis. 
       *** Diagnosis covering the entire study period. 
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Table 2.  Exposure to anti-infective classes during pregnancy and the risk of 
SGA* 
 
 
 Cases (n, %) 
(n=8192) (13%) 
Controls (n, %) 
(n=55146) (87%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Anti-infective drugs use by pharmacological class – 2nd or 3rd trimester 
 
Cephalosporins 
 
No 8012 (97.8) 54178 (98.2) 1.00 (reference) 1.00 (reference)
Yes 180 (2.2) 968 (1.7) 1.26 (1.07-1.47) 1.09 (0.92-1.30)
Macrolides 
 
No 7902 (96.5) 53626 (97.2) 1.00 (reference) 1.00 (reference)
Yes 290 (3.5) 1520 (2.8) 1.30 (1.14-1.47) 1.09 (0.95-1.24)
Penicillins 
 
No 7085 (86.5) 48060 (87.1) 1.00 (reference) 1.00 (reference)
Yes 1107 (13.5) 7086 (12.9) 1.06 (0.99-1.13) 0.94 (0.87-1.01)
Sulfonamides 
 
No 8141 (99.4) 54978 (99.7) 1.00 (reference) 1.00 (reference)
Yes 51 (0.6) 168 (0.3) 2.05 (1.50-2.80) 1.66 (1.20-2.30)
Urinary anti-infectives 
 
No 8074 (98.5) 54293 (98.4) 1.00 (reference) 1.00 (reference)
Yes 118 (1.5) 853 (1.6) 0.93 (0.76-1.13) 0.80 (0.65-0.97)
Others 
 
No 8126 (99.2) 54769 (99.3) 1.00 (reference) 1.00 (reference)
Yes 66 (0.8) 377 (0.7) 1.18 (0.90-1.50) 1.02 (0.78-1.33)
 
 
* Adjusted for all others variables present in Table 1 and calendar year of pregnancy. 
 
 
 199
Table 3.  Exposure to anti-infective classes during pregnancy and the risk of 
SGA (reference group: women exposed to penicillins)* 
 
 Cases (n, %) 
(n=8192) (13%) 
Controls (n, %) 
(n=55146) (87%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Class of anti-infective drug 
 
Cephalosporins 88 (1.07) 530 (0.96) 1.10 (0.86-1.39) 1.10 
 (0.86-1.39) 
Macrolides 200 (2.4) 1065 (1.9) 1.24 (1.05-1.46) 1.17  
(0.99-1.38) 
Penicillins 933 (11.4) 6178 (11.2) 1.00 (reference) 1.00 
(reference) 
Sulfonamides 28 (0.34) 92 (0.17) 2.01 (1.31-3.09) 1.91  
(1.23-2.95) 
Urinary anti-
infectives 
 
67 (0.8) 527 (0.96) 0.84 (0.64-1.09) 0.82  
(0.63-1.07) 
Others 42 (0.5) 244 (0.4) 1.14 (0.81-1.59) 1.10  
(0.79-1.55) 
 
* Adjusted for all variables present in Table 1 and calendar year of pregnancy. 
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Table 4.  Exposure to individual anti-infective drugs during pregnancy and the 
risk of SGA (reference group: women with no exposure to each drug)* 
 
 Cases (n, %) 
(n=8192) (13%)
Controls (n, %)
(n=55146) 
(87%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Effect of individual drugs 
 
Ampicillin 16 (0.20) 101 (0.18) 1.07  
(0.63-1.81) 
0.96  
(0.57-1.65) 
Amoxicillin 890 (10.8) 5827 (10.5) 1.03  
(0.95-1.11) 
0.92  
(0.85-0.99) 
Azithromycin 56 (0.68) 354 (0.64) 1.06  
(0.80-1.41) 
0.87  
(0.65-1.17) 
Ciprofloxacin 20 (0.24) 60 (0.11) 2.24  
(1.35-3.72) 
1.56  
(0.92-2.64) 
Clindamicin 55 (0.67) 299 (0.54) 1.24 
 (0.92-1.65) 
1.06  
(0.80-1.43) 
Doxyciclin 5 (0.06) 14 (0.03) 2.40  
(0.86-6.68) 
1.13  
(0.40-3.19) 
Erythromycin 239 (2.9) 1204 (2.2) 1.34 
 (1.17-1.55) 
1.15  
(0.99-1.33) 
Fluconazole 25 (0.3) 95 (0.2) 1.77  
(1.14-2.75) 
1.34  
(0.85-2.12) 
Metronidazole 47 (0.6) 276 (0.5) 1.14  
(0.84-1.56) 
0.98  
(0.72-1.35) 
Nitrofurantoin 118 (1.4) 853 (1.5) 0.93  
(0.76-1.12) 
0.80  
(0.66-0.98) 
Sulfamethoxazole/ 
trimethoprim 
49 (0.6) 165 (0.3) 2.00 
 (1.45-2.76) 
1.61  
(1.16-2.23) 
 
* Adjusted for all variables present in Table 1 and calendar year of pregnancy. 
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5.5.1. ABSTRACT 
 
Background: Metronidazole is an anti-infective drug used against infections, 
such as tricomoniasis and bacterial vaginosis. Given that these conditions are 
known risk factors for preterm birth, this agent is potentially useful during 
pregnancy. However, available data on the risk of metronidazole during 
gestation is contradictory and controversial.  
 
Objectives: To present an overview of the evidence concerning the 
association between the use of metronidazole during pregnancy and the risk 
of preterm delivery and birth defects. 
 
Methods: We systematically searched PUBMED and EMBASE databases for 
etiologic studies with data on human subjects that examined the association 
between gestational exposure to metronidazole and the risk of preterm birth 
or birth defects. Combinations of the following MeSH terms were used: 
“metronidazole” or “prematurity” or “preterm birth” or “congenital 
malformations” or “birth defects” or “anomalies” or “pregnancy” or “antibiotics” 
or “bacterial vaginosis” or “trichomoniasis”. All relevant articles, published in 
English or French between 1964 and 2010, were reviewed.  If authors did not 
report the odds ratio (OR) for preterm birth or birth defects, crude ORs and 
95% confidence intervals (CI) were calculated.  
 
Results: 17 studies that investigated the association between exposure to 
oral metronidazole during pregnancy and the risk of preterm birth were 
included. Twelve of these studies were randomized clinical trials. We also 
retrieved 13 studies that investigated the association between exposure and 
the risk of birth defects. Ten of these were cohort studies; one was a case-
control study and two were meta-analysis. 
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Conclusions: Treatment with metronidazole is effective against bacterial 
vaginosis and tricomoniasis during pregnancy, and offers no teratogen risk for 
babies of exposed women. Benefit of metronidazole in the reduction of 
preterm birth rates was demonstrated only for the combination of this agent 
with other antibiotics. More evidence is needed on the risk of birth defects, 
when metronidazole is used in association.   
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5.5.2. INTRODUCTION 
 
Metronidazole is an anti-infective drug used particularly against anaerobic 
infections. It is widely prescribed for the treatment of tricomoniasis and 
bacterial vaginosis in women of childbearing age. Given that these conditions 
are known risk factors for adverse pregnancy outcomes, such as preterm 
rupture of membranes and preterm birth, metronidazole is a potentially useful 
agent during pregnancy (1). However, this drug is able to cross the placenta 
throughout gestation and evidence from animal studies suggests that, when 
used in association with miconazole, metronidazole is a teratogen (2-4). Data 
on the risk of this agent during pregnancy is contradictory and hence, the use 
of metronidazole during pregnancy has been controversial (5).  
 
There is also lack of consensus on the use of metronidazole to prevent 
preterm birth. Metronidazole taken between 24th and 29th weeks of gestation 
for the treatment of trichonomiaisis is associated with an increased risk of 
preterm birth (6). In another study, treatment with metronidazole did not 
reduce early preterm birth in pregnant women at higher risk and without 
abnormal vaginal flora (7). However, other studies showed that the drug 
effectively reduces preterm birth rates when used in association with other 
agents for the treatment of pregnant women with bacterial vaginosis (8). In 
addition, women that had preterm birth in their previous pregnancy saw their 
risk of subsequent preterm birth reduced after treatment with metronidazole 
(9). Current clinical practice guidelines recommend oral treatment with 
metronidazole during pregnancy if the objective of therapy is to eradicate 
bacterial vaginosis and tricomoniasis (10). 
 
We present an overview of the evidence available on the association between 
the use of metronidazole during gestation and the risk of preterm delivery and 
birth defects. 
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5.5.3. METHODS 
 
We systematically searched MEDLINE (accessed via PubMed) and EMBASE 
databases for human studies published between 1964 and 2010. 
Combinations of the following MeSH terms were used: “metronidazole” or 
“prematurity” or “preterm birth” or “congenital malformations” or “birth defects” 
or “anomalies” or “pregnancy” as well as “antibiotics” or “bacterial vaginosis” 
or “trichomoniasis”. Additional references were identified from the reference 
lists of retrieved articles. All relevant articles, including prospective and 
retrospective studies, reviews and meta-analysis, published in English or 
French that examined the association between gestational exposure to 
metronidazole and the risk of adverse pregnancy outcomes (having data on 
preterm birth or birth defects) were reviewed. Only etiologic studies with 
clinical relevant definition of exposure were considered (exposure during the 
last two trimesters of pregnancy for studies evaluating preterm birth and 
exposure during the first trimester for birth defects). The initial selection 
criteria were broad enough to ensure that as many studies as possible were 
assessed for review. Case series and studies that reported exposure to other 
routes of administration (topical or intravenous) without data on oral exposure 
were excluded. 
 
For each selected study, the following information was retrieved: first author’s 
name, year of publication, study population, study design, exposure definition, 
data source, results including p-values, and relative risks (RR) or odds ratios 
(OR) when provided.  
 
When authors did not report the OR for preterm birth or birth defects, we 
calculated crude ORs and 95% confidence intervals (CI) from the available 
data in order to compare study results and interpret data. We also calculated 
the prevalence of preterm birth and birth defects, for papers where these data 
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were not reported.  Analyses were performed using the SAS System for 
Windows Version 9.1.3 (SAS Institute Inc, North Carolina, USA). 
 
5.5.4. RESULTS 
 
5.5.4.1. Studies on gestational exposure to metronidazole and the risk of 
preterm birth 
 
Our search strategy retrieved a total of 908 references, from which 225 were 
initially considered for inclusion. After an exhaustive assessment of their titles 
and abstracts, 187 documents were rejected, leaving 38 for full text 
evaluation. 17 studies that investigated the association between exposure to 
oral metronidazole during pregnancy and the risk of preterm birth met 
inclusion criteria and were included for analysis. The majority of these studies 
(12) were randomized clinical trials (RCT). Three were cohort studies and two 
were systematic reviews or meta-analysis. Delivery before 37 weeks of 
gestation was the primary outcome for the majority of these studies. Exposure 
to metronidazole alone was the main exposure definition in 10 studies, 
whereas the rest of the articles assessed exposure to metronidazole in 
association with other antibiotics. Characteristics of reviewed studies are 
presented in table 1 and 2. 
 
5.5.4.2. Studies on gestational exposure to metronidazole and the risk of 
birth defects 
 
Our search strategy retrieved a total of 131 references, from which 98 were 
initially considered for inclusion. After an exhaustive assessment of their titles 
and abstracts, 52 documents were rejected, leaving 46 for full text evaluation. 
Finally, we retrieved 13 studies that investigated the association between 
exposure to metronidazole during pregnancy and the risk of birth defects. Ten 
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were cohort studies; one was a case-control study and two were meta-
analysis. Any birth defect was the primary outcome for the majority of these 
studies, whereas some articles assessed only major defects. Exposure to 
metronidazole (alone or in combination) during the first trimester of pregnancy 
was the main exposure in all the studies. Some articles also assessed 
exposure during the third trimester of pregnancy. Characteristics of reviewed 
articles are presented in table 3. 
 
5.5.5. DISCUSSION 
 
5.5.5.1. Gestational exposure to metronidazole alone and the risk of 
preterm birth 
 
In 1994, Morales et al. used a placebo-controlled RCT to determine if 
treatment of bacterial vaginosis with metronidazole was effective in reducing 
preterm birth rates in patients with preterm delivery in their previous 
pregnancy (9). The authors concluded that treatment (250 mg of 
metronidazole three times a day for 7 days) was effective in reducing preterm 
births (calculated crude OR: 0.27, 95%CI: 0.10-0.76). Nevertheless, at that 
time it was not clear whether pregnant women in their first gestation would 
benefit with treatment.  
 
To clarify this question, in 1997 McDonald et al. randomised 879 pregnant 
women with a diagnosis of bacterial vaginosis at 19 weeks of gestation to 
receive oral metronidazole (400 mg) or placebo twice daily for two days (11). 
Intention-to-treat analysis showed no difference between metronidazole and 
placebo groups in overall preterm birth rates [(31/429 - 7.2% of cases among 
exposed) versus (32/428 - 7.5% of cases among unexposed)] or 
spontaneous preterm birth (4.7% versus 5.6%). In a subgroup of women with 
previous history of preterm birth, the authors were able to verify the same 
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protective effect reported earlier by Morales et al. (9): exposure to 
metronidazole reduced the risk of spontaneous preterm birth by 85% when 
compared to placebo (adjusted OR: 0.14, 95% CI: 0.01-0.84). 
 
However, results from a population-based observational study conducted by 
Sorensen et al. in 1999 suggested a lack of effect of metronidazole in 
reducing rates of delivery before 37 weeks of gestation (OR: 0.80, 95%CI: 
0.35-1.83). However, information on previous preterm births and indication for 
use were lacking in their dataset (12).   
 
This issue was further addressed in 2000 by Carey et al. who also did not find 
any evidence of a protective effect of metronidazole in the reduction of 
preterm births in a general obstetrical population (RR: 1.0, 95%CI: 0.8–1.2) 
(13). In this RCT, women with previous preterm birth history did not benefit 
with therapy (RR: 1.3, 95%CI: 0.8–2.0). Similar results were obtained by the 
same team in 2001: treatment of pregnant women asymptomatic for bacterial 
vaginosis was ineffective in preventing preterm delivery, and may even had 
increased the risk when compared to placebo (RR: 1.8, 95%CI: 1.2–2.7) (6). 
In the same year, Goldenberg et al. published another RCT conducted in 
which pregnant women with a positive test result for cervicovaginal fetal 
fibronectin and bacterial vaginosis had lower rates of preterm delivery after 
exposure to metronidazole (14). However, despite findings suggesting a 
protective effect, authors stated that it is unknown whether any antibiotic 
regimen reduced preterm birth associated with an intrauterine infection.  
 
At that point of the evidence, metronidazole treatment of infections that 
predispose to preterm birth only showed to be effective for pregnant women 
with a previous inflammatory process caused by a chronic infection and 
hence, treatment of asymptomatic women would not be useful. This could 
partially explain the results of Morales et al. (9) and McDonald et al. (11). In 
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these studies, the subjects with a history of preterm birth suffered from a 
chronic bacterial processes, and this could be responsible for their findings of 
lower rates of preterm birth after exposure to metronidazole. In 2005, 
Odendaal et al. conducted a RCT in which metronidazole did not reduce the 
prevalence of preterm labour in pregnant women with a previous history of 
preterm birth and active bacterial vaginosis infection (15). Furthermore, 
results of a larger RCT conducted by Shennan et al. (7), the PREMET study, 
did not corroborate the previous results of Goldenberg et al. (14). The 
PREMET study showed that metronidazole did not reduce early preterm birth 
in high-risk pregnant women selected by history of previous preterm birth and 
positive test result for cervicovaginal fetal fibronectin (RR: 1.9, 95%CI: 0.72–
5.09). Rate of delivery before 37 weeks of gestation was increased after 
exposure to metronidazole (RR: 1.6, 95% CI: 1.05–2.4). In addition, a 
systematic review published in 2005 by Okun et al. found no evidence to 
support the use of antibiotic treatment for bacterial vaginosis or Trichomonas 
vaginalis in order to reduce the risk of preterm birth or its associated 
morbidities (16).  
 
Based on the results of their meta-analyis, Morency and Bujold concluded 
that the use of metronidazole should be avoided during the second trimester 
of pregnancy (17).  It is not clear why metronidazole used alone may increase 
the risk of early delivery but it is possible that the eradication of normal 
bacterial vaginal flora caused by this agent allows growth of harmful 
organisms, leading to ascending infection, stimulation of the inflammatory 
process and early delivery.  
 
Even if a recent observational study conducted in 2009 by Mann et al. 
showed that treatment with oral metronidazole was associated with a 
decrease in the risk of preterm birth (RR = 0.69, 95%CI 0.50-0.95) (18), most 
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of the available evidence from prior RCTs indicate that metronidazole used 
alone is not effective in reducing preterm delivery (Figure 1).  
 
5.5.5.2. Gestational exposure to metronidazole in association with other 
antibiotics and the risk of preterm birth 
 
In spite of the controversy regarding the use of metronidazole alone for the 
treatment of infections that predispose to preterm birth, the benefits of the 
association of this agent with other antibiotics was demonstrated during the 
decade of 1990. In 1994, Norman et al. conducted a multicentre RCT with 81 
pregnant women, and showed the efficacy of the association ampicillin plus 
metronidazole for the prevention of preterm birth in women with intact 
membranes (OR: 0.34, 95%CI: 0.13-0.94) (19). Similar results were found 
when the association was done with erythromycin (RCT conducted in 1995 by 
Hauth et al. with 624 patients (8)), ampicillin (RCT conducted in 1997 by 
Svare et al. with 112 patients, calculated OR: 0,41, 95%CI: 0.19-0.87 (20)), 
tinidazole and secnidazole (retrospective cohort conducted in 2005 by 
Camargo et al., calculated OR: 0.13, 95%CI: 0.05-0.38 (21)), and cephalexin 
(RCT conducted in 2005 by Sen et al. with 224 patients, OR: 0.60, 95%CI: 
0.19-1.88 (22)), although in this study, results were not statistically significant.  
 
Despite these findings, which seemed to indicate a clear benefit of treating 
bacterial vaginosis with metronidazole in association with other antibiotics, a 
large systematic review conducted by Okun et al. in 2005 concluded that 
there is no evidence to support antibiotic treatment of pregnant women with 
bacterial vaginosis if the objective is to reduce preterm birth (RR: 0.93, 
95%CI: 0.70-1.22) (16). The authors however, did not assess the benefits of 
metronidazole in association with other antibiotics. 
 
 211
In 2003, Andrews et al. conducted an RCT that showed no benefit of 
treatment with metronidazole in association with erythromycin during the 
second trimester of gestation for asymptomatic women with a positive cervical 
or vaginal fetal fibronectin test (OR: 1.17, 95% CI: 0.80-1.70) (23).  Similar 
results were found when metronidazole and azithromycin were used during 
the interpregnancy interval in non-pregnant women with a previous preterm 
birth (RR: 1.12, 95%CI: 0.76-1.64) (24). However, this trial was designed to 
evaluate the potential benefit of administering an antibiotic intervention to 
non-pregnant women before conception in an effort to reduce preterm 
delivery in the subsequent pregnancy; hence exposure did not take place 
during pregnancy.  
 
The lack of efficacy of treatment with metronidazole associated with other 
agents showed by some studies raised the question if there is an adverse 
interaction between the antibiotics and the physiological process inducing 
preterm birth, which could be responsible for the increase in the risk. To 
investigate this effect, in 2007 Tita et al. analyzed the existence of an 
interaction between the endometrial bacterial micro-flora and antibiotics 
administered to prevent preterm birth (25). Using subgroup analysis of a 
previous trial (24), the authors demonstrated that when present in the vaginal 
environment, specific microorganisms interact with metronidazole and 
azithromycin to increase the rate of preterm birth (RR: 1.45, 95%CI: 1.08-1.94 
when Gardnerella vaginalis was present, and RR: 1.36, 95%CI: 1.03-1.79, 
when Gram-negative rods were present).  
 
Even if the reviewed evidence shows a potential benefit for the use of 
metronidazole in association with other antibiotics (Figure 2), caution should 
be exercised in prescribing metronidazole with other drugs to pregnant 
women solely for the purpose of preventing preterm birth. 
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5.5.5.3. Gestational exposure to metronidazole and the risk of birth 
defects 
 
One of the early studies that examined whether exposure to metronidazole 
during pregnancy is associated with any birth defects was a retrospective 
cohort conducted by Scott-Gray et al. in 1964 (26). The authors analyzed 
outcomes of 183 pregnancies and exposure during the first and third 
trimesters of gestation. There was no case of birth defects in children of 
women exposed during the first trimester of pregnancy. A noteworthy finding 
of this study was a case of spontaneous abortion after exposure to the drug. 
Similar results were found in a cohort of 190 pregnant women followed by 
Robinson and Mirchandani in 1965 (27), and in a cohort study of 32 subjects 
conducted by Rodin and Hass in 1966 (28). Again, no cases of birth defects 
were detected after exposure during the first trimester of gestation. The work 
of Rodin and Hass (28) was the only study to have no children with birth 
defects in the comparison group. Peterson et al. in 1966 was unable to verify 
an association between exposure and birth defects (prospective cohort of 128 
pregnant women) (29). In all these studies, the primary outcome was any 
birth defects.  
 
The first studies that pointed to a possible link between exposure to 
metronidazole and the risk of birth defects appeared in the decade of 1970. 
Any major congenital malformation was the outcome of interest in a 
prospective cohort study with data on 50282 pregnancies conducted by 
Heinonen et al. in 1977 (30). The authors found a non-statistically significant 
association between exposure during the first trimester of pregnancy and the 
risk of birth defects (RR: 2.15, 95%CI: 0.75-6.13). Four cases of birth defects 
were detected among 31 children of exposed women. The rate of such birth 
defects in the control group was 6.4%. Morgan conducted a similar cohort 
study with 350 subjects two years later and did not find any increased risk of 
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malformation after exposure during the first trimester (RR: 1.14, 95%CI: 0.23-
5.52) (31). Both studies lacked statistical power and the number of exposed 
subjects was small. 
 
In 1987, Rosa et al. conducted a large retrospective cohort study of 104339 
subjects, using data issued from computerized Medicaid records (32). The 
authors assessed prescriptions filled during the first trimester of pregnancy for 
several antimicrobial compounds. 63 cases of birth defects were counted 
among 1083 women exposed to metronidazole during the first trimester of 
pregnancy, compared to 6501 cases in 103 256 non-exposed women. No 
association was found (OR: 0.92, 95%CI: 0.71-1.19). 
 
Piper at al. published a cohort study using data from Tennessee Medicaid 
enrollment files (33). Two cohorts of pregnant women who delivered live-born 
or stillborn infants were identified. The exposed cohort consisted of 1387 
women who filled a prescription for metronidazole between 30 days before 
and 120 days after the onset of their last normal menstrual period. The 
unexposed cohort consisted of 1387 comparable women who did not fill a 
prescription for metronidazole during the same time. Pregnancy outcomes 
were similar for the exposed and unexposed cohort subjects. There was no 
excess of any birth defect occurrence in the offspring of exposed women (RR:  
1.2, 95%CI: 0.9-1.6). 
 
Using data from previous reports (26-32), Burtin et al. published a meta-
analysis where they concluded that metronidazole does not appear to be 
associated with an increased risk of birth defects (34).  The overall weighted 
OR for exposure versus no exposure during the first trimester calculated was 
0.93 (95% CI: 0.73-1.18).  
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A subsequent meta-analysis published by Caro-Paton et al. pooled findings 
from previous studies (30-33) and added results from a case-control study 
conducted with data of 41862 subjects (35). The authors found no association 
between metronidazole exposure during the first trimester of pregnancy and 
the risk of birth defects (OR = 1.08, 95% CI: 0.90-1.29), corroborating the 
findings of the meta-analysis of Burtin et al (34). 
 
The use and refinement of data from administrative databases in the decade 
of 1990s and in the early 2000’s, was reflected by the publication of several 
case-control and retrospective cohort studies conducted with large number of 
subjects. These advancements increased statistical power to addressing rare 
issues such as birth defects (36).  In one of such study, Czeizel and 
Rockenbauer conducted a case-control analysis using the Hungarian Case-
Control Surveillance of Congenital Abnormalities dataset (37). The control 
group consisted of 30 663 pregnant women who had healthy babies. The 
case group consisted of 17 300 pregnant women. Prevalence of exposure to 
metronidazole was 3.4% and 3.8% in the control and case groups, 
respectively. Authors concluded that treatment with oral metronidazole during 
the first trimester of pregnancy was not associated with congenital 
abnormalities (OR= 1.14, 95% CI: 0.89-1.46). However, since data on 
exposure was obtained by questionnaire-oriented interview, results could be 
subject to recall bias. 
 
In order to avoid recall bias, Sorensen et al. conducted a retrospective cohort 
study using prescription filled data issued from the linkage of three Danish 
health administrative databases (12). Data on exposure was obtained from 
the pharmacoepidemiological prescription database from the North-Jutland, 
whereas data from birth defects was obtained from the Danish medical birth 
registry. The authors analyzed data of 138 prescriptions for metronidazole 
obtained by 124 women. The association between exposure during the first 
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trimester and the risk of birth defects was assessed by a case-cohort design. 
The prevalence of birth defects was 2.4% in the exposed group compared to 
5.2% in the control group, and no increase in risk was found (OR: 0.44, 
95%CI: 0.11-1.81). 
 
In 2001, Diav-Citrin et al. prospectively followed 228 women exposed to 
metronidazole during pregnancy, 86.2% of whom with first-trimester exposure 
(38). Pregnancy outcome was compared with that of women who were 
counseled during the same period for non-teratogenic exposure. There was 
no difference in the rate of major malformations between the groups (3 cases 
of birth defects among 190 women exposed (1.6%) compared to 8 cases 
among  575 unexposed (1.4%). The rate of major malformations did not differ 
between the groups even after including elective terminations of pregnancy 
due to prenatally diagnosed malformations (RR: 1.13, 95%CI: 0.30-4.23). 
 
The results from the studies discussed above do not indicate that 
metronidazole used alone poses a teratogenic threat for humans after 
exposure during the first trimester of pregnancy (Figure 3). However, a recent 
study demonstrated that rodents exposed in utero to metronidazole plus 
miconazole had a significant increment in the incidence of axial skeletal 
defects (26.6% of the fetus presented defective skeletogenesis after 
metronidazole - miconazole co-exposure) (4). In adition, a population-based 
case-control study conducted in 2005, warned for the possible correlation 
between use of topical metronidazole in combination with other anti-infectives 
and human birth defects (39). The analysis of cases and their matched 
controls indicated an association between second and third month exposure 
to vaginal metronidazole plus miconazole and the risk of poly-syndactyly 
(adjusted OR: 6.0, 95% CI: 2.4–15.2). Although recall bias and confounding 
by indication were present in this study, in a previous work (40) the same 
authors reported an association between vaginal metronidazole isolated 
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treatment during the second and third months of gestation and congenital 
hydrocephalus (OR: 10.7, 95% CI: 1.1–104.5). Their results however, were 
based only on five cases.    
 
5.5.6. CONCLUSION  
 
Evidence indicates that oral treatment with metronidazole is effective against 
bacterial vaginosis and tricomoniasis during pregnancy, and offers no 
teratogen risk for the babies of exposed women. Benefit of metronidazole in 
the reduction of preterm birth was demonstrated for the use of this agent in 
association with other antibiotics. However, more evidence is needed to 
assess the risk of birth defects, when metronidazole is used in combination 
with other drugs.  Therefore, once organogenesis is complete, associations of 
metronidazole with other antibiotics should be considered for treating 
infections that predispose to preterm birth, when other equally effective 
therapeutic options are not available or are contraindicated. 
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Table 1. Exposure to metronidazole and the risk of preterm birth. 
 
Author Source 
population, 
country 
Study 
Design 
Data source Exposure 
definition 
Main 
outcome 
definition 
Results Odds Ratio 
or Relative 
Risk 
(95% CI) 
1. 
Morales et 
al., 1994 
N=80 
United 
States 
 
Randomised 
controlled 
trial (double 
blinded, 
placebo 
controlled) 
Orlando 
Regional 
Medical 
Center 
250 mg of 
metronidazole 
three times a 
day for 7 days 
Preterm birth 
in women 
with a 
previous 
history 
Exposed: 44 
 
Unexposed: 36 
 
Cases among 
exposed: 8 
(18%) 
 
Cases among 
unexposed: 16 
(44.4%) 
 
OR: 0.27   
(0.10-0.76)* 
 
 
2. 
McDonald 
et al., 1997 
N=879 
Australia 
Randomised 
controlled 
trial (double 
blinded, 
placebo 
controlled) 
Women's 
and 
Children's 
Hospital, 
North 
Adelaide 
Exposure to 
oral 
metronidazole 
(400 mg) twice 
daily for two 
days 
Spontaneous 
preterm birth 
less than 37 
weeks of 
gestation 
Exposed: 429 
 
Unexposed: 
428 
 
Cases among 
exposed: 31 
(7.2%) 
 
Cases among 
unexposed: 32 
(7.5%) 
OR: 0.14 
(0.01-0.84) 
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3. 
Sorensen 
et al. 1999 
N=13451 
Denmark 
Retrospective 
cohort 
Danish 
Medical Birth 
Registry 
Exposure 30 
days before 
conception, 
during the first 
trimester and 
any time 
during 
pregnancy 
 
Delivery 
before 37 
weeks of 
gestation 
Exposed: 124 
 
Unexposed: 
13327 
 
Cases among 
exposed: 6 
(5%) 
 
Cases among 
unexposed: 93 
(6%) 
 
 
 
 
OR: 0.80 
(0.35-1.83) 
4. 
Carey et al. 
2000 
N=1953 
United 
States 
 
 
 
 
 
 
 
Randomised 
controlled 
trial (placebo 
controlled) 
National 
Institute of 
Child Health 
and Human 
Development
Two-dose 
regimen of 
2000mg each 
in women with 
bacterial 
vaginosis and 
without 
trichomoniasis 
Delivery 
before 37 
weeks of 
gestation 
Exposed: 966 
 
Unexposed: 
987 
 
Cases among 
exposed: 116 
(12%) 
 
Cases among 
unexposed: 
121 (12.2%) 
 
 
 
RR: 1.0 
(0.8–1.2) 
Continuation of Table 1 
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5. 
Goldenberg 
et al. 2001 
N=89 
United 
States 
 
Randomised 
controlled 
trial (placebo 
controlled) 
National 
Institute of 
Child Health 
and Human 
Development
Two-dose 
regimen of 
2000mg each 
in women with 
bacterial 
vaginosis and 
a positive test 
result for 
cervicovaginal 
fetal 
fibronectin 
Delivery 
before 37 
weeks of 
gestation 
Exposed: 48 
 
Unexposed: 41 
 
Cases among 
exposed: 4 
(8.3%) 
 
Cases among 
unexposed: 6 
(14.6%) 
 
 
OR: 0.5 
(0.13-1.92)* 
 
 
6. 
Klebanoff 
et al. 2001 
N=617 
United 
States 
 
Randomised 
controlled 
trial (placebo 
controlled) 
National 
Institute of 
Child Health 
and Human 
Development
Two-dose 
regimen of 
2000mg each 
in women with 
asymptomatic 
trichomoniasis 
Delivery 
before 37 
weeks of 
gestation 
Exposed: 320 
 
Unexposed:297
 
Cases among 
exposed: 60 
(19%) 
 
Cases among 
unexposed: 32 
(10.7%) 
 
 
 
 
 
 
 
RR: 1.8 
(1.2–2.7) 
Continuation of Table 1 
 226
7. 
Odendaal 
et al. 2002 
N=269 
South 
Africa 
 
Randomised 
controlled 
trial (placebo 
controlled) 
Tygerberg 
Hospital 
400 mg 
metronidazole, 
orally twice 
daily for 2 
days 
Delivery 
before 37 
weeks 
Exposed: 136 
 
Unexposed: 
133 
 
Cases among 
exposed: 42 
(30.8%) 
 
Cases among 
unexposed: 25 
(18.8%) 
 
OR: 1.93 
(1.09-3.40) 
8. 
Shennan et 
al. 2006 
 
 
N=100 
United 
Kingdom 
Randomised 
placebo-
controlled 
trial 
Fourteen UK 
hospitals 
Metronidazole 
400-mg for 
seven days 
Delivery 
before 
37 weeks of 
gestation 
 
Exposed: 53 
 
Unexposed: 47 
 
Cases among 
exposed: 18 
(39%) 
 
Cases among 
unexposed: 33 
(62%) 
 
 
 
 
 
 
 
RR: 1.6 
(1.05 - 2.4) 
Continuation of Table 1 
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9. 
Morency 
and Bujold, 
2007 
 
N=2779 
Canada 
Meta-
Analysis 
PubMed, 
Medline, and 
Embase 
Databases 
 
Exposure to 
oral 
metronidazole 
Delivery prior 
to 37 weeks’ 
gestation 
Exposed: 2779 
 
Unexposed: 
2531 
 
Cases among 
exposed: 464 
(16.7%) 
 
Cases among 
unexposed: 
359 (14.2%) 
OR: 1.10 
(0.95-1.29) 
10. 
Mann et al. 
2009 
 
 
 
 
N=3579 
United 
States 
 
Retrospective 
cohort 
Medicaid 
billing data 
and birth 
certificate 
records in 
South 
Carolina 
Prescription 
for oral 
metronidazole 
Delivery prior 
to 37 weeks’ 
gestation 
Exposed: 1436 
 
Unexposed: 
2143 
 
Cases among 
exposed: 182 
(12.7%) 
 
Cases among 
unexposed: 
327 (15.3%) 
HR: 0.69 
(0.52-0.92) 
 
 
 
 
 
Continuation of Table 1 
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Table 2. Exposure to metronidazole in association with other antibiotics and the risk of preterm birth. 
 
Author Source 
population, 
country 
Study 
Design 
Data source Exposure 
definition 
Main 
outcome 
definition 
Results Odds Ratio 
or Relative 
Risk 
(95% 
Confidence 
Intervals) 
1. 
Norman 
et al. 
1994 
N=81 
South 
Africa 
Randomised 
controlled 
trial. 
Tygerberg 
Hospital 
(University of 
Stellenbosch), 
Somerset 
Hospital 
(University of 
Cape Town) 
and 
Coronation 
Hospital 
(University of 
Witwatersrand,
Johannesburg)
Ampicillin 1 g 
intravenously 
repeated six 
hourly 
thereafter for 
24 h, followed 
by amoxicillin 
500 mg orally 
eight hourly 
for five days; 
concurrent 
metronidazole 
1 g 
suppository, 
then 400 mg 
orally eight 
hourly for five 
days.  
Delivery 
within 
seven 
days of 
admission.
Exposed: 43 
 
Unexposed: 
38 
 
Cases 
among 
exposed: 16 
(37.2%) 
 
Cases 
among 
unexposed: 
23 (60.5%) 
 
 
 
 
 
 
 
 
OR: 0.34 
(0.13-0.94) 
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2. 
Hauth et 
al. 1995 
N=624 
United 
States 
 
Randomised 
controlled 
trial (double 
blinded, 
placebo 
controlled) 
Public health 
clinics in 
Jefferson 
County, 
Alabama 
Metronidazole 
(250 
mg three 
times a day for 
7 days) and 
erythromycin 
(333 mg three 
times a day for 
14 days) 
Rate of 
delivery 
before 37 
weeks’ 
gestation 
among 
women 
with and 
without 
bacterial 
vaginosis 
Exposed:433
 
Unexposed: 
191 
 
Cases 
among 
exposed: 
112 (26%) 
 
Cases 
among 
unexposed: 
68 (36%) 
 
RR: 1.1 
(0.8–1.7) 
for all 
subjects 
 
 
RR: 1.6 
(1.1–2.1) 
for subjects 
with 
bacterial 
vaginosis 
 
3. 
Svare et 
al. 
1997 
N=112 
Denmark 
 
Randomised 
controlled 
trial (double 
blinded, 
placebo 
controlled) 
Six obstetric 
departments in 
the 
Copenhagen 
area 
Eight days 
intravenous 
and oral 
treatment with 
ampicillin and 
metronidazole 
Rate of 
delivery 
before 37 
weeks’ 
gestation 
among 
 
Exposed: 59 
 
Unexposed: 
51 
 
Cases 
among 
exposed: 25 
(42%) 
 
Cases 
among 
unexposed: 
33 (65%) 
 
 
OR: 0.41 
(0.19-0.87) 
Continuation of Table 2 
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4. 
Andrews 
et al. 
2003 
N=703 
United 
States 
 
 
Randomised 
controlled 
trial 
Department of 
Obstetrics and 
Gynecology, 
Center for 
Research in 
Women's 
Health 
Metronidazole 
(250 mg orally 
three times 
per day) and 
erythromycin 
(250 mg orally 
four times per 
day) 
Delivery 
before 37 
weeks' 
gestation 
after 
preterm 
labor or 
premature 
membrane 
rupture 
Exposed: 
347 
 
Unexposed: 
356 
 
Cases 
among 
exposed: 50 
(14.4%) 
 
Cases 
among 
unexposed: 
44 (12.4%) 
OR: 1.17 
(0.80-1.70) 
5. 
Camargo 
et al. 
2005 
N=205 
Brazil 
 
 
 
 
 
 
Retrospective 
cohort 
Obstetric 
Service at the 
Universidade 
Estadual de 
Campinas 
Metronidazole, 
750 mg/day, 
orally for 
seven 
days; 
metronidazole, 
tinidazole 
or 
secnidazole, 2 
g orally, single 
dose 
Delivery 
before 37 
weeks of 
gestation 
Exposed: 
134 
 
Unexposed: 
71 
 
Cases 
among 
exposed: 5 
(3.7%) 
 
Cases 
among 
unexposed: 
16 (22.5) 
 
OR: 0.13 
(0.05-0.38)* 
 
 
Continuation of Table 2 
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6. 
Okun et 
al. 2005 
 
 
 
 
N=6052 
Canada 
Systematic 
review 
Pre-Med, 
Medline, 
Embase and 
the Cochrane 
Library 
Exposure to 
metronidazole 
Delivery 
before 37 
weeks of 
gestation 
 
Exposed: 
3146 
 
Unexposed: 
2906 
 
Cases 
among 
exposed: 
426 (13.5%) 
 
Cases 
among 
unexposed: 
83 (13.17%) 
 
OR: 0.93 
(0.70-1.22) 
7. 
Sen et 
al. 2005 
 
N=224 
India 
Randomised 
controlled 
trial 
Government 
hospital in 
Kolkata, India 
Metronidazole 
200 mg  eight 
hourly for 
seven days 
and + 
cephalexin 
500 mg 
capsules 12 
hourly for five 
days. 
Delivery 
before 37 
weeks of 
gestation 
 
 
Exposed: 
112 
 
Unexposed: 
112 
 
Cases 
among 
exposed: 9 
(7.9%) 
 
Cases 
among 
unexposed: 
12 (10.7%) 
OR: 0.60 
(0.19-1.88)*
Continuation of Table 2 
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Table 3. Exposure to metronidazole and the risk of birth defects. 
 
Author Source 
population 
and 
country 
Study 
Design 
Data 
source 
Exposure 
definition 
Outcome 
definition
Results Chi squared, Odds 
Ratio or Relative 
Risk or Other 
(95% CI) 
1. 
Scott-
Gray, 
1964 
N=183 
United 
Kingdom 
Prospective 
cohort 
Edinburgh 
Royal 
Hospital 
Exposure 
during the first 
or third 
trimester of 
pregnancy with 
200mg of 
metronidazole 
Any birth 
defect 
Exposed:79 
 
Unexposed: 
104 
 
Cases among 
exposed: 0 
(0%) 
 
Cases among 
unexposed: 4 
(3.8%) 
 
 
 
 
 
 
 
 
 
 
 
 
Chi squared: 1.57 
p=0.21 
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2. 
Robinson 
and 
Mirchanda
-ni, 
1965 
N=190 
United 
States 
 
Prospective 
cohort 
 Exposure 
during the first 
or third 
trimester of 
pregnancy 
Any birth 
defect 
Exposed:14 
 
Unexposed: 
196 
 
Cases among 
exposed: 0 
(0%) 
 
Cases among 
unexposed: 4 
(2%) 
 
Chi squared: 0.158 
p=0.69 
3. 
Rodin and 
Hass 
1966 
N=32 
United 
Kingdom 
Prospective 
cohort 
Whitechap
el Clinic – 
London 
Hospital 
Exposure 
during the first 
trimester of 
pregnancy, 
200mg of 
metronidazole, 
T.I.D, 1 week 
Any birth 
defect 
Exposed:13 
 
Unexposed: 
19 
 
Cases among 
exposed: 0 
(0%) 
 
Cases among 
unexposed: 0 
 
 
 
 
 
 
 
No cases of birth 
defects 
Continuation of Table 3 
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4. 
Peterson 
et al. 
1966 
N=128 
United 
States 
 
Prospective 
cohort 
 Exposure 
during the first 
or third 
trimester of 
pregnancy 
Any birth 
defect 
Exposed: 54 
 
Unexposed: 
74 
 
Cases among 
exposed: 0 
(0%) 
 
Cases among 
unexposed: 1 
(1.35%) 
 
Chi squared: 0.025 
p=0.87 
5. 
Heinonen 
et al. 1977 
 
N=50282 
United 
States 
 
Prospective 
cohort 
 Exposure 
during the first 
of pregnancy 
Major 
birth 
defects 
Exposed: 31 
 
Unexposed: 
50251 
 
Cases among 
exposed: 4 
(13%) 
 
Cases among 
unexposed: 
3244 (6.4%) 
 
 
 
 
 
 
RR: 2.15 
(0.75-6.13) 
Continuation of Table 3 
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6. 
Morgan, 
1978 
 
N=350 
United 
States 
 
Retrospectiv
e cohort 
 Exposure 
during the first 
of pregnancy 
Any birth 
defect 
Exposed: 63 
 
Unexposed: 
287 
 
Cases among 
exposed: 2 
(3.2%) 
 
Cases among 
unexposed: 8 
(2.8%) 
 
RR: 1.14 
(0.23-5.52) 
7. 
Rosa et al. 
1987 
N=104339 
United 
States 
Retrospectiv
e cohort 
Computeriz
ed 
Medicaid 
records 
Exposure to 
miconazole, 
clotrimazole, 
nystatin, 
candicidin, 
aminacrine 
compounds, 
and 
metronidazole 
during the first 
trimester of 
pregnancy 
Any birth 
defect 
Exposed: 
1083 
 
Unexposed: 
103256 
 
Cases among 
exposed: 63 
(5.8%) 
 
Cases among 
unexposed: 
6501 (6.3%) 
 
 
 
 
 
RR: 0.92 
(0.8-1.6) 
Continuation of Table 3 
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8. 
Piper et al. 
1993 
N=2774 
United 
States 
Retrospectiv
e cohort 
Tennessee 
Medicaid 
files 
Exposure 
during the first 
trimester of 
pregnancy 
Major 
birth 
defects 
Exposed: 
1387 
 
Unexposed: 
1387 
 
Cases among 
exposed: 96 
(7%) 
 
Cases among 
unexposed: 
80 (5.7%) 
 
RR: 1.2 
(0.9-1.6) 
9. 
Burtin et 
al. 
1993 
N=104872 
Canada 
Meta-
Analysis 
 Exposure 
during the first 
or third 
trimester of 
pregnancy 
Any birth 
defect 
 
 
 
 
 
OR: 0.93 
(0.73-1.18) 
10. 
Caro-
Paton et 
al. 1997 
N=199451 
Spain 
Meta-
Analysis 
 Exposure 
during the first 
trimester of 
pregnancy 
 
Any birth 
defect 
 
 
 
 
 
 
 
 
 
 
 
 
OR=1.08 
(0.90-1.29) 
Continuation of Table 3 
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11. 
Czeizel 
and 
Rockenba
uer, 1998 
N=47963 
Hungary 
Case-control Hungarian 
Surveillanc
e of 
Congenital 
Abnormaliti
es 
database 
Exposure 
during the first 
trimester of 
pregnancy, 
250mg of 
metronidazole 
Major 
birth 
defects 
Cases: 17300
 
Controls: 
30663 
 
Exposed 
cases: 665 
(3.8%) 
 
Exposed 
controls: 
1041 (3.4%) 
 
OR: 1.14 
(0.89-1.46) 
12. 
Sorensen 
et al. 1999 
N=13451 
Denmark 
Retrospectiv
e cohort 
Danish 
Medical 
Birth 
Registry 
Exposure 30 
days before 
conception and 
during the first 
trimester of 
pregnancy 
Any birth 
defect 
Exposed: 124
 
Unexposed: 
13327 
 
Cases among 
exposed: 3 
(2.4%) 
 
Cases among 
unexposed: 
693 (5.2%) 
 
 
 
 
 
 
OR: 0.44 
(0.11-1.81) 
Continuation of Table 3 
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13. 
Diav-Citrin 
et al., 
2001 
N= 791 
Israel 
Prospective 
cohort 
Israeli 
Teratogen 
Information 
Service 
Exposure 
during the first 
trimester of 
pregnancy 
Major 
birth 
defects 
Exposed: 205
 
Unexposed: 
586 
 
Cases among 
exposed: 3 
(1.45%) 
 
 
Cases among 
unexposed: 8 
(1.3%) 
 
RR:1.13 
(0.30–4.23) 
 
 
 
 
 
  
 
Continuation of Table 3 
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 Figure 1. Exposure to metronidazole and the risk of preterm birth.
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Figure 2. Exposure to metronidazole in association with other antibiotics and 
the risk of preterm birth 
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Figure 3. Exposure to metronidazole and the risk of birth defects. 
 
 
 
  
Chapter 6 
DISCUSSION 
_____________________________________________________________ 
 
Considering the controversy regarding the use of anti-infective drugs during 
pregnancy, and the fact that part of this controversy is due to the 
methodological quality of the available evidence on the subject (see section 
2.4 of this thesis), we conducted 4 large population-based studies to further 
investigate the risk of these drugs during gestation. In addition, we 
systematically reviewed the available evidence on the risk of metronidazole, 
which is the first line agent for the treatment of bacterial vaginosis (a condition 
itself associated to preterm birth).  
 
Our main goal was to furnish additional evidence-based data on the risk of 
two placenta-mediated adverse outcomes (preterm birth and SGA) after 
exposure to anti-infectives drugs during critical periods of pregnancy. In 
addition, using data from health administrative databases, we aimed to 
overcome some of the methodological flaws that limited a reasonable 
interpretation of the results from previous published studies. 
 
Studies 1 and 2 presented in this thesis determined to whom, for which 
indications, why and to which extent anti-infective drugs were prescribed 
during pregnancy. These studies also determined trends in use, and helped 
us to establish the research agenda for the design of study 3 and 4.  
 
In Study 1, we found that 24.5% of pregnant women were exposed at least 
once to an anti-infective drug during gestation (15% of pregnant women were 
exposed at least once during the first trimester of pregnancy, 10% during the 
second or third trimester). The use of these drugs decreased once pregnancy 
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was diagnosed. Prevalence of use reached pre-pregnancy level after the end 
of gestation. This study also showed that, 66% of the anti-infective drugs 
used during the first trimester are considered safe – drugs that are not 
associated with adverse pregnancy outcomes, such as penicillins and 
macrolides. This number rises to 77% in the second, and to 86% in the third 
trimester of pregnancy. Predictors of use on the first day of gestation were 
factors related to lower socio-economic status and poor health conditions. 
Study 2 showed a decreasing trend in the overall use of anti-infective drugs 
during pregnancy from 1998 to 2002, and more specifically of broad-spectrum 
agents (p ≤ 0.05 for trends). These findings corroborate the results published 
by other studies from different countries [2, 49, 54]. At the time Study 1 was 
published, it was the most complete study examining exhaustively, the 
prevalence, indications and trends of anti-infective drugs use during 
pregnancy, and the only one that had data on relevant predictors of use. 
 
Findings of these studies indicate that physicians may be reluctant in 
prescribing anti-infective drugs once pregnancy is diagnosed. Furthermore, 
the decrease in the use of broad-spectrum antibiotics detected in Study 2 can 
be a direct consequence of a consensus among health care professionals to 
prescribe fewer anti-infective drugs in an effort to decrease resistance. Data 
from the Canadian Rx atlas indicates that there was a decrease in the 
inflation-adjusted per capita spending for oral antibiotics during the period 
comprised between 1997 and 2007 [265]. The same trend was observed in 
the age-standardized analysis and in all provinces. Given that the analyses 
were held with data issue of retail sales of prescriptions medicines sold in 
Canada, these results corroborate the conclusions of Study 2. 
 
Study 1 showed that respiratory tract infections was the most prevalent 
infection diagnosed in the registry. Some physiologic changes that occur 
during pregnancy can predispose pregnant women to these infections 
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(increased minute ventilation, which is caused by increased respiratory center 
sensitivity and drive; a compensated respiratory alkalosis; and a low 
expiratory reserve volume). Furtheremore, immunological modifications in the 
number and function of T and B lymphocytes and hormonal alterations also 
may play a role [266]. Other indications for use of anti-infective drugs during 
pregnancy detected in Study 1 was urinary tract infections and sexually 
transmitted infections. Given that these conditions are known risk factors for 
some adverse pregnancy outcomes, these findings led us to investigate the 
independent risk of preterm birth and SGA associated with exposure to anti-
infective drugs during pregnancy. 
 
Study 3 demonstrated that exposure to all anti-infective drugs combined 
during the last two trimesters of pregnancy had a protective effect on the risk 
of preterm birth (adjusted OR=0.78 [95%CI: 0.70-0.88]. After adjustment for 
indication for use and several other covariates, the classes of anti-infectives 
responsible for this effect were penicillins (adjusted OR=0.65 [95%CI: 0.53-
0.82] and macrolides (adjusted OR=0.65 [95%CI: 0.50-0.85]). Amoxicillin 
(adjusted OR=0.78 [95%CI: 0.70-0.87]) and erythromycin (adjusted OR=0.76 
[95%CI: 0.61, 0.95]) both reduced the risk of preterm birth when the reference 
group were women with no exposure to such drugs, while metronidazole was 
associated with a 81% increase in the risk (adjusted OR=1.81 [95%CI: 1.30-
2.54]).  
 
These findings corroborate most of the available evidence on the use of such 
drugs to prevent preterm birth. A noteworthy finding of this study was the 
protective effect of azithromycin in women with a diagnosis of PROM 
(adjusted OR= 0.31, 95% CI: 0.10-0.93). This subgroup of women also had 
benefit from treatment with other agents, such as macrolides (adjusted 
OR=0.61, 95%CI: 0.41-0.90). This result indicates that azithromycin can be 
an effective alternative to erythromycin for the treatment of infections that 
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predispose to preterm birth. Furthermore, results from a recent meta-analysis 
indicated that azithromycin had similar effectiveness and less adverse effects 
compared with erythromycin or amoxicillin, when used in pregnant women 
[267]. Moreover, the widespread use of erythromycin has been responsible 
for an increase in bacterial resistance and consequent reduction in its 
efficacy.  
 
Study 3 was the first study showing an association between the use of 
azithromycin and a decrease in the risk of preterm birth. In 2006, Sarkar et al. 
studied the effect of this drug on the prevalence of congenital malformations 
and preterm birth [127]. The authors concluded that azithromycin was not 
associated with a reduction in the risk of preterm birth. However, the results 
were based on a sample of only 123 pregnant women. Our results may 
encourage physicians in considering the use of this drug as an alternative in 
the management of infections that predispose to preterm birth. more research 
is needed to assess the risk of this drug with regards to other pregnancy 
outcomes.  
 
We acknowledge the possibility that pregnant women exposed to anti-
infective drugs to treat gestational infections could have had better clinical 
follow-up and access to health services, when compared to women that did 
not have anti-infective prescriptions. This factor could partially explain the 
protective effect of the use of anti-infective drugs among women with preterm 
birth.  
 
Study 4 showed that exposure to anti-infective drugs all combined during the 
last two trimesters of pregnancy was not associated with the risk of SGA 
(adjusted OR= 0.97, 95%CI: 0.91-1.04). Class analysis revealed that 
exposure to sulfonamides was significantly associated with the risk of SGA 
(adjusted OR= 1.66, 95%CI: 1.20-2.30). SXT was the individual sulfonamide 
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drug associated to SGA (adjusted OR= 1.61, 95%CI: 1.16-2.23). The use of 
urinary anti-infectives decreased the risk of SGA (adjusted OR= 0.80, 95%CI: 
0.65-0.97). Nitrofurantoin seemed to be responsible for this effect (adjusted 
OR= 0.80, 95%CI: 0.66-0.98). Amoxicillin was also associated with a 
decreased in the risk of SGA (adjusted OR =0.92, 95%CI: 0.85-0.99). 
 
Wen et al. found same results in the only available study that assessed the 
risk of SGA after exposure to folic-acid antagonists, such as SXT [13]. 
However, the exposure time-window used to determine risk was a major 
limitation in this study.  Indeed, a folic acid antagonist may have been 
dispensed up to 1 year before delivery. This means that a woman may have 
taken the medication up to 3 months before conception. It can be hard to 
justify that exposure before conception can have a lasting effect on the 
metabolism or the vascular integrity of a non-existent placenta [268]. 
Furthermore, in this study, the exposed group consisted of mothers who had 
received prescriptions for folic acid antagonists, all types combined. Although 
SXT is the most prevalent agent in the group, the estimates do not reflect the 
independent effect of this medication.  
 
SXT is the first-line agent for the treatment of UTIs among women allergic to 
penicillins. Given that UTIs are known risk factors for SGA, it is possible that 
women treated with SXT had more severe infections than women treated with 
nitrofurantoin or with amoxicillin. Therefore, confounding by indication cannot 
be ruled out. However, our findings can be supported by a strong biological 
plausibility. SXT is a folic acid antagonist that inhibits deoxyribonucleic acid 
synthesis by interfering with the production of folic acid. A placental 
microvascular disease may arise from a maternal folate-homocysteine 
metabolic defect caused by exposure to SXT. In the absence of confounding 
by indication, this can explain how SXT is associated with the development of 
events that lead to SGA newborns.  
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Study 4 is the first population-based study assessing the association between 
the use of anti-infective drugs and the risk of SGA in a large population of 
pregnant women, using a biologically plausible exposure time-window. Its 
findings suggest that physicians should consider the use of other therapeutic 
alternatives to SXT in the management of UTIs in pregnant women with other 
risk factors for SGA. Moreover, this study adds evidence on unsuspicious 
biological properties of well known anti-infective drugs (such as SXT), and the 
clinical implications of these properties during gestation. Further research is 
needed to address this issue.  
 
Finally, Study 5 is a systematic review of the evidence on the use of 
metronidazole during pregnancy with regards to the risk of birth defects and 
preterm birth. This study demonstrated that evidence from RCTs and 
observational studies indicates that oral treatment with metronidazole is 
effective against infections during pregnancy, and offers no teratogenic risk. 
However, with regards to prevention of preterm birth, benefits were only seen 
when metronidazole was used with other antibiotics. There is no evidence for 
the individual use of this drug to prevent preterm birth. These results 
corroborate the findings of Study 3, in which the use of oral metronidazole 
during the last two trimesters of pregnancy was associated with a 80% 
increase in the risk of preterm birth. More research is needed to determine 
the risk of birth defects, when metronidazole is used in combination with other 
drugs.   
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6.1. STRENGTHS AND LIMITATIONS 
 
A detailed discussion of the strengths and limitations of this thesis is 
presented in each of the manuscripts described in Chapter 5. This section 
summarizes the advantages and weaknesses.  
 
6.1.1. Strengths of the studies 
 
6.1.1.1. Use of large populational, evidence-based data from health 
administrative databases and decreased chance of Selection bias 
 
The first four studies presented in this thesis were conducted on a large 
sample of pregnant women obtained from the Quebec Pregnancy Registry. 
This registry is a longitudinal population-based pregnancy cohort established 
with the linkage of three health administrative databases from the province of 
Quebec. The use of these databases to measure associations between 
medication exposures during gestation and pregnancy outcomes presents 
many advantages over other data sources [269].  The Quebec Pregnancy 
Registry includes a wide variety of data, since it links several sources of 
health care information and includes a very large number of person-years of 
information. Data linkage is possible due to the high quality of the personal 
identifier in Quebec’s administrative databases (the Numero d’assurance 
maladie - NAM), which allows correct linkage between databases. 
 
Case-control studies can be highly vulnerable to selection bias, particularly in 
the selection of the control group. The essential purpose of the control group 
is to provide an estimate of exposure in the base population, the population 
from which the cases arise. Selection bias results if control selection is not 
neutral with respect to exposure. The population-based character of the 
Quebec Pregnancy Registry, allows the design of case-control studies nested 
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in pre-establihsed cohorts of pregnant women. Therefore, in Study 3 and 4, 
case and controls were selected from the same source population, which 
decreases the risk of selection bias.  
 
Other advantages of using the Quebec Pregnancy Registry are the increased 
methodological flexibility, lower cost, and increased generalizability, given 
that data on the database reflects real clinical practice. The Quebec 
Pregnancy Registry has often been used to assess the risks and benefits of 
drug use during pregnancy [270-274]. 
 
6.1.1.2. Assessment of outcome: validity of data on SGA and gestational 
age 
 
In study 3, preterm birth was defined as delivery before 37 completed weeks 
of gestation. This is the most used definition for preterm birth, which 
increases the comparability of our results [158]. Moreover, to ascertain SGA, 
we used a population-based Canadian reference for birth weight and 
gestational age, giving representative estimates for the study population 
[263]. In order to determine both outcomes, we used data on gestational age 
and birth weight, respectively.  
 
One critical point when conducting etiologic studies during pregnancy is the 
accurate determination of the first day of gestation [275]. In the Quebec 
Pregnancy Registry, the pregnancies are first identified by a prenatal visit in 
the RAMQ database or by a therapeutic procedure related to pregnancy in 
RAMQ or Med-Echo files. Furthermore, Med-Echo database includes data on 
the length of gestation (defined from the first day of the last menstrual period 
to the end of pregnancy, validated by ultrasound). Med-Echo is the first 
administrative database to give exact gestational age at the end of 
pregnancy, which is a great advantage for studies on drug use during 
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gestation where timing of exposure is essential. Furtheremore, gestational 
age in ISQ database was validated against medical charts [260].  
 
6.1.1.3. Study design and biological plausibility 
 
Despite their status as gold standards in clinical research, randomized clinical 
trials may have the drawback of not reflecting real clinical practice. 
Furthermore, pregnant women are routinely excluded from clinical trials due 
to the concern that drugs could be risky for the fetus [276]. Observational 
studies are the only way to close the knowledge gap in pregnant women 
[264].  
 
Studies 3 and 4 presented in this thesis are case-control studies conducted 
with data issued from the Quebec Pregnancy Registry. These studies are 
traditionally designed to investigate the risk of relatively rare outcomes (such 
as preterm birth and SGA), or to investigate multiple exposures (such as 
multiple classes and individual types of anti-infective drugs). Given that 
subjects are selected based on their outcome status, the case-control design 
permit increased power to detect events where baseline prevalence is 
different thatn zero, such as preterm birth and SGA. Furthermore, when 
compared to survival analysis and other study designs, the case-control 
design is particularly cost-effective with regards to computational time 
required to generate odds ratio that are close to the relative risk estimates 
[277]. 
 
In both studies, the exposure time-window chosen to evaluate the risk of 
preterm birth and SGA was the second or third trimester of gestation. Most of 
the risk factors for these two conditions take place during this critical period of 
pregnancy [72, 74]. Therefore, if anti-infective drug exposure is associated 
with the risk of these outcomes, exposure to these drugs should be assessed 
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during this period. To our knowledge, study 4 is the only available study in the 
literature that assessed the risk of SGA based on this assumption. In addition, 
most of the associations found in Study 3 and 4 are explained by biological 
mechanisms that result from the interaction between anti-infective drugs 
actions and the physiology of preterm birth and SGA. Biological plausibility is 
lacking in previous studies that investigated these outcomes [11, 13, 122, 
123, 127, 139, 153, 215].  
 
6.1.1.4. Increased statistical power to detect rare outcomes 
 
The ability to test hypotheses in analyses of associations depends on having 
a sufficient number of outcomes, anticipated magnitude of the association, 
and prevalence of exposure. As one of the largest pregnancy cohort in the 
world, the Quebec Pregnancy Registry ensured sufficient power for the 
targetted effect sizes for the risk of preterm birth and SGA after exposure to 
anti-infective drugs.  
 
Our studies on the prevalence, predictors and trends of anti-infective drugs 
use, were based on 97 680 subjects, which gave a very accurate picture of 
the use of these drugs during pregnancy, and furnished prevalence estimates 
for comparisons purposes. One of the largest available studies on the 
subject, analyzed data on 41 293 pregnant women in Germany [2].   
 
Study 3 and 4 analyzed data on 4650 cases of preterm birth and 8192 cases 
of SGA, respectively. Considering the prevalence of exposure for anti-
infective drugs in the general population of 18%, and a type I error of 0.05, 
these studies had a statistical power of 0.87 to detect a 10% increase in the 
risk of preterm birth or SGA, which includes all the significant associations 
found (www.biostat.mc.vanderbilt.edu/wiki/main/PowerSampleSize). If meta-
analysis and systematic reviews are excluded (see Table 5 and 6), our 
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studies have the larger statistical power of all the available etiologic studies in 
which these outcomes are the principal outcomes of interest.  
 
6.1.1.5. Lack of Recall bias 
 
The use of RAMQ database to assess drug exposure offers the advantage of 
avoiding recall bias, a major source of potential bias in observational 
research. This kind of information bias arises as a result of differential recall 
between cases and controls with regards to medication exposure that 
occurred at the beginning of pregnancy [275]. In case-control studies 
conducted during pregnancy, pregnant women identified as cases may be 
more likely than controls to recall their drug histories when their babies are 
born. The use of RAMQ databases allows access to the drug history over a 
long period of time (one year before and during pregnancy, for study 3 and 4) 
and for a very large number of subjects in a standardized format. Accurate 
information on name, dosage, and duration of treatment is, therefore 
available which could be virtually impossible with other methods of data 
collection.  
 
6.1.1.6. Control for Confounding  
 
Confounding is one of the major threats to internal validity when conducting 
epidemiologic studies. It refers to a situation in which the effect of a third 
variable is correlated with the exposure in a manner that will bias assessment 
of the outcome of interest [275]. In order for a variable to be considered a 
confounder, it has to be independently associated with the exposure and the 
outcome of interest, and it cannot be in the causal pathway. The use of data 
from administrative databases allows us to adjust for several variables related 
to anti-infective drug use and the risk of preterm birth and SGA. RAMQ and 
MedEcho databases give information on several potential confounding 
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variables, such as socio-economic variables (age, place of residence, welfare 
status), diagnosis, co-morbidities, indication for use, variables related to the 
access to the health care system, and concomitant exposure to other 
medications.   
 
6.1.2. Limitations of the studies 
 
The studies presented in this thesis have some limitations inherent to the use 
of health administrative databases. 
 
6.1.2.1. Assessment of exposure 
 
The RAMQ prescription drug plan provides information on prescriptions filled. 
Therefore, dispensing of a prescription does not mean that a patient actually 
took the medication or was completely compliant with treatment. However, 
the provincial drug plan requires that the beneficiary pay a portion of the costs 
for medications. This increases the likelihood that prescriptions that are filled 
are in fact consumed. In addition, in Study 3 and 4, exposure is defined in a 
dicothomous manner (yes/no), which means that our estimates are based in 
at least one consumption of the medication, regardeless the duration of 
prescription. This a very conservative approach to asses risk of adverse 
outcomes after exposure to medications. Moreover, it has been demonstrated 
that most filled prescriptions by pregnant women are taken [278].  
 
6.1.2.2. Assessment of outcome 
 
In study 3, we did not have statistical power to analyze preterm birth in the 
three subgroups (moderate or late preterm birth – 32 to 36 completed weeks 
of gestation, very preterm – between 28 and 32 weeks of gestation, and 
extreme preterm – delivery occurring before 28 weeks). Furthermore, in study 
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4, our definition of SGA has some drawbacks inherent to the use of the 
population-based Canadian reference for birth weight and gestational age, 
such as its cross-sectional nature. The curve is based on the birth weights of 
different infants born at different gestational ages, rather than longitudinal 
measurements of the same infants over the course of gestation [263].  
 
The linkage between data on the mother and child’s birth weight is not 
possible for 4% of pregnant women included in the Registry. Some reasons 
for that is the fact that birth weight is recorded whitin ISQ files, and some 
deliveries occur outside the province of Quebec. The ISQ database therefore 
does not contains data on these babies, even if the mother and child will be 
residents of Quebec after delivery. 
 
6.1.2.3. Information bias 
 
In case-control studies, in which information is obtained from past records, 
information bias can be introduced if the quality and extent of information 
obtained is different for cases when compared to controls. If a confounding 
variable is misclassified, the ability to control in the analysis is compromised. 
In Study 3 and 4, ICD-9 codes for infections were not validated. Therefore, 
information bias can be present for these variables. If there is nondifferential 
misclassification of subjects counted for in these variables, the estimates of 
increased risk of preterm birth and SGA  after exposure to anti-infective drugs 
tends to be diluted, and actually can be an underestimation of the real OR. If 
nondifferential classification was present for these variables, residual 
confounding by indication cannot be ruled out. 
 
In what concerns information bias related to the exposure variable, given that 
the RAMQ prescription drug plan only provides information on prescriptions 
filled, there is the possibility that some pregnant women did not take their 
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anti-infective drugs (see section 6.1.2.1). These women could have more 
severe infections and therefore, an increased risk for preterm birth or SGA. In 
study 3, if women selected as cases of preterm birth did not actually take their 
anti-infective drugs, the results of this study could reflect an underestimation 
of the protective effect of the exposure to anti-infective drugs on the risk of 
preterm birth. On the other hand, if women selected as controls did not take 
their anti-infectives, the results of the study 4 could be an overestimation of 
the effect of SXT on the risk of SGA. 
 
Given that 10% of women with bacterial vaginosis and UTIs are 
asymptomatic (and that in our analysis, this variable is dichotomously coded), 
is it possible that some subjects were misclassified for these variables. 
Women considered having a diagnosis of UTI can represent subjects with 
more severe cases. In addition, women considered not having sucg diagnosis 
can actually have less severe asymptomatic forms of infections. However, 
misclassification for these ariables, if exists, is probably nondiferential. 
Independent nondifferential misclassification of a dichotomous confounding 
variable reduce the extent to which the confounder can be controlled, causing 
a bias in the direction of the confounding variable [279]. This fact may 
generate distortions produced by uncorrect ascertainement of subjects into 
different analisys strata, which can partly explain some of the associations 
found in studies 3 and 4. However, given the low prevalence of asymptomatic 
cases, and the results of the sensitivity analises (Study 3), we don’t believe 
that these limitation undermine our conclusions. 
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6.1.2.4. Confounding by indication and lack of data on life styles factors 
and socio-demographic characteristics 
 
Confounding by indication occurs when a potential association between 
exposure to a medication and a given outcome is masked or enhanced by 
severity of the indication for which the medication was prescribed. To handle 
the problem of confounding by indication in our studies, we used multivariate 
logistic regression models to generate adjusted odds ratio, by simultaneously 
controlling for diagnosis of infections. However, given that we did not have 
information on severity of infections, it is possible that confounding by 
indication could partially explain some results of study 3 and 4. In fact, the 
North American UTI Collaborative Alliance (NAUTICA) showed that the rate 
of uropathogens resistance against SXT is 21%, whereas the reported 
resistance rate for nitrofurantoin is only 1.6% [280]. Therefore, women treated 
with SXT could present more severe forms of UTI, when compared to women 
exposed to nitrofurantoin. Furtheremore, women treated with SXT could 
present UTI sub-optimally treated, which can increase the risk of preterm birth 
and SGA.  
 
Confounding by indication can also explain the increased risk of preterm birth 
after exposure to metronidazole (Study 3). This drug is used for the treatment 
of BV, a condition itself associated with preterm birth (see section 2.2.2.). In 
the multivariate analysis, BV was accounted for in the ICD-9 codes for PID 
(614-616), which is a broad classification group. Therefore, the associations 
measured for metronidazole could be a reflection of the effects of BV on the 
risk of preterm birth. 
 
Most of the RCT that showed no beneficial effects of anti-infectives on pre-
term delivery, were trials designed to evaluate the comparative efficacy of 
these drugs used by pregnant women in hospital settings. In these trials, the 
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reference group consisted of women with infections (and therefore, at risk of 
preterm delivery) treated with an anti-infective drug, against which the agent 
of interest was compared.  Some hypothesis can be generated in order to 
explain why those trials did not show benefit, when compared to the results of 
study 3: 1) RCT of comparative efficacy sometimes lack statistical power to 
detect significant differences between two groups with the same condition 
and exposed to different interventions. These studies did not explore the use 
of all combined anti-infective drugs; 2) Study 3 is a case-control study where 
the reference category consists of pregnant women without preterm birth. It is 
possible that women treated with different anti-infective drugs had different 
severity of infections, and therefore different baseline risk for preterm birth. As 
stated before, the results of study 3 can have the influence of confounding by 
indication. 
 
Administrative databases are a cost-effective source of data for health 
services research, but lack of data on life styles factors and socio-
demographic characteristics are the main criticisms. Indeed, we were unable 
to measure some risk factors for preterm birth and SGA, such as the 
gestational intake of illicit substances, alcohol, and caffeine. In study 3, there 
is a possibility of residual confounding due to the absence of adjustement for 
previous history of preterm birth, a known risk factors for preterm birth and 
that can also be associated with infections. Furtheremore, in Study 4, residual 
confounding due to smoking can partially explain the association found 
between exposure to SXT and SGA. Smoking is a know risk factor for SGA 
and is associated with lower socio-economic status as well. Data on maternal 
height and weight are also lacking in the Quebec Pregnancy Registry. 
Therefore, residual confounding and confounding by indication may be 
present. 
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6.1.2.5. External validity 
 
Women included in the Quebec Pregnancy Registry are those who are 
covered by the RAMQ prescription drug plan for their medications. Therefore, 
this cohort may over represent women with lower socioeconomic status, 
which might affect the generalisability of some findings that may be more 
strongly associated with socio-demographic factors. However, it has been 
previously shown that in the Quebec Pregnancy Registry, socioeconomic 
status is an effect modifier, and thus doesn’t affect internal validity of the 
etiologic studies presented in this thesis (Study 3 and 4) [257]. In addition, 
pregnant women insured by the RAMQ drug plan and those insured by 
private drug insurance plans have been shown to have comparable co-
morbidity profiles and access to health care services, such as physician visits 
and hospitalizations.  
 
External validity and selection bias can be tanglible limitations for Study 1 and 
2, which are based in prescription practices and the use of anti-infectives 
among women of lower socio-economical status. Individuals of lower socio-
economical status have a higher probability of having infections and 
therefore, used more anti-infective drugs, implying that the results of Study 1 
and 2 are overrepresented. This selection bias can provide inconsistent 
estimators of prevalence [281]. As stated before, there are substantial 
differences between pregnant women insured by the Quebec’s Public Drug 
Insurance Plan and those insured by private drug insurance plans (see 
section 4.1). For this reason, results for predictors and trends of use, and 
types of anti-infective drugs found in these studies cannot be extrapolated for 
international comparisons.  
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6.1.2.6. Multiple testing 
 
Finally, we cannot exclude the possibility of chance findings for 5% of our 
statistically significant associations due to the number of comparisons made 
in our studies. Furthermore, multiple testing could partially explain some of 
our results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 7 
CLINICAL IMPLICATIONS AND RESEARCH AGENDA 
_____________________________________________________________ 
 
The United Nations Millennium Development Goals 4 and 5 target a two-third 
reduction in the deaths of children under five years old and a 75% reduction 
in the maternal mortality ratio between the years 1990 and 2015 [251]. 
Complications of preterm birth and infants born SGA are the leading direct 
cause and major risk factor for neonatal deaths and morbidity [160]. 
Approximately 45–50% of preterm births are idiopathic, and infections are 
one of the main modifiable causes of preterm birth and SGA. Given the social 
and economic burden of these adverse pregnancy outcomes, the 
development of strategies to improve access to effective anti-infective 
treatment of maternal infections must remain a top research and operational 
priority. Developing such strategies will depend on the design of evidence-
based studies that furnish improved estimates of the impact of such use on 
the health of the mother and children [174].  
 
This thesis provided knowledge on the use of anti-infective drugs during 
pregnancy that can be useful for health care professionals and pregnant 
women. First, it was demonstrated that the use of these drugs during 
pregnancy is prevalent, and decreases once pregnancy is diagnosed. A 
decrease in the gestational use of broad-spectrum agents was also observed. 
Prescribers seem to be concerned with the choice of older and well-known 
drugs with better safety profiles, such as penicillins. In our study, women that 
use these medications in the beginning of pregnancy belong to a low socio-
economic class and have poorer health. The main indications for the use of 
these agents during pregnancy are known risk factors for adverse pregnancy 
outcomes, such as UTIs and pelvic inflammatory disease.  
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Second, our results indicate that treatment with anti-infective drugs reduces 
the risk of preterm birth. Pregnant women that used penicillins and macrolides 
during the last two trimesters of gestation had a 35% decrease in the risk. In 
addition, results suggest that azithromycin can be an efficient substitute for 
less efficacious agents in the treatment of infections that predispose to 
preterm birth. Furthermore, some subgroup of women can have more benefit 
from treatment, such as women with preterm rupture of membranes. Our 
results also demonstrated that pregnant women exposed to 
sulfamethoxazole-trimethoprim had their risk of SGA increased by 60%, 
whereas the use of nitrofurantoin decreased the risk. Moreover, our results 
suggest that metronidazole should not be used alone for the prevention of 
preterm birth. However, the safety profile of its use in association with other 
agents must be further evaluated. 
 
Pregnant women diagnosed with infections during gestation must be closely 
monitored in order to avoid adverse impacts on pregnancy outcomes. The 
results of this thesis suggest that health care professionals must consider 
other therapeutic alternatives to metronidazole and sulfonamides, and special 
attention must be given to the evaluation of the benefit of treating subgroups 
of women with other risk factors for preterm birth or SGA.  
 
This study generated some research questions that would need to be 
addressed in future studies. Given its potential in preventing preterm birth, the 
safety profile of azithromycin during pregnancy must be further evaluated. In 
addition, more studies evaluating the effectiveness and safety of the use of 
metronidazole in association with other agents are needed.  Other therapeutic 
alternatives to sulfonamides in the treatment of UTIs must be investigated 
and their safety profiles must be established. Finally, specific clinical 
guidelines with recommendations for the use of anti-infective drugs during 
gestation must be developed. 
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